isth couverture 6.6.2012 10:21 page 1 - cdn.ymaws.com · anish sharda usa wie shi china jane skov...

ISTH Couverture 6.6.2012 10:21

Table of Contents

www.isth.org

33 Welcome Message from the Meeting President

33 Welcome Message from ISTH Council Chairman

44 Welcome Message from SSC Chairman

55 Committees

77 ISTH Future Meetings Calendar

88 Meeting Sponsors

99 Awards and Grants 2012

1122 General Information

2200 Programme at a Glance

2211 Day by Day Scientific Schedule & Programme

2222 Detailed Programme Tuesday, 26 June 2012

2255 Detailed Programme Wednesday, 27 June 2012

3333 Detailed Programme Thursday, 28 June 2012

4444 Detailed Programme Friday, 29 June 2012

5566 Detailed Programme Saturday, 30 June 2012

6688 Hot Topics Schedule

7711 ePoster Sessions

9977 Sponsor & Exhibitor Profiles

111100 Exhibition Floor Plan

111111 Congress Centre Floor Plan

ISTH 2012 11.6.2012 14:46 Page 1

ISTH 2012 11.6.2012 14:46 Page 2

Committees

3

Message from the ISTH SSC 2012 MMeeeettiinngg PPrreessiiddeenntt

Dear Colleagues and Friends,

We warmly welcome you to theScientific and Standardization Com-mittee (SSC) meeting of the Inter-national Society on Thrombosis andHaemostasis (ISTH) at Liverpool’s

UNESCO World Heritage Centre waterfront!

As setting standards is fundamental to all qualityoutcomes, our objective for this meeting in Liverpoolwill be to convey how the SSC is well-positioned totranslate new knowledge into better patient care.Promoting cross-information exchange and engagingwith external partners are key to deliver solutions forpatients with haemostatic and thrombotic problems.

Developing future leaders is also key to the vitality ofISTH and this meeting will be rooted in the themesof Education, Engagement and Translation. I amtherefore delighted that SSC 2012 offers a coherentprogramme with a Trainees’ Day on Consultative Coagu-lation, an Education Day on Setting Standards of Care,a Presidential Plenary on Translational Thrombosis &Haemostasis and enhanced opportunities to Meet-the-Experts.

I look forward to greeting you personally and wish youthe best of experiences in Liverpool !

With best wishes.

CHENG-HOCK TOH

M.D., FRCP, FRCPath

Welcome Messages

MMeessssaaggee ffrroomm tthhee IISSTTHHCChhaaiirrmmaann ooff CCoouunncciill


It is my distinct privilege to welcomeyou to Liverpool for our 2012 SSCmeeting.

Dr. Cheng-Hock Toh and his col-leagues have set up a great Pro-

gramme aiming at making our off-congress yearmeeting especially attractive for our participants.

Since 2008, beside the usual in-depth work of theSubcommittees, our SSC meetings include a largeeducational programme that targets young basic andclinical scientists. Because of the smaller format ofthese meetings, compared to our biennial congresses,it also allows to experiment with innovations. With avery encouraging number of abstracts submitted, wewill have stimulating “hot topic abstracts” reportinglate-breaking results in basic and clinical science, andalso regular abstracts featured as “e-posters”. Theseinnovations will further foster the exchange of know-ledge and the educational experience for our parti-cipants.

I look forward to meeting you in the course of the weekand attending and actively participating in what lookslike an outstanding program.

Thank you for attending our 58th SSC meeting toexperience the “science, culture, and friendship!”.

Welcome to Liverpool !

HENRI BOUNAMEAUX M.D.

Wel

com

e M

essa

ges

ISTH 2012 11.6.2012 14:46 Page 3

MMeessssaaggee ffrroomm tthhee SSSSCC CChhaaiirrmmaann


Following the success of the SSCmeeting in Kyoto, we are back inEurope and I warmly welcome you to anew and very innovative meeting inLiverpool.

As is the tradition of the SSC, the format of the 2012meeting is designed to favor an active exchange of newimportant information and topics of research, and tostimulate cross-disciplinary collaborations. The confe-rence will start with a strong educational programme,providing an opportunity of intensive training for ouryounger colleagues. Then the meetings of all sub-committees of the SSC will follow and the results of thenew and on-going projects of each subcommittee willbe extensively discussed. This will provide the newinsights into the most challenging practical issues inthrombosis and hemostasis, and also will grant anexpert view on the standardization of basic and clinicalresearch methods, nomenclature, preparation ofreference reagents, and evaluation of new tests andnew drugs.

Professor Cheng-Hock Toh and his colleagues on theLocal Organizing Committee have assembled a veryhigh-level programme, which will also include for thefirst time “Hot topic abstracts” and regular abstractsthat will be presented as e-posters. This novelty willhelp to highlight the most recent achievements in basicand clinical research and will be a great challenge foryoung investigators.

To maintain the high level reached by the SSC it isimportant that those who are not currently a member,not only participate in the meeting, but make an activecontribution, participating in the working projects andregistries, and become a member of one of the sub-committees.

The dynamic and energizing atmosphere of Liverpoolwill provide the perfect setting for the offspring of newprojects and collaborations, and will guarantee a greatsuccess of the 2012 ISTH/SSC conference.

Welcome to Liverpool !ANNA FALANGA M.D.

Welcome Messages

4

ISTH 2012 11.6.2012 14:46 Page 4

Com

mit

tees

Committees

5

Organizing Committee

Cheng-Hock Toh, President (United Kingdom)Jecko Thachil (United Kingdom)Simon Abrams (United Kingdom)Tina Dutt (United Kingdom)Ian Greer (United Kingdom)Colin Downey (United Kingdom)

Officers of the Scientific and StandardizationCommittee

Anna Falanga (Italy)Chairman (2010-2012)

David Lillicrap (Canada)Secretary/Chairman-Elect (2010-2012 / 2012-2014)

Subcommittees of the Scientific andStandardization Committee

AAnniimmaall,, CCeelllluullaarr,, aanndd MMoolleeccuullaarr MMooddeellss ooff TThhrroommbboossiissSusan S. Smyth (USA)

BBiioorrhheeoollooggyyMichael R. King (USA)

CCoonnttrrooll ooff AAnnttiiccooaagguullaattiioonnWalter Ageno (Italy)

DDiisssseemmiinnaatteedd IInnttrraavvaassccuullaarr CCooaagguullaattiioonn ((DDIICC))Hideo Wada (Japan)

EExxooggeennoouuss HHeemmoossttaattiicc FFaaccttoorrss,, RReeggiissttrryy ooffJan Rosing (The Netherlands)

FFaaccttoorr VVIIIIII && FFaaccttoorr IIXX Flora Peyvandi (Italy)

FFaaccttoorr XXII aanndd tthhee CCoonnttaacctt SSyysstteemmThomas Renne (Sweden)

FFaaccttoorr XXIIIIII aanndd FFiibbrriinnooggeennHans P Kohler (Switzerland)

FFiibbrriinnoollyyssiissAnn Gils (Belgium)

HHeemmoossttaassiiss && MMaalliiggnnaannccyy Agnes Y Y Lee (Canada)

LLuuppuuss AAnnttiiccooaagguullaanntt//PPhhoosspphhoolliippiidd--ddeeppeennddeennttAAnnttiibbooddiieessThomas L Ortel (USA)

PPeerriinnaattaall//PPeeddiiaattrriicc HHeemmoossttaassiissPaul Monagle (Australia)

PPllaassmmaa CCooaagguullaattiioonn IInnhhiibbiittoorrssSteven Kitchen (United Kingdom)

PPllaatteelleett IImmmmuunnoollooggyy Yves Gruel (France)

PPllaatteelleett PPhhyyssiioollooggyyPaul Harrison (United Kingdom)

PPrreeddiiccttiivvee HHeemmoossttaattiicc VVaarriiaabblleess aanndd CCaarrddiioovvaassccuullaarr DDiisseeaasseeJames Douketis (Canada)

Committees

ISTH 2012 11.6.2012 14:46 Page 5

Committees

6

VVaassccuullaarr BBiioollooggyyFrançoise Dignat-George (France)

VVoonn WWiilllleebbrraanndd FFaaccttoorrJeroen CJ Eikenboom (The Netherlands)

WWoommeenn’’ss HHeeaalltthh IIssssuueess iinn TThhrroommbboossiiss aanndd HHaaeemmoossttaassiiss Sabine Eichinger (Austria)

SSSSCC WWoorrkkiinngg GGrroouupp oonn CCooaagguullaattiioonn SSttaannddaarrddssAnthony Hubbard (United Kingdom)

Council of the International Society onThrombosis and Haemostasis (ISTH)

CChhaaiirrmmaann ooff CCoouunncciill ((22001100--22001122))Henri Bounameaux (Switzerland)

SSeeccrreettaarryy//CChhaaiirrmmaann--EElleecctt ooff CCoouunncciill ((22001100--22001122 // 22001122--22001144))Michael Berndt (Ireland)

TTrreeaassuurreerr ((22001111--22001155))Nuala Booth (United Kingdom)

CCllaassss ooff 22001122Michael Berndt (Ireland)Henri Bounameaux (Switzerland)Alan Nurden (France)Bjarne Østerud (Norway)Pieter Reitsma (The Netherlands)

CCllaassss ooff 22001144Nuala Booth (United Kingdom)Françoise Dignat-George (France)Nigel Key (USA)Robert Montgomery (USA)Hugo ten Cate (The Netherlands)

CCllaassss ooff 22001166Marco Cattaneo (Italy)Björn Dahlbäck (Sweden)Andreas Greinacher (Germany)Paula Tracy (USA)Yukio Ozaki (Japan)

Ex-Officio Council Members

Bruce Furie (USA) SSeeccrreettaarryy GGeenneerraall ((22001100--22001144))

Frits R. Rosendaal (The Netherlands)PPrreessiiddeenntt ooff tthhee XXXXIIVV CCoonnggrreessss ((AAmmsstteerrddaamm,, 22001133))&& IImmmmeeddiiaattee PPaasstt CChhaaiirrmmaann ooff CCoouunncciill

Pieter Reitsma (The Netherlands) VViiccee--PPrreessiiddeenntt ooff tthhee XXXXIIVV ((AAmmsstteerrddaamm,, 22001133))CCoonnggrreessss

Yasuo Ikeda (Japan)PPrreessiiddeenntt ooff tthhee XXXXIIIIII CCoonnggrreessss ((KKyyoottoo,, 22001111))

Mike Greaves and David Lane (United Kingdom)EEddiittoorrss--iinn--CChhiieeff,, JJoouurrnnaall ooff TThhrroommbboossiiss aannddHHaaeemmoossttaassiiss

Anna Falanga (Italy)CChhaaiirrmmaann,, SScciieennttiiffiicc aanndd SSttaannddaarrddiizzaattiioonn CCoommmmiitttteeee

Committees

ISTH 2012 11.6.2012 14:46 Page 6

Com

mit

tees

Committees

7

SSC 2012 Abstract Reviewers

Ken Bauer (USA)Nuala Booth (United Kingdom)James Crawley (United Kingdom)Françoise Dignat-George (France)Alison Goodall (United Kingdom)Tilman Hackeng (The Netherlands)Katherine Hajjar (USA)Keith Hoots (USA)Bendt Jilma (Austria)Paul Kyrle (Austria)Nigel Mackman (USA)Andrew Mumford (United Kingdom)Bjarne Østerud (Norway)Evan Sadler (USA)Hugo ten Cate (The Netherlands)Jecko Thachil (United Kingdom)Cheng-Hock Toh (United Kingdom)Theodore Warkentin (Canada)Steve Watson (United Kingdom)

IISSTTHH FFuuttuurree MMeeeettiinnggss CCaalleennddaarr

XXXXIIVV IISSTTHH CCoonnggrreessss aanndd 5599tthh AAnnnnuuaall SSSSCC MMeeeettiinnggFrits R. Rosendaal, PresidentAmsterdam, The Netherlands29 June - 4 July, 2013wwwwww..iisstthh22001133..ccoomm

6600tthh AAnnnnuuaall SSSSCC MMeeeettiinnggRobert R. Montgomery, PresidentMilwaukee, WI, USA2014

XXXXVV IISSTTHH CCoonnggrreessss aanndd 6611sstt AAnnnnuuaall SSSSCC MMeeeettiinnggSam Schulman, PresidentToronto, Canada2015

XXXXVVII IISSTTHH CCoonnggrreessss aanndd 6633rrdd SSSSCC MMeeeettiinnggJohannes Oldenburg, PresidentBerlin, Germany2017

XXXXVVIIII IISSTTHH CCoonnggrreessss aanndd 6655tthh SSSSCC MMeeeettiinnggRobert Medcalf, PresidentMelbourne, Australia2019

ISTH 2012 11.6.2012 14:46 Page 7

8

Meeting Sponsors

The ISTH and the SSC 2012 Local OrganizingCommittee would like to thank the following companiesfor their generous support of the 58th Annual Meetingof the Scientific and Standardization Committee of theISTH.

Platinum Level

Gold Level

Silver Level

Bronze Level

SSppoonnssoorrss,, EExxhhiibbiittoorrss aanndd PPaarrttnneerrssLLiisstt ccoorrrreecctt aass aatt 2222 MMaayy 22001122

4S DAWN Clinical SoftwareACC LiverpoolAffinity Biologicals Inc.AlexionAmgenBaxter Healthcare Inc.BayerBiogen Idec & Swedish Orphan BiovitrumBoehringer Ingelheim LimitedCSL BehringDaiichi Sankyo Europe GmbHEnzyme Research / r2 DiagnosticsGlasxoSmithKlineHaematologic Technologies, Inc.Haemonetics CorporationHelena Biosciences EuropeHPS Network UKHemaCore LLCInspiration Biopharmaceuticals, Inc.Instrumentation LaboratoryMicrovisk TechnologiesMitsubishi PharmaMultiplate - Verum Diagnostica GmbHNovo NordiskOctapharma AGPathway Diagnostics Ltd.Pentapharm / DSMPfizerPrecision BioLogicSanofiSchattauer GmbHSiemens / Healthcare Diagnostics Products GmbHStagoSysmex UK Ltd.Technoclone

ISTH 2012 11.6.2012 14:46 Page 8

Awar

ds &

Gra

nts

Committees

9

Awards and Grants 2012

ISTH Young Investigator Awards

The Young Investigator Awards wereprovided in the form of travel grants tomedical trainees and young scientists(under 35 years of age as of 27 June,2012) who submit highly rated abstracts.

These awards have been made possible thanks toISTH and the 58th Scientific and Standardization Com-mittee meeting of the International Society on Throm-bosis and Haemostasis.

Awardees Country

Simon Abrams United KingdomYasir Alhamdi United KingdomSeamus Allen IrelandSandra Baker USAAnna Balandina Russian FederationCecilia Becattini ItalyGiselle Begue ArgentinaSaartje Bloemen The NetherlandsMarc Blondon USAAnnemieke Bouman The NetherlandsRoza Chaireti SwedenKatarzyna Czerwin’ska- PolandJelonkiewiczHugoline de Haan The NetherlandsSusanne de Witt The NetherlandsJun Deng ChinaMing-Yang Deng ChinaErika Diani ItalyJonathan Douxfils Belgium

Natalia Dovlatova United KingdomLizaveta Drozd BelarusLisa Duffett CanadaPetra Erkens The NetherlandsElena Maria Faioni ItalyGiovanni Favuzzi ItalyLena Furmark USAIrma Geenen The NetherlandsJayandharan Giridhara Rao IndiaWenjuan He ChinaIvana Horvat CroatiaWalter Janse van Rensburg South AfricaJiang Jiang ChinaMiao Jiang ChinaYosuke Kanno JapanAlev Karasu The NetherlandsMarie-Claire Kleinegris The NetherlandsGerhardus Kuiper The NetherlandsRinske Loeffen The NetherlandsAna Lopez IrelandMarie Lordkipanidze United KingdomGillian Lowe United KingdomYeling Lu ChinaStephen Macdonald United KingdomIlaria Mancini ItalyMaura Marucci ItalyOlesya Matvienko Russian FederationAlexandra Mazharian United KingdomKate Monagle AustraliaMicah Mooberry USAChristopher Moxon United Kingdom

ISTH 2012 11.6.2012 14:46 Page 9

Committees

10

Awards and Grants 2012

Omonivie Okaisabor United KingdomAbimbola Onasoga USAMaria Teresa Pagliari ItalyLeonid Parunov Russian FederationLeonie Pelkmans The NetherlandsRachel Roach The NetherlandsNathan Schloemer USAHenrike Schouten The NetherlandsAnish Sharda USAWie Shi ChinaJane Skov DenmarkFrancesca Stufano ItalyCarmen Tartari ItalyClaudia Tersteeg The NetherlandsThea Tilley IrelandJasmijn Timp The NetherlandsJulien Toh United KingdomGiacomo Tuana ItalyThomas Vanassche BelgiumAnyou Wang ChinaYan Xia ChinaGuoling You ChinaJingyi Zhou ChinaXuemei Zhu ChinaXiaoyu Zhu ChinaStéphane Zuily France

ISTH Reach the World Travel Awards

In recognition of the expanding educa-tional format of ISTH’s SSC AnnualMeetings, the ISTH is extending its“Reach the World” initiative to enable

participation by scientists from all areas of the world inthe educational and working sessions of the SSC.

Bayer HealthCare has partnered withISTH to make possible these 2012Awards through a generous unrestrictededucational grant. Welcome to All ! We

hope that you will find attendance at SSC 2012 fruitfulin your continued research and educational activities.

Awardees Country

Magy Abdelwahab EgyptXia Bai ChinaVenina Barros BrazilMunira Borhany PakistanQiulan Ding ChinaIrina Gribkova Russian FederationTarandovskiy Ivan Russian FederationGwo-Ping Jong Taiwan, ChinaArshi Naz PakistanIra Puspitawati IndonesiaAnalía Sánchez-Luceros ArgentinaJianbo Wu China

ISTH 2012 11.6.2012 14:46 Page 10

ISTH 2012 11.6.2012 14:46 Page 11

Committees

12

General Information

International Society on Thrombosis and HaemostasisThe International Society on Thrombosis & Haemo-stasis (ISTH) is the leading worldwide organizationdedicated to the advancement of the understanding,prevention, diagnosis and treatment of thrombotic andbleeding disorders.ISTH is a global professional individual membershiporganization with over 3,000 members in more than 80countries around the world. Among its highly regardedactivities and initiatives are education and standard-ization programmes, research activities, meetings andconferences, peer-reviewed publications and expertcommittees.

ISTH offers 3 categories of membership:• Regular: for active researchers, educators and

clinicians in the field• Associate: for students, trainees, research staff,

post-doctoral fellows as well as allied health profes-sionals

• Reach-the-World: for researchers, educators andclinicians in non-industrialized countries

Membership benefits include:• A network of over 3,000 members in more than 80

countries• Priority registration and discounted fees for ISTH

meetings and congresses• Complimentary print and online subscription to

ISTH’s Journal of Thrombosis and Haemostasis• Access to the ISTH members-only online resour-

ces, including educational materials, e-learning andmembership directory

• Exclusive access and/or reduced fees for othereducational activities, Programmes and publications

• The quarterly ISTH Newsletter and regular e-updates

• The right to nominate, elect and serve on ISTHcommittees. For more information, please visitwww.isth.org

Contact InformationFor general information about the Society, pleasecontact ISTH at:

ISTH Headquarters610 Jones Ferry Road Suite 205Carrboro, NC 27510USAPhone: +1 919 929-3807Fax: +1 919 929-3935Email: [email protected]

For membership related questions, please contactISTH at Email: [email protected] For educational enquiries, please contact ISTH at:[email protected]

Meeting SecretariatSSC 2012 c/o MCI Suisse SA - Rue de Lyon 751211 Geneva 13 - SwitzerlandPhone: +41 22 33 99 588Fax: +41 22 33 99 631Email: [email protected]

AccommodationThe Mersey Partnership Conference BureauPhone: +44 (0) 151 237 3938Fax: +44 (0) 151 227 2621Email: [email protected] help desk for participants who have booked theiraccommodation in advance via The Mersey Partner-ship Conference Bureau is located in the registrationarea. The staff at this counter will also help you to findand book rooms, if required.

ISTH 2012 11.6.2012 14:46 Page 12

Gen

eral

Info

rmat

ion

Committees

13

General Information

Annual Business Meeting of the SSCSSaattuurrddaayy,, 3300 JJuunnee 22001122,, RRoooomm 1122 oonn LLeevveell 11 aatt tthheeCCoonnffeerreennccee CCeennttrreeThis business meeting is open to all interestedparticipants. The agenda includes brief oral reports ofthe Scientific Subcommittees’ sessions, action onreports and recommendations resulting from theSubcommittees, reports of Working Parties, liaisonactivities, and collaborative work. For furtherinformation, contact the ISTH Secretariat at Room 11Bon Level 1 at the Conference Centre.

Banks & Automatic Teller Machines (ATM)A Barclays cash machine is situated on site, on theriverside of the building. Walk down the steps beforethe exit and the machine is on the left; there is nocharge for using it.

Car ParkingThe Liverpool Waterfront Car Park is sign-posted'Waterfront' on the city wide 'available spaces' signage.

ClimateIn late June, average temperatures in Liverpool varybetween 18 and 23 degrees Celsius (approximately 64- 73 degrees Farenheit). There is always a chance foroccasional rain.

CloakroomA cloakroom facility will be provided by the ACCConference Centre. Items can be left in the cloakroomat a price of £1.00 (GBP) per item.

Coffee BreaksComplimentary coffee and tea will be served in theExhibition Area on the lower ground floor. Coffeebreaks are scheduled daily (10:00-10:30 and 16:00-16:30) from 27- 29 June 2012 and in the morning onlyon the 30 June.

Conference VenueBT Convention Centre (ACC)Kings DockLiverpool Waterfront, L3 4FP UKPhone: +44 151 475 8888Email: [email protected]: www.btconventioncentre.com

Continuing Medical EducationEEAACCCCMMEEThe 58th Scientific and StandardizationCommittee (SSC) meeting of the Inter-national Society on Thrombosis andHaemostasis (ISTH) Liverpool, United Kingdom (27-30 June 2012) has been accredited by the EuropeanAccreditation Council for Continuing Medical Edu-cation (EACCME) to provide the following CME activityfor medical specialists.The 58th Scientific and Standardization Committee(SSC) meeting of the International Society on Throm-bosis and Haemostasis (ISTH) is designated for amaximum of, or up to 20 European CME credits(ECMEC). Each medical specialist should claim onlythose credits that he/she actually spent in theeducational activity. The EACCME is an institution ofthe European Union of Medical Specialists (UEMS),www.uems.net. Through an agreement between theEuropean Union of Medical Specialists and theAmerican Medical Association, physicians mayconvert EACCME credits to an equivalent number ofAMA PRA Category 1 Credits™. Information on theprocess to convert EACCME credit to AMA credit canbe found at www.ama-assn.org/go/internationalcme.Live educational activities, occurring outside of Canada,recognized by the UEMS-EACCME for ECMEC creditsare deemed to be Accredited Group LearningActivities (Section 1) as defined by the Maintenance ofCertification Program of The Royal College of Physi-cians and Surgeons of Canada.

ISTH 2012 11.6.2012 14:46 Page 13

Committees

14

General Information

EEHHAA

The European Hematology Association has accreditedthe 58th Scientific and Standardization Committee(SSC) meeting of the International Society onThrombosis and Haemostasis (ISTH) Liverpool,United Kingdom (27- 30 June 2012) with 16 creditpoints. All participants may print a European Hema-tology Association CME System approved CMEcertificate indicating the number of EHA-CME CreditPoints awarded, directly from the system on the CMEsection of the EHA website at www.ehaweb.org. AnEHA-CME Credit Point account will be used by allinterested participants. Participants will receive a loginafter the meeting which will allow them to complete theonline evaluation in order to obtain the EHA credits.

BBSSHHTT

The British Society for Haemostasis & Thrombosis(BSHT) has accredited the 58th Scientific andStandardization Committee (SSC) meeting of theInternational Society on Thrombosis and Haemostasis(ISTH) Liverpool, United Kingdom (27-30 June 2012)with 16 credit hours as follows:• Wednesday, 27 June: Educational Programme:

08:30-12.00 [3.5 hours] and 13:15-15:00: [1.75 hours] followed by Special Symposia: 15.30-17:30 [2.00 hours]

• Thursday, 28 June:Plenary Programme: 08:45-12:00 [2.75 hours]

• Friday, 29 June:Hot Topics Programme: 14:00-17:00 [3.00 hours]followed by Poster discussion: 17:30-1900 [2.00 hours]

• Saturday, 30 June:Technical Programme: 08:00-09:00 [1.00 hour]

Each medical specialist should claim only those hoursof credit that she/he actually spends in the educationalactivity.

Certificate of AttendanceCertificates of attendance will be available from 14:00on Friday, 29 June 2012 in the registration area.Participants will need to scan the bar-code on theirbadge in order to print out their certificate.

Cyber CaféA wired internet zone is locatedwithin the exhibition and isgenerously sponsored by Inspi-ration Biopharmaceuticals, Inc.

Delegate Bags You will receive your delegate bag at the registrationarea. No replacements for lost bags are available.

ElectricityThe UK, Scotland and Republic of Ireland use a 13amp plug with 3 rectangular pins which is different tothe rest of Europe. As such, an adaptor may be neededdepending on the country you are coming from.

ePostersePosters are an electronic version of the traditionalscientific Posters. The objective of the ePosters is toreach an audience beyond that of a traditional postersession. Attendees can view all posters during thededicated ePoster session, throughout the meeting atdesignated touch-screen stations, or on their personalcomputer to interact with the poster author. From asingle location attendees may browse posters on topicor keyword, provide comments, contact the authordirectly with questions or download the poster for laterviewing (when allowed by presenter). Authors alsohave the option to keep their posters online after themeeting in Liverpool to reach even the non-attendeeISTH members.

ISTH 2012 11.6.2012 14:46 Page 14

Gen

eral

Info

rmat

ion

Committees

15

General Information

The ePoster stations in the Exhibition Hall providelarge touch-screens for easy reading and browsing. Anew innovation for SSC meetings; kindly see for your-self the future of poster presentation!

Exhibition hours:Wednesday, 27 June 2012 10.00 - 17.00Thursday, 28 June 2012 10.00 - 17.00Friday, 29 June 2012 10:00 - 19.00Saturday, 30 June 2012 10.00 - 13.00

Important Local Numbers:999 for fire, police, ambulance or coastguard services.Emergency calls are free from pay phones - you will beasked which service you require by the operator.

Industry ExhibitionThe SSC 2012 Industry Exhibition is located on thelower ground level. Please see details on pages 97-110.

Insurance and LiabilityParticipants have been advised to obtain adequateinsurance coverage for travel, health and accidentsbefore departure from their countries of residence.ISTH and MCI as organisers cannot accept respon-sibility for personal injuries, or loss of, or damage to,private property belonging to the conference partici-pants and accompanying persons.

ISTH SecretariatThe ISTH Secretariat is located at Room 11B on Level1 of the Conference Centre. It is open during the samehours as the Registration Desks (see “RegistrationDesk” for opening hours).

LanguageThe Official language of the meeting is English. Thereis no simultaneous translation service provided.

“Liverpool Now” Reception (supported by ACC Liverpool) & “...the Beat goes on”Social EventsOn Wednesday, 27 June 2012, eli-gible delegates are invited to attend areception which will be held on thelower ground level and +1 level of theConference Centre. This reception isfree to all eligible participants from 18.00-19.30. Thebeat then continues as of 20.00 at the PanAm, a venuewithin walking distance from the Conference Centre,where participants will experience an outstandingevening of Beatles music, dance and fun. Attendanceto this 2nd part of the evening requires the payment ofa fee of £25 per person. For additional tickets, pleasecontact the Registration Desk located near theentrance of the Conference Centre. As the venue iscentrally located, no transfers will be provided.DDrreessss ccooddee:: CCaassuuaall

Local CurrencyThe official currency in Liverpool is the British Pound(£). Conversion rates as of 1 June 2012:1£ = 1,24 EUR1£ = 1,54 USD

LunchesPlease note that lunch is not included in the delegateregistration fee for SSC 2012. Participants can pur-chase their lunch on-site at the ACC from one of thefood outlets available. Please note that lunch may beprovided at some lunch-time Satellite Symposia.

Mobile TelephonesAs a courtesy to speakers and other participants, allmobile phones and pagers must be switched off whenattending sessions or symposia.

ISTH 2012 11.6.2012 14:46 Page 15

Committees

16

General Information

Name Badges Participants will receive their name badges whencollecting their meeting documents on site. You arekindly requested to wear your name badge during allmeeting events, including the Liverpool Now Recep-tion. Please note that admission to scientific sessionsand the exhibition is restricted to participants wearingtheir badges.

Registration DeskThe registration desk is located on the ground floor,next to the main entrance of the venue.OOppeenniinngg HHoouurrss::

Tuesday 26 June 2012: 12.00 - 19.00Wednesday 27 June 2012 07.00 - 18.00Thursday 28 June 2012 07.30 - 18.30Friday 29 June 2012 07.30 - 18.00Saturday 30 June 2012 07.30 - 13.00

RestaurantsLooking for a Restaurant in Liverpool? The restaurantscene in Liverpool has never been more lively anddiverse with a fantastic mix to suit all taste buds. Go to:www.liverpool.com/listings/restaurants.html for moreinformation.

ShoppingLiverpool shopping is world class, which is only fittingfor a city that can shop till it drops. Shoppers are spoiltfor choice between gleaming new city-centre shoppingcentres to boutique arcades, bohemian streets andfarmers markets.Liverpool ONE, right in the heart of the city, is the shinynew designer Liverpool shopping centre that is hometo more than 160 famous high street names, from JohnLewis to Apple, Topshop to Cath Kidston

SmokingPlease note that this is a non-smoking meeting.Smoking is neither permitted in or outside the meetinghalls nor in the exhibition area.

TransportationNo transportation is provided during the conferencesince the Conference Venue is very centrally locatedand most hotels are within walking distance. If youneed to arrange for a transfer to the airport, pleaserefer to the “Information” menu item on the conferencewebsite: www.ssc2012.org where you will find moreinformation under “Transportation”.

Speaker Ready Room RRoooomm 1111AA ((LLeevveell ++11))Speakers are asked to upload their formatted pre-sentations (PowerPoint presentations) at the SpeakerReady Room at least 2 hours before their session orthe day before for an early morning presentation. Allconference rooms feature state-of-the-art technicalequipment. Audiovisual material will be available foryour presentation.OOppeenniinngg HHoouurrss::

Wednesday 27 June 2012 07.30 - 18.00Thursday 28 June 2012 07.30 - 18.30Friday 29 June 2012 07.30 - 18.00Saturday 30 June 2012 07.30 - 13.00

Wireless InternetWireless internet will be available on-site. Eachdelegate will receive a username and passwordwith their badge. This wire-less connection is generouslysponsored by Inspiration Bio-pharmaceuticals, Inc.

ISTH 2012 11.6.2012 14:46 Page 16

Abo

ut L

iver

pool

Committees

17

About Liverpool

LiverpoolLiverpool is one of Europe’s most vibrant andcosmopolitan cities offering both European Capital ofCulture and UNESCO World Heritage Site Status. Aswell as its worldwide reputation for music (Beatles andCavern Club), sport (Liverpool F.C. and Everton F.C.)and humour, it has an abundance of architecturaltreasures and more museums and galleries than anyother UK city outside London, including; WorldMuseum; Maritime Museum; International SlaveryMuseum; Tate Modern Art Gallery; Walker Art Gallery;and Lady Lever Art Gallery. Public art is right on ourdoorsteps and our rich cultural heritage is alsoexemplified by magnificent civic buildings, two iconicAnglican and Roman Catholic cathedrals as well asthe oldest Chinatown in Europe. A huge regenerationProgramme has transformed the city with one of themajor development projects, Liverpool One (awardwinning retail, leisure and residential scheme) beingthe largest of its kind in Europe. Liverpool is a greatcity from which to explore the surrounding region,which offers miles of beautiful coastline, Champion-ship links golf courses, ancient cities like Chester andthe stunning scenery of North Wales and the LakeDistrict.

Liverpool has long been regarded as the friendliestdestination for delegates and visitors, a fact which isbacked by numerous accolades including the citywinning Condé Nast Traveller UK’s FriendliestDestination in 2010 and 2011, Group Leisuremagazine’s Best UK City 2011, and Britain’s BestNightlife Destination 2011 awarded by TripAdvisor.

Liverpool is set to become even more affable with itsDelegate Goodnight campaign.

The Goodnight campaign will complete the experienceof delegates in the city, providing recommendations forevent spaces with panoramic views, restaurants andbars in which to wind down after a conference or hostgala dinners, the best accommodation, as well asattractions from which to view the city’s skyline andsunsets as part of a social itinerary. Together, theinnovative Delegate Welcome and Goodnight sche-mes will provide all delegates with exclusive discountsfor Virgin Trains’ high speed service from London toLiverpool with on board welcome announcements,signage and flags at entry points into the city, and afree dedicated accommodation booking service.

ISTH 2012 11.6.2012 14:46 Page 17

ISTH 2012 11.6.2012 14:46 Page 18

ISTH 2012 11.6.2012 14:46 Page 19

Programme at a Glance

20

ISTH 2012 11.6.2012 14:46 Page 20

ISTH 2012 11.6.2012 14:46 Page 21

Programme Overview

22

Tuesday, 26 June 2012

TTrraaiinneeeess’’ FFrr iinnggee MMeeeettiinngg RRoooomm 44AA

How to start a career in coagulation

08:30 - 13:00 Trainees in research Ian Peake, Gill Lowe

14:15 - 18:00 Practical / on call issues in haemostasis John Pasi, David Keelingand thrombosis

18:00 - 19:00 SSC 2012 Trainees’ Welcome Drinks Reception

ISTH 2012 11.6.2012 14:46 Page 22

Tues

day

23

Detailed Programme Tuesday, 26 June 2012

TTrraaiinneeeess’’ FFrriinnggee MMeeeettiinngg (supported by the British Society for Haemostasis and Thrombosis) 0088::4455 -- 1177::3300

HHooww ttoo ssttaarrtt aa CCaarreeeerr iinn CCooaagguullaattiioonn RRoooomm 44AA

Chairpersons: Ian Peake, Gill Lowe, John Pasi, David Keeling

Trainees in research - part IIan PeakeIntroduction Gill Lowe 09:25 - 09:30A beginners guide to laboratory coagulationSteve Kitchen (Sheffield) 09:30 - 10:00Setting up research studies / A beginners guide to ethicsGill Lowe (Birmingham) 10:00 - 10:30Research opportunities in non malignant haematology in the UKJohn Pasi (London) 10:30 - 11:00

TTeeaa // CCooffffeeee BBrreeaakk RRoooomm 44BB

Trainees in research - part IIGill LoweHow to write a research grant / get a research fellowshipSam Machin (London) 11:20 - 11:50How to get a paper published Steve Watson (Birmingham) 11:50 - 12:20Planning a research careerMike Laffan (London) 12:20 - 12:50A historical perspective in researching von Willebrand’s disease - highs and lowsIan Peake (Sheffield) 12:50 - 13:20

ISTH 2012 11.6.2012 14:46 Page 23

Detailed Programme Tuesday, 26 June 2012

Practical / on call issues in haemostasis and thrombosis - part IJohn PasiClinical issues from abnormal coagulation testsDavid Keeling (Oxford) 14:15 - 14:45Clinical and laboratory Issues in thrombophiliaTrevor Baglin (Cambridge) 14:45 - 15:15On call issues in obstetric haematology Beverly Hunt (London) 15:15 - 15:45

TTeeaa // CCooffffeeee BBrreeaakk RRoooomm 44BB

Practical / on call issues in haemostasis and thrombosis - part IIDavid KeelingOn call transfusion Issues with a focus on NAITMike Murphy (Oxford) 16:15 - 16:45On call issues in inherited bleeding disordersMike Markis (Sheffield) 16:45 - 17:15Issues in diagnosis and management of antiphospholipid syndromeMike Greaves (Aberdeen) 17:15 - 17:45

SSSSCC 22001122 TTrraaiinneeeess’’ WWeellccoommee DDrriinnkkss RReecceeppttiioonn 1188::0000 -- 1199::3300

Upper Galleria (sponsored by the Faculty of Health & Life Sciences, University of Liverpool)

24

ISTH 2012 11.6.2012 14:46 Page 24

Wed

nesd

ay

Programme Overview

25

Wednesday, 27 June 2012

Educational Session

Time Title Chairpersons

08:30 - 12:00 Thrombosis & haemostasis issues in cancer (Hall 2E) Agnes Lee & Jeffrey Zwicker

Thrombosis & haemostasis issues in critical infection and trauma (Hall 2F) Jecko Thachil & Hideo Wada

Thrombosis & haemostasis Issues in women’s health (Hall 2L) Sabine Eichinger & Flora Peyvandi

Thrombosis & haemostasis Issues in child health (Hall 2N) Anthony Chan & Paul Monagle

LLuunncchh BBrreeaakk -- OOnn YYoouurr OOwwnn

13:15 - 15:00 Anti-phospholipid syndrome (Hall 2E) Thomas Ortel

Point-of-care & personalised treatment (Hall 2F) Steven Kitchen

Thrombotic microangiopathies (Hall 2L) Paul Harrison & Changgeng Ruan

Inherited bleeding disorders (Hall 2N) Marco Cattaneo

15:30 - 17:30 The Mike Nesheim “Meet the Expert” Sessions Halls 2E, 2F, 2L, 2N

18:00 - 19:30 “Liverpool Now” Reception (supported by ACC Liverpool)

20:00 - 24:00 “... and the Beat goes on”

ISTH 2012 11.6.2012 14:46 Page 25

Detailed Programme Wednesday, 27 June 2012

26

EEdduuccaattiioonnaall SSeessssiioonn 0088::3300 -- 1122::0000

TThhrroommbboossiiss && HHaaeemmoossttaassiiss IIssssuueess iinn CCaanncceerr HHaallll 22EE

Chairpersons: Agnes Lee (Canada), Jeffrey Zwicker (USA)

Overview with learning objectivesAgnes Lee (Canada) 08:30 - 08:45

Session one: State-of-the-art updatesJeffrey Zwicker (USA)Complexities in tissue factor measurement and standardizationNigel Key (USA) 08:45 - 09:15Roles of CRP and D-dimer in diagnosis, treatment and prognosisIngrid Pabinger (Austria) 09:15 - 09:45Screening for occult malignancy: where does the evidence stand?Marc Carrier (Canada) 09:45 - 10:15

TTeeaa // CCooffffeeee BBrreeaakk EExxhhiibbiittiioonn hhaallll,, lloowweerr lleevveell

Session two: Controversies & debateAgnes Lee (Canada)

Debate: incidental VTE: to treat or not to treatYes: Howard Liebman (USA) - No: Menno Huisman (The Netherlands) 10:30 - 11:15Debate: outpatient thrombo-prophylaxis in cancer patientsYes: Lord Ajay Kakkar (United Kingdom) - No: Alok Khorana (USA) 11:15 - 12:00

TThhrroommbboossiiss && HHaaeemmoossttaassiiss IIssssuueess iinn CCrriittiiccaall IInnffeeccttiioonn aanndd TTrraauummaa HHaallll 22FF

Chairpersons: Jecko Thachil (United Kingdom), Hideo Wada (Japan)

Overview with learning objectivesJecko Thachil (United Kingdom), Hideo Wada (Japan) 08:30 - 08:45

Session one: Day-to-day dilemmasHow I manage thrombocytopenia in critically ill patientsAndreas Greinacher (Germany) 08:45 09:15The relationship between inflammation and thrombosis in critically ill patientsHugo Ten Cate (The Netherlands) 09:15 - 09:45How I manage peri-operative coagulation issuesSibylle Kozek-Langenecker (Austria) 09:45 - 10:15

ISTH 2012 11.6.2012 14:46 Page 26

Wed

nesd

ay


27


Session two: Emerging translationAcute Coagulopathy of Trauma: Relevance of the Protein C pathwayKarim Brohi (United Kingdom) 10:30 - 11:00Malaria and thrombosis: relevance of vWF & plateletsAlister Craig (United Kingdom) 11:00 - 11:30Current persepctives in the management of atypical haemolytic uremic syndromeTim Goodship (United Kingdom) 11:30 - 12:00

TThhrroommbboossiiss && HHaaeemmoossttaassiiss IIssssuueess iinn WWoommeenn’’ss HHeeaalltthh HHaallll 22LL

Chairperons: Sabine Eichinger (Austria), Flora Peyvandi (Italy)

Overview with learning objectivesSabine Eichinger (Austria), Flora Peyvandi (Italy)

Session one: Thrombotic tendencyHow I manage recurrent miscarriage in relation to thrombophiliaIan Greer (United Kingdom) 08:45 - 09:15

Shirley Johnson Memorial LectureHow I manage women with mechanical heart valves during pregnancyClaire McLintock (New Zealand) 09:15 - 09:45

How I advise contraception in relation to thrombophiliaJacqueline Conard (France) 09:45 - 10:15


ISTH 2012 11.6.2012 14:46 Page 27


28

Session two: Bleeding tendencyHow I manage ITP in pregnancyDrew Provan (United Kingdom) 10:30 - 11:00How I manage and coordinate care of the haemophilia carrier in pregnancyClaude Negrier (France) 11:00 - 11:30How I treat menorrhagia in women with bleeding disordersRezan Abdul-Kadir (United Kingdom) 11:30 - 12:00

TThhrroommbboossiiss && HHaaeemmoossttaassiiss IIssssuueess iinn CChhiilldd HHeeaalltthh HHaallll 22NN

Chairpersons: Anthony Chan (Canada), Paul Monagle (Australia)

Overview with learning objectivesAnthony Chan (Canada), Paul Monagle (Australia)

Session one: State-of-the-art updatesCan childhood stroke be prevented? Fenalla Kirkham (United Kingdom) 08:45 - 09:15Management of post-thrombotic syndrome in childrenShoshana Revel-Vilk (Israel) 09:15 - 09:45Bleeding in children with major organ failureChristine MaCartney (United Kingdom) 09:45 - 10:15


Session two: Controversies & debateWill the newer anticoagulants still require monitoring? Adults Trevor Baglin (United Kingdom) - Children Christoph Male (Austria) 10:30 - 11:00Debate: Thrombophilia testing in children, with a few specific exceptions, is a waste of timeYes Suzan Williams (Canada) - No Elizabeth Chalmers (United Kingdom) 11:00 - 11:30Chronic severe ITP in children. Rituximab should be offered before splenectomy Yes Paula Bolton-Maggs (United Kingdom) No Jenny Despotovic (USA) 11:30 - 12:00

ISTH 2012 11.6.2012 14:46 Page 28

Wed

nesd

ay


29

EEdduuccaattiioonnaall SSeessssiioonn 1133::1155 -- 1155::0000

AAnnttii--PPhhoosspphhoolliippiidd SSyynnddrroommee ((AAPPSS)) HHaallll 22EE

Chairperson: Thomas Ortel (USA)

Overview with learning objectives 13:15 - 13:30Thomas Ortel (USA)

Session: from laboratory to patientNew mechanistic understanding in APSPG de Groot (The Netherlands) 13:30 - 14:00Guidance in laboratory testing to diagnose APSKatrien Devreese (Belgium) 14:00 - 14:30Novel therapies in addition to anticoagulation for APSMunther Khamashta (United Kingdom) 14:30 - 15:00

PPooiinntt--ooff--CCaarree && PPeerrssoonnaalliisseedd TTrreeaattmmeenntt HHaallll 22FF

Chairperson: Steven Kitchen (United Kingdom)

Overview with learning objectivesSteven Kitchen (United Kingdom) 13:15 - 13:30

Session: from laboratory to patientAssessing quality in point-of-care haemostasis testingDianne Kitchen (United Kingdom) 13:30 - 14:00Point-of-care global haemostasis testing in operating theatresAlastair Nimmo (United Kingdom) 14:00 - 14:30Pharmacogenetics of warfarin in personalising treatment at point-of-careMunir Pirmohamed (United Kingdom) 14:30 - 15:00

ISTH 2012 11.6.2012 14:46 Page 29


30

TThhrroommbboottiicc MMiiccrrooaannggiiooppaatthhiieess HHaallll 22LL

Chairpersons: Paul Harrison (United Kingdom), Changgeng Ruan (China)

Overview with learning objectivesPaul Harrison (United Kingdom), Changgeng Ruan (China) 13:15 - 13:30

Session: from laboratory to patientUnderstanding vWF-ADAMTS13 in vivo Karen Vanhoorelbeke (Belgium) 13:30 - 14:00Diagnosing and treating Thrombotic Thrombocytopaenic Purpura (TTP)Marie Scully (United Kingdom) 14:00 - 14:30Translational approaches to TTPFlora Peyvandi (Italy) 14:30 - 15:00

IInnhheerriitteedd BBlleeeeddiinngg DDiissoorrddeerrss HHaallll 22NN

Chairperson: Marco Cattaneo (Italy)

Overview with learning objectivesMarco Cattaneo (Italy)

Session: from laboratory to patientAdvances in diagnosing congenital platelet disordersAlan Nurden (France) 13:30 - 14:00Safety, efficacy issues with haemophilia factor concentrates and the emerging treatmentsMike Makris (United Kingdom) 14:00 - 14:30New considerations and treatment paradigms for von Willebrand diseaseDavid Lillicrap (Canada) 14:30 - 15:00


ISTH 2012 11.6.2012 14:46 Page 30

Wed

nesd

ay


31

MMeeeett tthhee EExxppeerrttss 1155::3300 -- 1166::3300 // 1166::3300 -- 1177::3300

TThhee MMiikkee NNeesshheeiimm ““MMeeeett tthhee EExxppeerrtt ”” SSeessssiioonnss

Chairpersons: Johanthan Foley (USA), Hugh Hoogendoorn (Canada), Paul Kim (Canada), Fletcher B. Taylor (USA),Paula Tracy (USA), Yotis Senis (United Kingdom), Cheng Hock Toh (United Kingdom), David Lillicrap (Canada)

Protein C pathway Hall 2EHugh Hoogendoorn (Canada)Björn Dahlbäck (Sweden) 15:30 - 16:30Venous thromboembolism Hall 2FFletcher B. Taylor (USA)Sam Schulman (Canada) 15:30 - 16:30Atrial fibrillation & arterial thrombotic disease Hall 2NPaul Kim (Canada)Gregory Lip (United Kingdom) 15:30 - 16:30Fibrinolysis Hall 2LJohanthan Foley (USA)Nuala Booth (United Kingdom) 15:30 - 16:30Von Willebrand disease Hall 2David Lillicrap (Canada)Robert Montgomery (USA) 16:30 - 17:30Platelets Hall 2FYotis Senis (United Kingdom)Steve Watson (United Kingdom) 16:30 - 17:30Haemophilia Hall 2NCheng Hock Toh (United Kingdom)Pier MannucciItaly (Italy) 16:30 - 17:30Tissue factor Hall 2LPaula Tracy (USA)Bjarne O/ sterud (Norway) 16:30 - 17:30

SSC 2012 “Liverpool Now” Reception 18:00 - 19:30

Upper and Lower Galleria (supported by ACC Liverpool)

“... and the Beat goes on” 20:00 - 24:00

PanAm - Albert Docks (tickets available for purchase from registration area)

ISTH 2012 11.6.2012 14:46 Page 31

ISTH 2012 11.6.2012 14:46 Page 32

Thur

sday

Programme Overview

33

Thursday, 28 June 2012Presidential Plenary: SSC in Translation AAuuddiittoorriiuumm 11

Time Title Speaker08:30 - 09:00 Relevance of the SSC to translational medicine Cheng-Hock Toh 09:00 - 09:30 Marion Barnhart Memorial Lecture

Translational medicine in thrombosis and haemostasis Garret FitzGerald09:30 - 10:00 Arthur Bloom Memorial Lecture

From gene to therapy I: Haemophilia Edward Tuddenham10:00 - 10:30 Pia Glas Greenwalt Memorial Lecture

From gene to therapy II: Thrombocytopaenia Kenneth Kaushansky11:00 - 11:30 Collen Foundation - Life Sciences Research Partners Award

Emerging translation I: Complement & coagulation Markus Huber-Lang 11:30 - 12:00 Kenneth M. Brinkhouse Memorial Lecture

Emerging translation II: NETs & thrombosis Denisa Wagner

Satellite SymposiaTime Company Title12:15 - 13: 45 Novo Nordisk Pharmacokinetics in haemophilia: guiding patient care (Hall 2E)

Pfizer Clinical leadership in haemophilia - setting new standards? (Hall 2F)Sanofi VTE prophylaxis in 2012: where we are and where we are going (Hall 2L)

SSC Session

Time Title Chairpersons14:00 - 15:30 Pro-thrombotic markers and global hemostatic tests (Auditorium1) Anna Falanga & David Lillicrap15:30 - 18:00 Disseminated Intravascular Coagulation (DIC) (Hall 2L) Hideo Wada

Factor XI and the contact system (Hall 2F) Thomas RennePredictive variables in cardiovascular disease (Room 3A) James DouketisFibrinolysis (Room 3B) Ann GilsPlasma coagulation inhibitors (Room 12) Steven KitchenISTH BAT standing committee public session (Hall 2E) Francesco Rodeghiero

Satellite Symposia

Time Company Title18:15 - 19:45 Bayer HealthCare Novel oral anticoagulant for the management of venous (Hall 2E)

thromboembolism - a practical consideration

SSyymmppoossiiuumm oonn WWiiddeenniinngg PPaarrttiicciippaattiioonn

18:15 - 19:45 University of Liverpool Little big medicine (Hall 2N)

ISTH 2012 11.6.2012 14:46 Page 33

Detailed Programme Thursday, 28 June 2012

34

PPrreessiiddeennttiiaall PPlleennaarryy 0088::3300 -- 1122::0000

PPrreessiiddeennttiiaall PPlleennaarryy:: SSSSCC iinn TTrraannssllaattiioonn AAuuddiittoorriiuumm 11

Chairpersons: Cheng Hock Toh (United Kingdom), Henri Bounameaux (Switzerland)

Welcome and introduction 08:30 - 08:45

Relevance of the SSC to translational medicineCheng-Hock Toh (United Kingdom) 08:45 - 09:00

Marion Barnhart Memorial LectureTranslational medicine in thrombosis and haemostasisGarret FitzGerald (USA) 09:00 - 09:30

Arthur Bloom Memorial LectureFrom gene to therapy I: haemophiliaEdward Tuddenham (United Kingdom) 09:30 - 10:00

Pia Glas Greenwalt Memorial LectureFrom gene to therapy II: thrombocytopaeniaKenneth Kaushansky (USA) 10:00 - 10:30


Collen Foundation - Life Sciences Research Partners AwardEmerging translation I: complement & coagulationMarkus Huber-Lang (Germany) 11:00 - 11:30

Kenneth M. Brinkhouse Memorial LectureEmerging translation II: NETs & thrombosisDenisa Wagner (USA) 11:30 - 12:00

ISTH 2012 11.6.2012 14:46 Page 34

Thur

sday


35

SSaatteelllliittee SSyymmppoossiiaa 1122::1155 -- 1133::4455

NNoovvoo NNoorrddiisskk HHaallll 22EEChairperons: Steven Pipe (USA), Stephanie Seremetis (Denmark)

Pharmacokinetics in haemophilia: guiding patient careWelcome and introduction Steven Pipe (USA) Stephanie Seremetis (Denmark) 12:15 - 12:20Assessment of recombinant glycoPEGylated FVIII (N8-GP): pathfinderTM1 - a first human dose trial Andreas Tiede (Germany) 12:20 - 12:40Characterising the PK profile of turoctocog alfa: results from the GUARDIANTM trialsCamilla Buöen Stenmo (Denmark) 12:40 - 13:00Exploring the clinical application of recombinant glycoPEGylated FIX (N9-GP): population PK modelling and simulationsPeter Collins (United Kingdom) 13:00 - 13:20Panel discussionAll 13:20 - 13:35Concluding remarksSteven Pipe (USA) 13:35 - 13:45

PPffiizzeerr HHaallll 22FFChairperson: David Keeling (United Kingdom)

Clinical leadership in haemophilia - setting new standards?Welcome and introduction David Keeling (United Kingdom) 12:15 - 12:20Specialised services in haemophilia - a national policy perspectiveAlison Rylands (United Kingdom) 12:20 - 12:35 Developing an evidence base to support best practiceGerry Dolan (United Kingdom) 12:35 - 12:50 Defining clinical outcomes - optimising existing resourcesJohn Pasi (United Kingdom) 12:50 - 13:05 Delivering best clinical practice through partnershipsSusan Mather (United Kingdom) 13:05 - 13:20 Panel discussionAll 13:20 - 13:40Concluding remarks David Keeling (United Kingdom) 13:40 - 13:45

ISTH 2012 11.6.2012 14:46 Page 35


36

SSaannooffii HHaallll 22LL

Chairpersons: Job Harenberg (Germany), Lord Kakkar (United Kingdom)

VTE prophylaxis in 2012: where we are and where we are goingWelcome and introductionJob Harenberg (Germany) 12:15 - 12:20New understanding of heparin propertiesLudovic Drouet (France) 12:20 - 12:35Anticoagulants: from clinical trials to real life Russell D. Hull (Canada) 12:35 - 12:50Anticoagulants in medical prophylaxis: where do we stand?Roger D. Yusen (USA) 12:50 - 13:05Biosimilar LMWHs: regulatory perspectives Job Harenberg (Germany) 13:05 - 13:20Anticoagulation: challenges in the coming years Lord Kakkar (United Kingdom) 13:20 - 13:35Questions and answers and closing remarks Lord Kakkar (United Kingdom) 13:35 - 13:45

SSSSCC SSeessssiioonnss 1144::0000-- 1155::3300

PPrroo--tthhrroommbboottiicc MMaarrkkeerrss aanndd GGlloobbaall HHeemmoossttaattiicc TTeessttss AAuuddiittoorriiuumm 11

Chairpersons: Anna Falanga (Italy), David Lillicrap (Canada)

Part IAdvantages and limitations of clot-lysis assaysJonathan Foley (USA) 14:05 - 14:20Elevated fibrin related markers in patients with malignant diseases associated with DIC or DVT Hideo Wada (Japan) 14:20 - 14:35Overall discussion part IAnna Falanga (Italy), David Lillicrap (Canada) 14:35 - 14:45

ISTH 2012 11.6.2012 14:46 Page 36

Thur

sday


37

Part IIThe use of global coagulation assays to evaluate: treatments with LMWHs and VKA in patients with acquired hypercoagulable state Grigoris Gerotziafas (France) 14:45 - 15:00The use of global coagulation assays to evaluate: treatments with by-passing agents in haemophiliaArmando Tripodi (Italy), Elena Santagostino (Italy) 15:00 - 15:15Overall discussion part IIAnna Falanga (Italy), David Lillicrap (Canada) 15:15 - 15:30

SSSSCC SSeessssiioonnss 1155::3300-- 1188::0000

DDiisssseemmiinnaatteedd IInnttrraavvaassccuullaarr CCooaagguullaattiioonn ((DDIICC)) HHaallll 22LL

Chairpersons: Hideo Wada (Japan), Satoshi Gando (Japan), Hyun Kyung Kim (Republic of Korea), JornNielsen (Denmark), Jecko Thachil (United Kingdom)

Fibrin related markers Carl-Erik Dempfle (Germany) 15:30 - 15:55Treatment of DIC with rh thrombomodulinYun Mimuro, Hoyu Takahashi, Isao Kitajima, Hajime Tsuji, Yutaka Eguchi, Tadashi Matsushita, Tatsuhiko Kuroda Yoichi Sakata (Japan) 15:55 - 16:20Chairman’s report 16:20 - 16:30DIC and COT/ACOTS in traumaSatoshi Gando (Japan) 16:30 - 16:45DIC and thrombotic microangiopathy: what are the differences and the shared features? Shinichiro Kurosawa (USA) 16:45 - 17:00Fibrinogen, pathological coagulation and DIC’?Jecko Thachil (United Kingdom) 17:00 - 17:15Topics on diagnosis of DICJorn Nielsen (Denmark) 17:15 - 17:30The prognostic value of thrombomodulin expression on monocytes subset?Hyun Kyung Kim (Republic of Korea) 17:30 - 17:45DAMPs/PAMOs in DICIkuro Maruyama (Japan) 17:45 - 18:00

ISTH 2012 11.6.2012 14:46 Page 37


38

FFaaccttoorr XXII aanndd tthhee CCoonnttaacctt SSyysstteemm HHaallll 22FF

Chairpersons: Thomas Renne (Sweden), Jonas Emsley (United Kingdom), David Gailani (USA), Keith McCrae(USA), Joost Meijers (The Netherlands), Christine Mannhalter (Austria), Ophira Salomon (Israel)

Bleeding in FXI deficiencyFactor XI -setting the scenePaula Bolton-Maggs (United Kingdom) 15:30 - 15:50

Genetics and genomicsGenotypic variations of complement factors and phenotypic effectsChristine Mannhalter (Austria) 15:50 - 16:05Epidemiology and genetics of aPTT and contact factorsGordon Lowe (United Kingdom) 16:05 - 16:20


Activation of factor XIIStructure of the FXII protease domainJonas Emsley (United Kingdom) 16:30 - 16:45Functional insights into FXII contact activationCoen Maas (The Netherlands) 16:45 - 17:00

Novel functions of FXI and the contact system in thrombosisCharacterization of factor XII autoactivation by a physiologicalNicola Mutch (United Kingdom) 17:00 - 17:15Contact system activation by microparticlesHelen Philippou (United Kingdom) 17:15 - 17:30Contact pathway inhibition: characterization of effect on clot formationHenry Spronk (The Netherlands) 17:30 - 17:40Targeting factor XII inhibits the pathological process of thrombus formation on ruptured plaques in vivo and in vitroJudith Cosemans (The Netherlands) 17:40 - 17:50A chromogenic FXIa method with low interference for in-process and final testing of immunologlobulin preparationsSteffen Rosén (Sweden) 17:50 - 18:00

ISTH 2012 11.6.2012 14:46 Page 38

Thur

sday


39

PPrreeddiiccttiivvee VVaarriiaabblleess iinn CCaarrddiioovvaassccuullaarr DDiisseeaassee RRoooomm 33AA

Chairpersons: James Douketis (Canada), Frederick Spencer (Canada), Alberto Tosetto (Italy), Richard White(USA), Alex Spyropoulos (USA), Shinya Goto (Japan), Karel Moons (The Netherlands)

Part A: new project on the determinants of thrombosis and bleeding risk in the perioperative settingAlex Spyropoulos (USA)Sessions objectivesJames Douketis (Canada) 15:30 - 15:35Managing patients on new oral anticoagulants who need surgery: how to minimize risk for thrombosis and bleeding? Marc Samama (France) 15:35 - 15:50Managing patients on new oral anticoagulants who need surgery: how to use and interpret coagulation tests? Beverly Hunt (United Kingdom) 15:50 - 16:10Managing patients on antiplatelet drugs who need surgery: can platelet function assays predict bleeding? Jerrold Levy (USA) 16:10 - 16:30Weighting of thrombosis and bleeding risk in clinical trials: application to the perioperative settingAlex Spyropoulos (USA) 16:30 - 16:45


Part B: update of SSC-Related activitiesJames Douketis (Canada)The Austrian study on recurrent venous thromboembolism (AUREC): an updatePaul Kyrle (Austria) 17:00 - 17:15Assessing patients’ risk for stroke and bleeding: how this informs decisions about which anticoagulant to useShinya Goto (Japan) 17:15 - 17:30Patient risk scores: how to assess their usefulness in clinical practice?Karel Moons (The Netherlands) 17:30 - 17:45CHADS2 and CHADS2VASc to determine stroke risk: one or both? Scott Kaatz (USA) 17:45 - 18:00

ISTH 2012 11.6.2012 14:46 Page 39


FFiibbrriinnoollyyssiiss RRoooomm 33BB

Chairpersons: Ann Gils (Belgium), Jonathan Foley (USA), Shirley Uitte de Willige (Netherlands), Paul Kim(Canada), Osamu Matsuo (Japan), Tetsumei Urano (Japan), Nicola Mutch (United Kingdom), Craig Thelwell(United Kingdom)

An update on WHO International Standards: a report on the Urokinase study; a proposal to replace the plasmin IS and other ongoing projectsCraig Thelwell (United Kingdom) 15:30 - 16:00Measuring the mechanical properties and fibrinolytic potential of blood clots formed via the tissue factor pathway of coagulationJonathan Foley (USA) 16:00 - 16:20


Alpha-2-antiplasmin: a heterogeneous fibrinolysis inhibitorShirley Uitte de Willige (The Netherlands) 16:40 - 17:00Roles of kringle domains in plasminogen activation and plasmin activityPaul Kim (Canada) 17:00 - 17:20What’s in a name? An evaluation of TAFI/pro-CPU nomenclatureJonathan Foley (USA) 17:20 - 17:40

PPllaassmmaa CCooaagguullaattiioonn IInnhhiibbiittoorrss RRoooomm 1122

Chairpersons: Steven Kitchen (United Kingdom); Piet Meijer (The Netherlands), Laurent Mosnier (USA),Elisabetta Castoldi (The Netherlands), Tilman Hackeng (The Netherlands), Richard Marlar (USA)

Welcome and update on subcommittee projectsSteven Kitchen (United Kingdom) 15:30 - 15:40

Session 1: effects of new oral anticoagulants on plasma coagulation inhibitor testingSteven Kitchen (United Kingdom); Piet Meijer (The Netherlands)The effect of rivaroxaban on laboratory testing for coagulation inhibitors: experience from ECAT surveysPiet Meijer (The Netherlands) 15:40 - 15:55

40

ISTH 2012 11.6.2012 14:46 Page 40

Thur

sday


41

Effects of dabigatran on PC, PS and AT assaysBob Gosselin (USA) 15:55 - 16:10Effects of rivaroxaban and dabigatran on plasma inhibitor testingAndreas Hillarp (Sweden) 16:10 - 16:25

Session 2 Steven Kitchen (United Kingdom), Richard Marlar (USA)The effect of CRP on clot based protein C and protein S assaysJun Teruya (USA) 16:25 - 16:40Stability of AT, PC and APC-R in whole bloodK Hickey (United Kingdom) 16:40 - 16:55Total protein S assay system: clinical significance and pre-analytical quality controlHiroko Tsuda (Japan) 16:55 - 17:10Genotype and laboratory phenotype of hereditary protein S deficiencyMichael Spannagl (Germany) 17:10 - 17:25

Session 3Laurent Mosnier (USA), Tilman Hackeng (The Netherlands)Novel assays for EPCR encryption and cellular APC resistanceEveline A. Bouwens (USA), Laurent Mosnier (USA) 17:25 - 17:40Thrombin generation as an intermediate phenotype for genetic studies on venous thrombosisElisabetta Castoldi (The Netherlands) 17:40 - 18:00

ISTH 2012 11.6.2012 14:46 Page 41


42

IISSTTHH BBAATT SSttaannddiinngg CCoommmmiitttteeee PPuubblliicc SSeessssiioonn HHaallll 22EE

Chairperson: Francesco Rodeghiero (Italy)

IntroductionPresentation of the ISTH-Bleeding Assessment Tool (BAT) Standing Committee operative rules and projects Francesco Rodeghiero (Italy) 16:05 - 16:20Rockefeller University repository Barry Coller (USA) 16:20 - 16:35

Ongoing/planned projectsJeroen Eikenboom (The Netherlands), Paul Monagle (Australia)

Bleeding phenotype of severe VWD3 versus milder VWD forms: current experiences and future perspectives Augosto Federici (Italy) 16:35 - 17:35Preliminary data on bleeding manifestations in adult controls and adults with Type 1 VWD Paula James (Canada) 16:35 - 17:35Defining the incidence of bleeding in normal adults Alberto Tosetto (Italy) 16:35 - 17:35Towards harmonization of different BATs in rare congenital bleeding disorders K Mussallam (Italy), Flora Peyvandi (Italy) 16:35 - 17:35

Proposals and suggestions from the attendees 17:35 - 17:55David Lillicrap (Canada), Sabine Eichinger (Austria)

ConclusionsFrancesco Rodeghiero (Italy) 17:55 - 18:00

ISTH 2012 11.6.2012 14:46 Page 42


43


BBaayyeerr HHeeaalltthhCCaarree HHaallll 22EE

Chairperson: Ander Cohen (United Kingdom)

Novel oral anticoagulant for the management of venous thromboembolism - a practical considerationWelcome and introduction Ander Cohen (United Kingdom) 18:15 - 18:20EINSTEIN PE results and their impact on VTE treatmentAnder Cohen (United Kingdom) 18:20 - 18:45 Treating VTE: the single drug approachGerry Dolan (United Kingdom) 18:45 - 19:05Orthotep PresentationJan Beyer-Westendorf (Germany) 19:05 - 19:15Novel anticoagulants in clinical practice – panel discussion and closeAnder Cohen (United Kingdom), Gerry Dolan (United Kingdom), Jan Beyer-Westendorf (Germany), Simon Nobel (United Kingdom), Raj Patel (United Kingdom) 19:15 - 19:45

SSyymmppoossiiuumm oonn WWiiddeenniinngg PPaarrttiicciippaattiioonn 1188::1155 -- 1199::4455

UUnniivveerrssiittyy ooff LLiivveerrppooooll HHaallll 22NN

Chairperson: Mike Parker (Liverpool Vision)

Little Big Medicine Welcome to school studentsMike Parker (Liverpool Vision)Nourishing the creative mindRichard Piper (Roald Dahl Foundation)The emerging importance of nanomedicineAndrew Owen (University of Liverpool)Panel discussion with scientist, clinician and industryAndrew Owen (University of Liverpool), Saye Khoo (Royal Liverpool University Hospital), Geoff Wainwright (2Bio)

ISTH 2012 11.6.2012 14:46 Page 43

Programme Overview

44

Friday, 29 June 2012

SSC Session


08:00 - 09:30 Joint session Von Willebrand Factor Flora Peyvandi & Paula Jamesand Factor VIII and IX (Hall 2E)

09:30 - 12:00 Von Willebrand Factor, part I (Hall 2E) Jeroen EikenboomFactor VIII and IX, part I (Hall 2F) Flora PeyvandiPerinatal/pediatric (Hall 2L) Paul MonagleAnimal models (Hall 2N) Susan Smyth

08:00 - 12:00 Lupus anticoagulant (Room 3A) Thomas OrtelPlatelet physiology (Room 3B) Paul HarrisonVascular biology (Room 4) Françoise Dignat-GeorgeBiorheology (Room 12) Michael King

Satellite Symposia

Time Company Title

12:15 - 13:45 Daiichi Sankyo Novel anticoagulation for venous thromboembolism - (Hall 2E)new perspectives and treatment strategies

Stago DIC - The next frontier in thrombosis and haemostasis (Hall 2F)

14:00 - 17:00 Hot Topics Halls 2L and 2N

1177::0000 -- 1199::0000 eePPoosstteerr SSeessssiioonn

20:00 - 22:00 Football Match - Europe versus the World

ISTH 2012 11.6.2012 14:48 Page 44

Frid

ay

Detailed Programme Friday, 29 June 2012

45

SSSSCC SSeessssiioonnss 0088::0000 -- 1122::0000

JJooiinntt SSeessssiioonn:: VVoonn WWiilllleebbrraanndd FFaaccttoorr aanndd FFaaccttoorr VVIIIIII aanndd IIXX HHaallll 22EE

Chairpersons: Flora Peyvandi (Italy), Paula James (Canada)

Bleeding scoresIntroductionPaula James (Canada) 08:00 - 08:05Update from the standing committee on Bleeding Assessment ToolFrancesco Rodeghiero (Italy) 08:05 - 08:25Web based Bleeding Assessment Tool (BAT)Barry Coller (USA) 08:25 - 08:45What type of scoring system is necessary in hemophiliaAlberto Tosetto (Italy) 08:45 - 09:05Bleeding score in rare bleeding disordersKhaled Musallam (Italy) 09:05 - 09:25General discussion

VVoonn WWiilllleebbrraanndd FFaaccttoorr,, ppaarrtt II HHaallll 22EE

Chairpersons: Jeroen Eikenboom (The Netherlands), Daniel Hampshire (United Kingdom), Thomas Abshire(USA), Jorge DiPaola (USA), Yoshihiro Fujimura (Japan), Paula James (Canada), Imre Bodo (Hungary),Johanna Kremer Hovinga (Switzerland)

Standardization of assays Thomas Abshire (USA)Review of the available WHO IS for all VWF-related analytes, and VWFpp calibrationAnthony Hubbard (United Kingdom) 10:00 - 10:15Standardization of the high quality multimer assay: a Hamburg-Budapest projectImre Bodo (Hungary) 10:15 - 10:30International reference preparation for ADAMTS13 activityJohanna Kremer Hovinga (Switzerland) 10:30 - 10:40Gene mutation analysis for Upshaw-Schulman syndromeKoichi Kokame (Japan) 10:40 - 10:55Comparison of VWF activity assaysImre Bodo (Hungary) 10:55 - 11:05

ISTH 2012 11.6.2012 14:48 Page 45


46

VWF, VWD and TTP registriesJorge DiPaola (USA)VWF databaseDaniel Hampshire (United Kingdom) 11:05 - 11:20Platelet type- VWD registry/database Maha Othman (Canada) 11:20 - 11:35International registry on acquired von Willebrand syndrome Augusto Federici (Italy) 11:35 - 11:45Hereditary TTP registryJohanna Kremer Hovinga (Switzerland) 11:45 - 12:00

FFaaccttoorr VVIIIIII aanndd IIXX,, ppaarrtt II HHaallll 22FF

Chairpersons: Flora Peyvandi (Italy), Leonard Valentino (USA), Claude Negrier (France), Midori Shima (Japan),Jan Astermark (Sweden), Kathelijn Fischer (The Netherlands), Steven Pipe (USA)

Report on SSC-FVIII&FIX activity 2010-2011 Flora Peyvandi (Italy) 09:30 - 09:40

Projects reports IGuy Young (USA), Alok Srivastava (India)Standardization of whole blood viscoelastic measurement of clot formation and clot stabilityMeera Chitlur (USA) 09:40 - 09:50Standardization of methods for performing the thrombin generation testClaude Negrier (France) 09:50 - 10:00Standardization of methods for performing the clot wave form analysisMidori Shima (Japan) 10:00 - 10:10General discussion

Projects reports II: FDA and EMEA regulatories: clinical trial requirementsFlora Peyvandi (Italy), Mike Makris (United Kingdom)New regulation of FDA for rare disordersNisha Jain (USA) 10:20 - 10:30New European guidelines for clinical trials in rare disordersAnneliese Hilger (Germany) 10:30 - 10:40Clinical trial design for haemophiliaDonna DiMichele (USA) 10:40 - 10:50

ISTH 2012 11.6.2012 14:48 Page 46

Frid

ay


47


Projects reports IIISteven Kitchen (United Kingdom), Leonard Valentino (USA)Using pharmacokinetics to individualize treatment: updatePeter Collins (United Kingdom) 11:10 - 11:20Potency labelling of clotting factor concentrates: updateAnthony Hubbard (United Kingdom) 11:20 - 11:30Consensus definitions in haemophiliaAlok Srivastava (India) 11:30 - 11:40Consensus definitions in rare bleeding disordersFlora Peyvandi (Italy) 11:40 - 11:50General discussion

PPeerriinnaattaall//PPeeddiiaattrriicc HHaallll 22LL

Chairpersons: Paul Monagle (Australia), Paolo Simioni (Italy), Mariana Bonduel (Argentina), ElizabethChalmers (United Kingdom), Anthony Chan (Canada), Christoph Male (Austria), Janna Journeycake (USA),Guy Young (USA)

Introduction and update on the work of the SSCPaul Monagle (Australia) 08:00 - 08:15IVC filters in childrenSuzan Williams (Canada) 08:15 - 08:45Measurement of long term consequences of specific organ thrombosis Madhvi Rajpurkar (USA) 08:45 - 09:15Systematic assessment of PTS of the upper venous sytemShoshana Revel-Vilk (Israel) 09:15 - 09:45Evidence for FFP use in neonates and childrenJohn Puetz (USA) 09:45 - 10:15


Establishment of a registry of homozygous protein CVicky Price (Canada) 10:30 - 11:00

ISTH 2012 11.6.2012 14:48 Page 47


48

Brief updates on ongoing SSC projectsAntiplatelet therapy in childrenJanna Journeycake (USA) 11:00 - 11:10HIT in childrenGuy Young (USA) 11:10 - 11:20Point-of-care testing in childrenPaul Monagle (Australia) 11:20 - 11:30Investigation of the bleeding childPaolo Simioni (Italy) 11:30 - 11:45Conclusion and planningPaul Monagle (Australia) 11:45 - 12:00

AAnniimmaall MMooddeellss HHaallll 22NN

Chairpersons: Susan Smyth (USA), Cecile Denis (France), Nigel Mackman (USA), Toshiyuki Miyata (Japan),David Motto (USA), Hugo Ten Cate (The Netherlands), Timothy Nichols (USA), Eva-Maria Muchitsch (Austria),Tom Knudsen (Denmark)

ARFI ultrasound method of detecting bleeding and documenting hemostasis in the hemophilic and VWD dogsTimothy Nichols (USA) 08:05 - 08:30Pharmacokinetics and pharmacodyanmics of recombinant canine FVIIa in dogsTom Knusden (Denmark, Novo Nordisk AS) 08:30 - 08:55Pro-hemostatic agents in a pig model of coagulopathyHenry Spronk (The Netherlands) 08:55 - 09:20Assessment of thrombogenicityEva-Maria Muchitsch (Austria, Baxter Innovations GmbH) 09:20 - 09:45


ISTH 2012 11.6.2012 14:48 Page 48

Frid

ay


49

Coagulant proteins in murine models of atherosclerosisHugo Ten Cate (The Netherlands) 10:00 - 10:25Platelet signatures in mice and humansAndy Weyrich (USA) 10:25 - 10:50Contributions of platelet TGF-b1 in vitro and in vivo to plasma TGF-b1 and its biologic effectsJasimuddin Ahamed (USA) 10:50 - 11:15Bleeding phenotype and coagulation variables of BALB/c, C57BL/6 and 129S1/Sv miceAlexandra Schiviz (Austria, Baxter Innovations GmbH) 11:15 - 11:40Planning for the 59th Annual SSC Meeting with XXIV ISTH Congress: Amsterdam, The Netherlands, June 29 - July 4, 2013 11:40 - 12:00

LLuuppuuss AAnnttiiccooaagguullaanntt RRoooomm 33AA

Chairperons: Thomas Ortel (USA), Katrien Devreese (Belgium), Armando Tripodi (Italy), Silvia Pierangeli(USA), Bas de Laat (The Netherlands), Tatsuya Atsumi (Japan), Guido Reber (Switzerland), Vittorio Pengo(Italy)

Anticardiolipin, anti-beta-2-glycoprotein I, and antiprothrombin antibodiesUpdate on criteria antiphospholipid task force and establishing units of measurement for anti-beta-2-glycoprotein I antibodiesSilvia Pierangeli (USA) 08:00 - 08:30Conformation of beta-2-glycoprotein IBas de Laat (The Netherlands) 08:30 - 09:00Phosphatidylserine dependent antiprothrombin antibodies: significance and international standardizationTatsuya Atsumi (Japan) 09:00 - 09:30Standardization of the antiphospholipid antibody assaysKatrien Devreese (Belgium), Thomas Ortel (USA) 09:30 - 10:00

Lupus anticoagulantsDiagnosis of lupus anticoagulants in the presence of new anticoagulant therapiesPG de Groot (The Netherlands) 10:00 - 10:30Problems and possible solutions in the detection of antiphospholipid antibodiesGuido Reber (Switzerland) 10:30 - 11:00

ISTH 2012 11.6.2012 14:48 Page 49


50

New assaysUpdate on the annexin A5 resistance assay and proposal for an SSC trial analogous to the anti-D1 studyJacob Rand (USA) 11:00 - 11:30

Proposal for new guidelines for diagnosis of APSProposed guidelines for the diagnosis of antiphospholipid syndromeVittorio Pengo (Italy) 11:30 - 12:00

PPllaatteelleett PPhhyyssiioollooggyy RRoooomm 33BB

Chairpersons: Paul Harrison (United Kingdom), Paolo Gresele (Italy), Christian Gachet (France), Dermot Kenny(Republic of Ireland), Diego Mezzano (Chile), Andrew Mumford (United Kingdom), Marco Cattaneo (Italy), AlanNurden (France)

Introduction and overviewPaul Harrison (United Kingdom) 08:00 - 08:15

Guidelines for the diagnosis of platelet disordersSurvey updatePaolo Gresele (Italy) 08:15 - 08:40Consensus of working groupPaolo Gresele (Italy) 08:40 - 09:05Platelet type VWDMaha Othman (Canada) 09:05 - 09:30Therapeutic monitoring of anti-P2Y12 drugsDirk Sibbing (Germany) 09:30 - 10:00


Analysis of the platelet transcriptomeNew generation sequencing, transcription profiling and whole exome analysis of platelet disordersKathleen Freson (Belgium) 10:30 11:00ThrombogeneticsGraham Kiddle (United Kingdom) 11:00 11:30In vitro microfluidic devicesJohan Heemskerk (The Netherlands) 11:30 12:00

ISTH 2012 11.6.2012 14:48 Page 50

Frid

ay


51

VVaassccuullaarr BBiioollooggyy RRoooomm 44

Chairpersons: Françoise Dignat-George (France), Michael Berndt (Ireland, Republic of), John Griffin (USA),Peter Newman (USA), Florence Toti-Orfanoudakis (France), Nigel Key (USA), Rienk Nieuwland (The Netherlands), Elizabeth Gardiner (Australia)

Shed proteins/receptorsElizabeth Gardiner (Australia), Peter Newman (USA)

Shear-induced release of platelet receptors by metalloproteinasesElizabeth Gardiner (Australia) 08:00 - 08:15Metalloproteinase shedding influencing leukocyte functionElaine Raines (USA) 08:15 - 08:30ADAMs mediated shedding in vascular biologyAndreas Ludwig (Germany) 08:30 - 08:45Function of GPV and its utility as a marker of thrombosis in cardiovascular disordersFrançois Lanza (France) 08:45 - 09:00

Detection and characterization of circulating endothelial cells and their progenitorsFrançoise Dignat-George (France), John Griffin (USA)Endothelial progenitor cell measurement for assessment of cardiovascular riskGianpaolo Fadini (Italy) 09:00 - 09:15Flow cytometric identification and functional characterization of immature and mature circulating endothelial cellsJamie Case (USA) 09:15 - 09:30Changes in circulating endothelial cells and their progenitors during percutaneous coronary intervention: a reflect of endothelial response to injury with prognosis significance.Florence Sabatier (France) 09:30 - 09:45


Determination and characterization of (circulating) microparticlesNigel Key (USA), Florence Toti-Orfanoudakis (France)

Challenges and opportunities for multiparameter analysis of cell derived microvesicle by flow cytometryJohn Nolan (USA) 10:15 - 10:30Characterization of microparticles from blood plasma and activated platelets by cryo-electron microscopyAlain Brisson (France) 10:30 - 10:45

ISTH 2012 11.6.2012 14:48 Page 51


52

Is decrease of microparticles related to improvement of hemostasis after the treatment in hemophilia AJovan Antovic (Sweden) 10:45 - 11:00Effect of different triggering techniques on MP analysis by flow cytometryMicah Mooberry (USA) 11:00 - 11:15Flow cytometry-based standardized microparticle counting: forward or side scatterPhilippe Poncelet (France) 11:15 - 11:30Development of standards for MP determinationRienk Niewland (The Netherlands) 11:30 - 11:45Closing remarksFrançoise Dignat-George (France) 11:45 - 12:00

BBiioorrhheeoollooggyy RRoooomm 1122

Chairperons: Michael King (USA), Lawrence Brass (USA), Shaun Jackson (Australia), Armin Reininger(Switzerland), Mitsuhiko Sugimoto (Japan), Keith Neeves (USA), Owen McCarty (USA)

Part 1: in vitro assays of thrombosis and haemostasis under flowMichael King (USA)Platelet aggregates as prerequisite for fibrin polymerization under flowArmin Reininger (Switzerland) 08:05 - 08:25Fibrin generation within thrombi generated in antibody-induced hemophilic whole blood under flow condition: In vitro evaluation for hemostatic effects of anti-hemophilic agentsMitsuhiko Sugimoto (Japan) 08:25 - 08:45Fibrin formation under flow correlates to FVIII levels in hemophilia A in a tissue factor-collagen flow assayKeith Neeves (USA) 08:45 - 09:05Characterization of the physical parameters of mass, volume and density of platelet aggregates and thrombus formationOwen McCarty (USA) 09:05 - 09:25Methods and readouts for investigating the effects of fluid shear stress on haemostatic and inflammatory responses of endothelial cellsGerard Nash (United Kingdom) 09:25 - 09:45


ISTH 2012 11.6.2012 14:48 Page 52

Frid

ay


53

Part 2: multiscale modeling and high throughput assays of thrombus growth under flowArmin Reininger (Switzerland), Mitsuhiko Sugimoto (Japan)High throughput microfluidics and platelet phenotyping for patient-specific simulation of thrombosis and bleedingScott Diamond (USA) 09:55 - 10:15Multiparameter assessment of thrombus formation: a systems biology approachJohan Heemskerk (The Netherlands) 10:15 - 10:35A novel platform for multiscale modeling of human thrombiTom Diacovo (USA) 10:35 - 10:55Modeling platelet deposition and coagulation under flow: transport of platelets and proteins to and within the thrombusAaron Fogelson (USA) 10:55 - 11:15Estimating the robustness and fragility of the coagulation cascade using a population of mathematical modelsJeff Varner (USA) 11:15 - 11:35Multiscale simulation of platelet tethering and translocationMichael King (USA) 11:35 - 12:00


DDaaiiiicchhii SSaannkkyyoo HHaallll 22EE

Chairpersons: Gregory YH Lip (United Kingdom), Henri Bounameaux (Switzerland)

Novel anticoagulation for venous thromboembolism - new perspectives and treatment strategiesWelcome and introduction Gregory YH Lip (United Kingdom), Henri Bounameaux (Switzerland) 12:15 - 12:20Venous thromboembolism - a clinicianÕs viewHenri Bounameaux (Switzerland) 12.20 - 12:40New perspectives with novel anticoagulants, beyond venous thromboembolismGregory YH Lip (United Kingdom) 12:40 - 13:00Edoxaban - current evidence of a new once-daily factor Xa inhibitorSebastian M Schellong (Germany) 13:00 - 13:20

ISTH 2012 11.6.2012 14:48 Page 53


54

Edoxaban in venous thromboembolism - what can the HOKUSAI-VTE study tell us?Harry Büller (The Netherlands) 13:20 - 13:35PPaanneell ddiissccuussssiioonn // QQ&&AA All 13:35 -13:40Meeting closeGregory YH Lip (United Kingdom), Henri Bounameaux (Switzerland) 13:40 - 13:45

SSttaaggoo HHaallll 22FF

Chairpersons: Cheng-Hock Toh (United Kingdom), Fletcher B. Taylor Jr. (USA)

DIC - The next frontier in thrombosis and haemostasisWelcome and introductionCheng-Hock Toh (United Kingdom), Fletcher B. Taylor, Jr. (United Kingdom) 12:15 - 12:20Mission: impossible-DIC protocolCheng-Hock Toh (United Kingdom) 12:20 - 12:45Platelets in DIC and severe sepsisBernd Jilma (Austria) 12:45 - 13:10Laboratory innovation in the management of patients with severe sepsisFrançoise Dignat-George (France) 13:10 - 13:35Concluding remarksCheng-Hock Toh (United Kingdom) 13:35 - 13:45

Hot Topics 14:00 - 17:00

Basic Science (see page 68) Hall 2 L

Chairpersons: Michael Berndt (Ireland), Pieter Reitsma (The Netherlands)

Clinical Science (see page 69) Hall 2 N

Chairpersons: Anna Falanga (Italy), Henri Bounameaux (Switzerland)

eePPoosstteerr SSeessssiioonn 1177::0000 -- 1199::0000

Football Match - Europe versus the World 2200::0000 -- 2222::0000

ISTH 2012 11.6.2012 14:48 Page 54

ISTH 2012 11.6.2012 14:48 Page 55

Programme Overview

56

Saturday, 30 June 2012

Technical Session

Time Company Title

08:00 - 09:00 Inspiration Biopharmaceuticals, Inc. Assay techniques for recombinant porcine FVIII and recombinant human FIX(Hall 2E)

SSC Session


09:00 - 13:00 Von Willebrand Factor, part II (Hall 2E) Jeroen EikenboomWomen’s health issues in thrombosis and haemostasis (Hall 2F) Sabine EichingerControl of anticoagulation (Hall 2L) Walter AgenoHemostasis and Malignancy (Hall 2N) Agnes LeeFactor VIII and IX, part II (Room 3) Flora PayvandiPlatelet immunology (Room 12) Yves GruelFactor XIII and fibrinogen (Room 4A) Hans Kohler

14:00 - 16:30 SSC Business Meeting Room 12

ISTH 2012 11.6.2012 14:48 Page 56

Satu

rday

Detailed Programme Saturday, 30 June 2012

57

Technical Session 08:00 - 09:00

IInnssppiirraattiioonn BBiioopphhaarrmmaacceeuuttiiccaallss,, IInncc.. HHaallll 22EE

Chairperson: Dougald Monroe (USA)

Assay techniques for recombinant porcine FVIII and recombinant human FIXWelcome and introductionDougald Monroe (USA) 08:00 - 08:05Recombinant porcine FVIIIMartin L Lee (USA) 08:05 - 08:20Factor IX assayElaine Gray (United Kingdom) 08:20 - 08:35Recombinant human FIXDougald Monroe (USA) 08:35 - 08:50Questions and answersElaine Gray (United Kingdom), Martin L Lee and Dougald Monroe (USA) 08:50 - 09:00

SSSSCC SSeessssiioonnss 0099::0000 -- 1133::0000

VVoonn WWiilllleebbrraanndd FFaaccttoorr,, ppaarrtt IIII HHaallll 22EE

Chairpersons: Jeroen Eikenboom (The Netherlands), Daniel Hampshire (United Kingdom), Thomas Abshire(USA), Paula James (Canada), Johanna Kremer Hovinga (Switzerland), Imre Bodo (Hungary), Jorge DiPaola(USA), Yoshihiro Fujimura (Japan)

Multicenter studies on VWDDaniel Hampshire (United Kingdom), Imre Bodo (Hungary)European project on type 3 VWDAugusto Federici (Italy) 09:00 - 09:15EUVWD cooperative groupAnne Goodeve (United Kingdom), Carlo Castaman (Italy) 09:15 - 09:30Zimmerman project (ZPMCB-VWD)Robert Montgomery (USA) 09:30 - 09:45VWD international prophylaxis (VIP) studyThomas Abshire (USA) 09:45 - 10:00

ISTH 2012 11.6.2012 14:48 Page 57


58

WIN (Willebrand in Netherlands)Frank Leebeek (The Netherlands) 10:00 - 10:15Canadian type 3 VWD studyPaula James (Canada) 10:15 - 10:30Belgian-Czech cooperation in the Brno-VWD studyAlain Gadisseur (Belgium) 10:30 - 10:45


Genetic modifiers of VWF levelsJohanna Kremer Hovinga (Switzerland), Jeroen Eikenboom (The Netherlands)Potential role of novel VWF clearance pathwaysDavid Lillicrap (Canada) 11:15 - 11:30Genetic variability as a determinant of in vivo release of VWFFrank Leebeek (The Netherlands) 11:30 - 11:45Genetic modifiers of VWF antigen levels in healthy young adultsKarl Desh (USA) 11:45 - 12:00Genetic modifiers of VWD in large pedigrees: association and linkageJorge DiPaola (USA) 12:00 - 12:15

Animal studiesMouse modifiers of VWFJordan Shavit (USA) 12:15 - 12:30Modifier screens in zebrafish and possible application to VWFJordan Shavit (USA) 12:30 - 12:45General discussion and concluding remarks

WWoommeennÕss HHeeaalltthh IIssssuueess iinn TThhrroommbboossiiss aanndd HHaaeemmoossttaassiiss HHaallll 22FF

Chairpersons: Sabine Eichinger (Austria), Takao Kobayashi (Japan), Claire Phillip (USA), Andra James (USA),Barbara Konkle (USA), Rezan Abdul-Kadir (United Kingdom), Claire McLintock (New Zealand), SaskiaMiddeldorp (The Netherlands)

Educational activitiesEducational program of SSC meetings: overview and future perspectivesSabine Eichinger (Austria) 09:05 - 09:10

ISTH 2012 11.6.2012 14:48 Page 58

Satu

rday


59

Report on the women’’s health issues in thrombosis and haemostasis symposium 2011 Benjamin Brenner (Israel) 09:10 - 09:15

ACCP guidelines on “venous thromboembolism, thrombophilia, antithrombolic therapy, and pregnancy” 2012: panelistsÕ update of relevant changes1. Thromboprophylaxis after caesarean section Ian Greer (United Kingdom) 09:15 - 10:152. Prevention of VTE in pregnant women at increased risk Saskia Middeldorp (The Netherlands) 09:15 - 10:153. Thrombophilia and pregnancy complicationsIan Greer (United Kingdom) 09:15 - 10:15Update on investigator initiated trials in womenÕs issues (Highlow study, ALIFE II) Saskia Middeldorp (The Netherlands) 10:15 - 10:30


Hormone use and the risk of venous thrombosis: clinical issues Astrid van Hylckama-Vlieg (The Netherlands) 10:50 - 11:15Heparanase procoagulant assay in women on hormonal therapy Yona Nadir (Israel), Benjamin Brenner (Israel) 11:15 - 11:30

Spotlight on “malignancy and womenÕs health issues in thrombosis and haemostasisÓPregnancy and malignancy Benjamin Brenner (Israel) 11:30 - 12:00

Menorrhagia working groupClaire Phillip (USA)Recombinant activated factor VII (rFVIIa/NovoSeven) in the management of severe postpartum hemorrhage: Initial report of a multicenter case series in JapanTakao Kobayashi (Japan) 12:00 - 12:30Report from the bleeding assessment tool standing committee - what is relevant for women and girls Sabine Eichinger (Austria) 12:30 - 12:50Closing remarks

ISTH 2012 11.6.2012 14:48 Page 59


60

CCoonnttrrooll ooff AAnnttiiccooaagguullaattiioonn HHaallll 22LL

Chairpersons: Walter Ageno (Italy), Rebecca Beyth (USA), Elaine Hylek (USA), John Olson (USA), GualtieroPalareti (Italy), Henry Watson (United Kingdom), Trevor Baglin (United Kingdom)

Update on the laboratory monitoring of the vitamin K antagonistsValidation of certified plasmas for ISI calibration and INR derivationTon van den Besselaar (The Netherlands) 09:00 - 09:15INR simplified: the PT/INR lineS. Ibrahim (United Kingdom) 09:15 - 09:30Intra-individual variation of INR in warfarin-treated patients: consequences for desirable analytical precisionTon van den Besselaar (The Netherlands) 09:30 - 09:45

WHO-SSC collaborative study on low molecular weight heparinResults of the 3rd international standard for low molecular weight heparinElaine Gray (United Kingdom) 09:45 - 10:00

The laboratory monitoring of the new oral anticoagulant drugs (NOACs)Which tests should we use? Armando Tripodi (Italy), Marc Samama (France) 10:00 - 10:35When and how to measuring new oral anticoagulants (NOAC): working towards a recommendation from the subcommittee on control of anticoagulationTrevor Baglin (United Kingdom) 10:35 - 10:50Update on SSC activities: dabigatranElaine Gray (United Kingdom) 10:50 - 11:00

Clinical experiences with the NOACsMajor orthopaedic surgery, venous thromboembolism, atrial fibrillation: reports from daily clinical practiceJ. Beyer (Germany) 11:00 - 11:15Atrial fibrillation: gaps in trials and current practiceElaine Hylek (USA) 11:15 - 11:30Venous thromboembolism: gaps in trials and current practiceGiancarlo Agnelli (Italy) 11:30 - 11:45

ISTH 2012 11.6.2012 14:48 Page 60

Satu

rday


61

Proposal of an SSC project: an international register on anticoagulated patientsGualtiero Palareti (Italy) 11:45 - 12:00

Bleeding in patients receiving NOACs: problems and possible managementUpdate on current evidences from the real world and presentation of ongoing studiesPeter Kamphuisen (The Netherlands) 12:00 - 12:15Suggestions for the management of invasive procedures and bleeding events with the NOACsSam Schulman (Canada) 12:15 - 12:30Management of obese patients with the old and new anticoagulantsHenry Watson (United Kingdom) 12:30 - 12:45Proposal for an SSC recommendation for the guidance on the management of patients treated with the NOACsWalter Ageno (Italy) 12:45 - 12:55

Update on research activity on unusual site thrombosisSplanchnic vein thrombosisWalter Ageno (Italy) 12:55 - 13:00

HHeemmoossttaassiiss aanndd MMaalliiggnnaannccyy HHaallll 22NN

Chairpersons: Agnes Lee (Canada), Marina Marchetti (Italy), Dominique Farge (France), Alok Khorana (USA),Howard Liebman (USA), Ingrid Pabinger (Austria), Wolfram Ruf (USA), Marc Carrier (Canada), Jeffrey Zwicker(USA)

Session one: update on current projects and clinical trials Agnes Lee (Canada)Standardization of tissue factor assaysMarina Marchetti (Italy) 09:00 - 09:20Defining VTE in oncology trialsMarc Carrier (Canada) 09:20 - 09:40International guidelines for antithrombotics in cancer patientsDominique Farge (France) 09:40 - 10:002012 ACCP guidelines on cancer-associated thrombosisAlok Khorana (USA) 10:00 - 10:20Updates on clinical trials and registriesAgnes Lee (Canada) 10:20 - 10:40

ISTH 2012 11.6.2012 14:48 Page 61


62


Session two: new proposals and hypothesesAlok Khorana (USA)Prothrombotic state and metastasis in preclinical modelsWolfram Ruf (USA) 11:00 - 11:20The role of genetic polymorphisms in thrombosis and colorectal cancerCarla Vossen (The Netherlands) 11:20 - 11:40Biomarkers in clinical practiceCihan Ay (Austria) 11:40 - 12:00Competing risks in oncology trialsJeffrey Zwicker (USA) 12:00 - 12:20Registry on incidental PEMarcello Dinisio (Italy) 12:20 - 12:40New oral anticoagulants in CATAgnes Lee (Canada) 12:40 - 13:00

FFaaccttoorr VVIIIIII aanndd IIXX,, ppaarrtt IIII RRoooomm 33

Chairpersons: Flora Peyvandi (Italy), Marilyn Manco-Johnson (USA), Raimondo De Cristofaro (United Kingdom), Donna DiMichele (USA), Anthony Hubbard (United Kingdom), Steven Pipe (USA), Carmen Escuriola (Germany)

Clinical issuesMarilyn Manco-Johnson (USA), Carmen Escuriola (Germany)The incidence of inhibitors in long terms experience in prophylaxisErik Berntorp (Sweden) 09:00 - 09:10Research of determinants of inhibitor development among previously untreated patients with haemophilia (RODIN study)Marijke van den Berg (The Netherlands) 09:10 - 09:20Extending prophylaxis around the world - What doses can we start with?Alok Srivastava (India) 09:20 - 09:30Immunotolerance induction using plasma derived productsCarmen Escuriola (Germany) 09:30 - 09:40ITI International study projectCharles Hay (United Kingdom) 09:40 - 09:50General discussion

ISTH 2012 11.6.2012 14:48 Page 62

Satu

rday


63

Standardisation issuesRaimondo De Cristofaro (United Kingdom), Anthony Hubbard (United Kingdom)4th international standard for FII and X, concentrateElaine Gray (United Kingdom) 10:10 - 10:20A report on the collaborative study to calibrate the WHO 2nd international standard for factor VII concentrateCraig Thelwell (United Kingdom) 10:20 - 10:30FVIII Inhibitors assay (SMIA): a new approach in measurementSanj Raut (United Kingdom) 10:30 - 10:40General discussion


Critical issues on evaluation of efficacy of treatment in hemophiliaDonna DiMichele (USA), Steven Pipe (USA)Measuring clinical efficacy and laboratory parameters in patients treated with porcine factor VIIIÓMartin Lee (Inspiration Biopharmaceuticals) 11:00 - 11:10Development of new rFVIII and rFIX molecules: clinical and laboratory evaluation of safety and efficacyStephanie Seremetis (Novo Nordisk) 11:10 - 11:20Evolution of clinical trials in haemophilia: from simple replacement to pharmacological evidenceRupert Sandbrink (Bayer) 11:20 - 11:30Correlation of potency assignment and clinical performance of rFVIII-Fc and rFIX-Fc fusion proteins through field studies, ex vivo coagulation and global hemostasis assaysJurg Sommer (Biogen Idec) 11:30 - 11:40Clinical research challenges in developing novel compounds to treat hemophilia: the rIX-FP and rVIII-SingleChain experienceDebbie Bensen-Kennedy (CSL Behring) 11:40 - 11:50Standardised specific assays or general tests of haemostatic potential? PfizerÕs view on precise science or clinical relevanceBrian Colvin (Pfizer) 11:50 - 12:00Novel assays for novel hemophilia therapies - practice of clinical testingduring clinical studies 2012 and beyondPeter Turecek (Baxter) 12:00 - 12:10

ISTH 2012 11.6.2012 14:48 Page 63


64

A clinically validated technology for elongating the half life of coagulation factors, enabling a 1\ prolonged haemostatic activity in hemophilic animal modelsGili Hart (Prolor Biotech) 12:10 - 12:20General discussion

PPllaatteelleett IImmmmuunnoollooggyy RRoooomm 1122

Chairpersons: Yves Gruel (France), Andreas Greinacher (Germany), Hartmut Kroll (Germany), YoshiakiTomiyama (Japan), Donald Arnold (Canada), Beng Chong (Australia)

Drug-induced and autoimmune thrombocytopeniaDonald Arnold (Canada), Beng Chong (Australia)Standardization of methods/ evaluation of drug-induced ITP testingDonald Arnold (Canada) 09:05 - 09:20Animal model of drug-induced ITPBeng Chong (Australia) 09:20 - 09:35In vivo animal model of drug-induced thrombocytopenia: the clinical relevance of anti-protamine sulfate antibodiesTamam Bakchoul (Germany) 09:35 - 09:50Drug-induced antibody effects on megakaryocytesBeng Chong (Australia) 09:50 - 10:05Application of PLT antibody testing in ITP trials: the effect of rituximab on PLT antibodies in ITPDonald Arnold (Canada) 10:05 - 10:20

Alloimmune and isoimmune thrombocytopeniaYves Gruel (France)Usefulness and biological aspects of a national registry of donors for the treatment and prevention of alloimmune thrombocytopeniaFrançoise Boehlen (Switzerland) 10:20 - 10:35Usefulness of surface plasmon resonance technology for monitoring pregnancies with expected NAITTamam Bakchoul (Germany) 10:35 - 10:50Development of antibodies to aIIbb3 in a French cohort of Glanzmann thrombasthenia patientsMathieu Fiore (France) 10:50 - 11:00

ISTH 2012 11.6.2012 14:48 Page 64

Satu

rday


65


Heparin-induced thrombocytopenia - pathogenesis of HITAndreas Greinacher (Germany)Binding study of HIT antibodies to PF4 modified by enoxaparin oligosaccharides using SPRD Leroux (France), Yves Gruel (France) 11:20 - 11:30Gene variations and modulation of FcRlla- dependent platelet activationJ Rollin 11:30 - 11:40

Heparin-induced thrombocytopenia - diagnosis of HITAndreas Greinacher (Germany)Validation of the multiplate assay for HIT diagnosisGreifswald Group 11:40 - 11:50Functional assays for HIT in Australia: where do they fit in current algorithms?Christopher Ward (Australia) 11:50 - 12:00Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patientsLorenzo Alberia (Switzerland) 12:00 - 12:10Prospective evaluation of a lateral flow immunoassayYves Gruel (France) 12:10 - 12:20AcuStar HIT-IgG and HIMEA for rapid diagnosis of type-II HITFrançois Mullier (Belgium) 12:20 - 12:30Difference between enzyme immunoassays in the high heparin step are independent of the source of PF4Greifswald Group (Germany) 12:30 - 12:40Final discussion and perspective

FFaaccttoorr XXIIIIII aanndd FFiibbrriinnooggeenn RRoooomm 44AA

Chairpersons: Hans Kohler (Switzerland), Sanj Raut (United Kingdom), Marguerite Neerman-Arbez(Switzerland), Helen Philippou (United Kingdom), Verena Schroeder (Switzerland), Aida Inbal (Israel), Moniekde Maat (The Netherlands), John Weisel (USA)

International collaborative study for the value assignment of the 2nd International Standard for fibrinogen, concentrate - an updateSanj Raut (United Kingdom) 09:05 - 09:25

ISTH 2012 11.6.2012 14:48 Page 65


66

Modeling fibrinogen deficiency in the zebrafishMarguerite Neerman-Arbez (Switzerland) 09:25 - 09:45An international, collaborative study on the standardisation of the permeability measurement of fibrin clot structure: methodological considerations and implications for healthy control valuesMoniek de Maat (The Netherlands), John Weisel (USA), Marlien Pieters (South Africa), Anettas Undas (Poland), Rita Marchi (Venezuela),Colin Longstaff (United Kingdom), Robert A.S. Ariëns (United Kingdom) 09:45 - 10:05Fibrinogen gammaÕ measurements Moniek de Maat (The Netherlands) 10:05 - 10:25In vivo measurement of FXIII activity and fibrin formation in real time Helen Philippou (United Kingdom) 10:25 - 10:45


Current practice in investigation of FXIII deficiency; data from UK NEQAS (blood coagulation)Ian Jennings, Isobel Walker, Timothy Woods, Steven Kitchen, Dianne Kitchen (United Kingdom) 11:00 - 11:20First case of FXIII-A type II deficiency Vytautas Ivaskevicius (Germany) 11:20 - 11:40Project on value assignment for FXIII B-subunit (total & free) to the WHO 1st IS Factor XIII plasma (2/206)Hans Kohler, Verena Schroeder (Switzerland), Sanj Raut (United Kingdom) 11:40 - 12:00Factor XIII B: just a carrier of factor XIII A subunit or a plasma protein of its own right?Laszlo Muszbek (Hungary) 12:00 - 12:20Japanese criterion 2012 for the diagnosis and treatment of acquired hemorrhaphilia XIII/13 Akitada Ichinose (Japan) 12:20 - 12:40A novel point-of-care test for the detection of anti-factor XIII antibodies in patients with autoimmune hemorrhaphilia XIII/13, by using immunochromatographyYasuo Magari, Shoichi Kawato, Keiko Ninomiya, Masayoshi Souri, Akitada Ichinose (Japan) 12:40 13:00

SSC Business Meeting - Room 12 14:00 - 16:30

ISTH 2012 11.6.2012 14:48 Page 66

ISTH 2012 11.6.2012 14:48 Page 67

Hot Topics Schedule

68

FFrriiddaayy,, 2299 JJuunnee 22001122

HHoott TTooppiiccss 1144::0000 -- 1177::0000

BBaassiicc SScciieennccee HHaallll 22 LL

Chairpersons: Michael Berndt (Ireland), Pieter Reitsma (The Netherlands)

HTB01 14:00 -14:15

TTHHEE IITTIIMM RREECCEEPPTTOORR GG66BB--BB IISS AA CCRRIITTIICCAALLRREEGGUULLAATTOORR OOFF MMEEGGAAKKAARRYYOOCCYYTTEE AACCTTIIVVAATTIIOONN,,PPLLAATTEELLEETT PPRROODDUUCCTTIIOONN AANNDD FFUUNNCCTTIIOONN

A. Mazharian* (United Kingdom) - Y. J. Wang - J. Mori - S. Heising - B. G. Neel - S. P. Watson - Y. A. Senis

HTB02 14:15-14:30

PLLAATTEELLEETT GGEENNEE TTHHEERRAAPPYY CCOORRRREECCTTSS TTHHEEHHEEMMOOPPHHIILLIICC PPHHEENNOOTTYYPPEE IINN IIMMMMUUNNOOCCOOMMPPRROOMMIISSEEDDHHEEMMOOPPHHIILLIIAA AA MMIICCEE TTRRAANNSSPPLLAANNTTEEDD WWIITTHHGGEENNEETTIICCAALLLLYY MMAANNIIPPUULLAATTEEDD HHUUMMAANN CCOORRDD BBLLOOOODDSSTTEEMM CCEELLLLSS

Q. Shi* (USA) - E. L. Kuether - J. A. Schroeder - S. A. Fahs -R. R. Montgomery

HTB03 14:30-14:45

NNUUCCLLEEAARR FFAACCTTOORR ((NNFF))--””BB IISS AA MMAAJJOORR RREEGGUULLAATTOORROOFF BBLLOOOODD IINNDDUUCCEEDD JJOOIINNTT DDAAMMAAGGEE IINN AA MMUURRIINNEEMMOODDEELL OOFF HHEEMMOOPPHHIILLIIAA AA

D. Sen* (India) - A. Chapla - N. Walter - V. Daniel - S. Yesupatham - A. Srivastava - G. R. Jayandharan

HTB04 14:45-15:00

SSTTRRUUCCTTUURREE OOFF FFAACCTTOORR XXII IINN CCOOMMPPLLEEXX WWIITTHH AA HHIIGGHH MMOOLLEECCUULLAARR WWEEIIGGHHTT KKIINNIINNOOGGEENNPPEEPPTTIIDDEE

S. S. Wong* (United Kingdom) - G. Hall - H. Stennicke - J. Emsley

HTB05 15:00-15:15

IINNVVOOLLVVEEMMEENNTT OOFF 22--AANNTTIIPPLLAASSMMIINN IINN DDEENNDDRRIITTIICCGGRROOWWTTHH DDUURRIINNGG MMEEMMOORRYY FFOORRMMAATTIIOONN

E. Kawashita* (Japan) - Y. kanno - H. Asayama - K. Okada - S. Ueshima - H. Kaji - O. Matsuo - H. Matsuno

HTB06 15:15-15:30

MMOODDUULLAATTIIOONN OOFF TTAAFFII--DDEEPPEENNDDEENNTT RREEGGUULLAATTIIOONN OOFFFFIIBBRRIINNOOLLYYSSIISS BBYY EEXXTTRRAACCEELLLLUULLAARR HHIISSTTOONNEESS

L. O. Mosnier* (USA) - D. Rozenshteyn

HTB07 16:00-16:15

TTIISSSSUUEE FFAACCTTOORR EEXXPPRREESSSSIINNGG NNEEUUTTRROOPPHHIILLSS IINNIITTIIAATTEECCOOAAGGUULLAATTIIOONN OONN IINNJJUURREEDD VVEESSSSEELL WWAALLLLSS

R. Darbousset - G. Thomas - S. Mezouar - T. Renne - N. Mackman - F. Dignat-George - L. Panicot-Dubois — C. Dubois* (France)

HTB08 16:15-16:30

EEGGFFPP--EEGGFF11 PPRROOTTEEIINN CCOONNJJUUGGAATTEEDD PPEEGG--PPLLGGAANNAANNOOPPAARRTTIICCLLEESS FFOORR CCEERREEBBRRAALL TTHHRROOMMBBIITTAARRGGEETTIINNGG DDRRUUGG DDEELLIIVVEERRYY

W. Shi* (China) - Y. Hu - H. Mei - J. Deng - B. Zhang - C. Chen - F. H. Wang - T. Guo

ISTH 2012 11.6.2012 14:48 Page 68

Hot

Top

ics

Hot Topics Schedule

69

HTB09 16:30-16:45

LLOOSSSS OOFF PPRROOTTEEIINN CC RREECCEEPPTTOORRSS LLIINNKKSSCCOOAAGGUULLAATTIIOONN AANNDD IINNFFLLAAMMMMAATTIIOONN TTOO PPAARRAASSIITTEESSEEQQUUEESSTTRRAATTIIOONN IINN CCEERREEBBRRAALL MMAALLAARRIIAA

C. A. Moxon* (United Kingdom) - S. C. Wassmer - D. A. Milner - N. V. Chisala - T. E. Taylor - K. B. Seydel - M. E. Molyneux - B. Faragher - C. T. Esmon - C. Downey -C.-H. Toh - A. G. Craig - R. S. Heyderman

HTB10 16:45-17:00

EEXXTTRRAACCEELLLLUULLAARR HHIISSTTOONNEESS AARREE EELLIICCIITTIINNGG FFAACCTTOORRSS FFOORR DDIICC

T. Ito* (Japan) - M. Nakahara - I. Maruyama

CClliinnccaall SScciieennccee HHaallll 22 NN

Chairpersons: Anna Falanga (Italy), Henri Bounameaux(Switzerland)

HTC01 14:00 -14:15

PPRREEVVEENNTTIIOONN OOFF VVEENNOOUUSS TTHHRROOMMBBOOEEMMBBOOLLIISSMMAAFFTTEERR AANN IISSOOLLAATTEEDD,, NNOONN--SSUURRGGIICCAALL BBEELLOOWW--KKNNEEEE IINNJJUURRYY.. BBEENNEEFFIITT//RRIISSKK OOFFFFOONNDDAAPPAARRIINNUUXX VVEERRSSUUSS LLOOWW MMOOLLEECCUULLAARR WWEEIIGGHHTTHHEEPPAARRIINN:: TTHHEE FFOONNDDAACCAASSTT SSTTUUDDYY

C. M. Samama* (France) - B. Riou - P.-M. Roy - A. Sautet - P. Mismetti and the FONDACAST study group

HTC02 14:15-14:30

MMUULLTTIIPPLLEE SSNNPP TTEESSTTIINNGG IIMMPPRROOVVEESS RRIISSKK PPRREEDDIICCTTIIOONNOOFF FFIIRRSSTT VVEENNOOUUSS TTHHRROOMMBBOOSSIISS

H. G. De Haan* (The Netherlands) - I. D. Bezemer - C. J. Doggen - S. Le Cessie - P. H. Reitsma - A. R. Arellano -C. H. Tong - J. J. Devlin - L. A. Bare - F. R. Rosendaal - C. Y. Vossen

HTC03 14:30-14:45

AA RRAANNDDOOMMIIZZEEDD--CCOONNTTRROOLLLLEEDD PPHHAASSEE IIII TTRRIIAALL OOFFPPRRIIMMAARRYY TTHHRROOMMBBOOPPRROOPPHHYYLLAAXXIISS WWIITTHH EENNOOXXAAPPAARRIINNIINN CCAANNCCEERR PPAATTIIEENNTTSS WWIITTHH EELLEEVVAATTEEDD TTIISSSSUUEE FFAACCTTOORRBBEEAARRIINNGG MMIICCRROOPPAARRTTIICCLLEESS ((TTHHEE MMIICCRROOTTEECC SSTTUUDDYY))

J. Zwicker* (USA) - H. A. Liebman - K. A. Bauer - T. Caughey- R. Rosovsky - S. Mantha - C. M. Kessler - J. Eneman — V. Raghavan - H. J. Lenz - A. Bullock - E. Buchbinder - F. Campigotto - D. Neuberg - B. Furie

ISTH 2012 11.6.2012 14:48 Page 69

Hot Topics Schedule

70

HTC04 14:45-15:00

IINNDDIIRREECCTT CCOOMMPPAARRIISSOONN OOFF EEFFFFIICCAACCYY AANNDD SSAAFFEETTYYOOFF DDAABBIIGGAATTRRAANNÕSS RREE--LLYY,, RRIIVVAARROOXXAABBAANNÕSS RROOCCKKEETT--AAFF,, AANNDD AAPPIIXXAABBAANNÕSS AARRIISSTTOOTTLLEE TTRRIIAALL IINN PPAATTIIEENNTTSSWWIITTHH NNOONN--VVAALLVVUULLAARR AATTRRIIAALL FFIIBBRRIILLLLAATTIIOONN

J. Harenberg* (Germany) - S. Marx - H.-C. Diener - G. Lip -V. Marder - C. Weiss - M. Wehling

HTC05 15:00-15:15

AAUUTTOOAANNTTIIBBOODDIIEESS DDIIRREECCTTEEDD AAGGAAIINNSSTT DDOOMMAAIINN II OOFFBBEETTAA22--GGLLYYCCOO--PPRROOTTEEIINN II IINNDDIICCAATTEE AANN IINNCCRREEAASSEEDDRRIISSKK FFOORR TTHHRROOMMBBOOEEMMBBOOLLIICCEEVVEENNTTSS IINN PPAATTIIEENNTTSS WWIITTHH AANNTTIIPPHHOOSSPPHHOOLLIIPPIIDDAANNTTIIBBOODDIIEESS.. AA PPRROOSSPPEECCTTIIVVEE CCOOHHOORRTT SSTTUUDDYY

S. Zuily* (France) - B. De Laat - V. Regnault - F. Guillemin - P. Kaminsky - R. Albesa - G. Norman - P. G. De Groot — T. Lecompte - D. Wahl

HTC06 15:15-15:30

WWHHOOLLEE--EEXXOOMMEE SSEEQQUUEENNCCIINNGG IIDDEENNTTIIFFIIEESS NNOOVVEELL RRIISSKKVVAARRIIAANNTTSS FFOORR TTHHRROOMMBBOOTTIICC SSTTOORRMM

T. L. Ortel* (USA) - G. Beecham - D. Hedges - P. Whitehead - A. Beecham - S. E. Hahn - J. W. Lawson - D. Erkan — L. R. Brandao - A. H. James - M. J. Manco-Johnson - R.Kulkarni - C. S. Kitchens - M. A. Pericak-Vance - J. M. Vance

HTC07 16:00-16:15

AA NNOOVVEELL GGEENNEETTIICC VVAARRIIAANNTT OOFF TTHHEE CCYYTTOOSSOOLLIICCPPHHOOSSPPHHOOLLIIPPAASSEE AA22 AALLPPHHAA AASSSSOOCCIIAATTEEDD WWIITTHHBBLLEEEEDDIINNGG DDIIAATTHHEESSIISS AANNDD DDUUOODDEENNAALL UULLCCEERRSS IINN AANN IITTAALLIIAANN FFAAMMIILLYY

E. M. Faioni* (Italy) - C. Razzari - G. Podda - M. Trinchera - G. Fontana - M. Cattaneo

HTC08 16:15-16:30

NNOOVVEELL MMHHCC PPEEPPTTIIDDEE-- TT CCEELLLL RREECCEEPPTTOORRIINNTTEERRFFAACCEESS AARREE NNEECCEESSSSAARRYY FFOORR IINNHHIIBBIITTOORRFFOORRMMAATTIIOONN IINN MMIILLDD//MMOODDEERRAATTEE HHAAEEMMOOPPHHIILLIIAA AASSEECCOONNDDAARRYY TTOO MMIISS--SSEENNSSEE MMUUTTAATTIIOONN GGEENNOOTTYYPPEESS

D. P. Hart* (United Kingdom) - S. Skelton - D. S. Moss - K. Gomez - C. Sansom - A. Shepherd

HTC09 16:30-16:45

SSPPAATTIIAALL BBLLOOOODD CCOOAAGGUULLAATTIIOONN IINN TTHHEE PPRREESSEENNCCEE OOFFAANNTTII--TTFFPPII AAPPTTAAMMEERR BBAAXX449999 IINN HHEEMMOOPPHHIILLIIAA AAPPAATTIIEENNTTSS AAFFTTEERR FFVVIIIIII IINNFFUUSSIIOONN

L. A. Parunov* (Russia) - N. P. Soshitova - O. A. Fadeeva - A. N. Balandina - K. G. Kopylov - M. A. Kumskova — K. E. McGinness - M. A. Panteleev - F. I. Ataullakhanov - R. G. Schaub - J. C. Gilbert

HTC10 16:45-17:00

TTHHEE IINNCCIIDDEENNCCEE OOFF FFAACCTTOORR VVIIIIII IINNHHIIBBIITTOORRSS IINNSSEEVVEERREE HHAAEEMMOOPPHHIILLIIAA AA FFOOLLLLOOWWIINNGG AA MMAAJJOORRPPRROODDUUCCTT SSWWIITTCCHH IINN TTHHEE UUKK:: AAPPRROOSSPPEECCTTIIVVEECCOONNTTRROOLLLLEEDD SSTTUUDDYY IINN 11221144 PPRREEVVIIOOUUSSLLYY TTRREEAATTEEDDPPAATTIIEENNTTSS

C. R. M. Hay* (United Kingdom) - P. Collins - B. Palmer - R. Liesner - E. Chalmers - D. Hart - S. Rangarajan - S. Ragarajan - K. Talks - M. Williams -

ISTH 2012 11.6.2012 14:48 Page 70

ePos

ters

ePoster Session

71

AAnnttiitthhrroommbboottiicc tthheerraappyy

Chairperson: Nigel Key (USA)

AATTTT0011 XXAAMMOOSS:: AA NNOONN--IINNTTEERRVVEENNTTIIOONNAALL SSTTUUDDYYCCOOMMPPAARRIINNGG TTHHRROOMMBBOOPPRROOPPHHYYLLAAXXIISS UUSSIINNGGOORRAALL RRIIVVAARROOXXAABBAANN WWIITTHH CCOONNVVEENNTTIIOONNAALLRREEGGIIMMEENNSS AAFFTTEERR MMAAJJOORR OORRTTHHOOPPAAEEDDIICCSSUURRGGEERRYY OOFF TTHHEE HHIIPP AANNDD KKNNEEEE A. G. Turpie* (USA) - W. Jamal - A. Schmidt - M. R. Lassen - L. Mantovani - R. Kreutz - S. Haas

AATTTT0022 RRIISSKK OOFF TTHHRROOMMBBOOEEMMBBOOLLIISSMM,, RREECCUURRRREENNTTBBLLEEEEDDIINNGG AANNDD DDEEAATTHH AAFFTTEERR WWAARRFFAARRIINNIINNTTEERRRRUUPPTTIIOONN FFOORR GGAASSTTRROOIINNTTEESSTTIINNAALLBBLLEEEEDDIINNGG D. M. Witt* (USA) - T. Delate - D. Garcia - N. Clark- E. Hylek - W. Ageno - F. Dentali - M. Crowtherand WARPED Consortium

AATTTT0033 DDEESSPPIITTEE PPHHAARRMMAACCOOLLOOGGIICCAALLEEQQUUIIVVAALLEENNCCEE,, GGEENNEERRIICC VVEERRSSIIOONNSS OOFFEENNOOXXAAPPAARRIINN MMAAYY DDIIFFFFEERR IINN TTHHEEIIRRPPHHAARRMMAACCOODDYYNNAAMMIICC AACCTTIIOONNSS.. PPOOTTEENNTTIIAALLTTHHEERRAAPPEEUUTTIICC IIMMPPLLIICCAATTIIOONNSS W. Jeske* (USA) - J. M. Walenga - E. McGeehan - J. Harenberg - E. Ramacciotti - J. Fareed

AATTTT0044 PPEERRCCEEIIVVEEDD SSTTRREESSSS RREEDDUUCCEESS TTHHEESSTTAABBIILLIITTYY OOFF VVIITTAAMMIINN KK--AANNTTAAGGOONNIISSTTTTRREEAATTMMEENNTT J. Skov* (Denmark) - A. Leppin - E.-M. Bladbjerg - J. J. Sidelmann - J. Gram

AATTTT0055 OONNEE WWEEEEKK VVEERRSSUUSS FFOOUURR WWEEEEKK HHEEPPAARRIINNPPRROOPPHHYYLLAAXXIISS AAFFTTEERR LLAAPPAARROOSSCCOOPPIICCSSUURRGGEERRYY FFOORR CCOOLLOORREECCTTAALL CCAANNCCEERR.. TTHHEEPPRROO--LLAAPPSS PPIILLOOTT FFEEAASSIIBBIILLIITTYY SSTTUUDDYY C. Becattini - M. C. Vedovati* (Italy) - F. Rondelli - M. Boncompagni - G. Camporese - R. Balzarotti -E. Mariani - O. Flamini - G. Natalini - A. Donini -M. Giustozzi - G. Agnelli

AATTTT0066 TTHHEE SSAAFFEETTYY AANNDD EEFFFFIICCAACCYY OOFF IINNFFEERRIIOORRVVEENNAA CCAAVVAA FFIILLTTEERRSS:: TTHHEE EEXXPPEERRIIEENNCCEE OOFFTTHHEE OOTTTTAAWWAA HHOOSSPPIITTAALL L. D. Duffett* (Canada) - A. Cheung - G. Bose - A. Forster - P. Wells

AATTTT0077 EEVVAALLUUAATTIIOONN OOFF AA CCOOMMMMUUNNIITTYY PPHHAARRMMAACCYYAANNTTIICCOOAAGGUULLAATTIIOONN MMAANNAAGGEEMMEENNTT SSEERRVVIICCEEUUTTIILLIISSIINNGG PPOOIINNTT--OOFF--CCAARREE TTEESSTTIINNGG AANNDDOONNLLIINNEE CCOOMMPPUUTTEERRIISSEEDD DDEECCIISSIIOONNSSUUPPPPOORRTTP. Harper* (New Zealand) - J. Shaw - J. Harrison - J. Harrison

AATTTT0088 IISS TTHHEERREE AA GGRREEAATTEERR RROOLLEE FFOORRTTHHRROOMMBBOOLLYYSSIISS IINN TTHHEE AACCUUTTEEMMAANNAAGGEEMMEENNTT OOFF DDEEEEPP VVEEIINN TTHHRROOMMBBOOSSIISS((DDVVTT))?? RREEVVIIEEWW OOFF TTHHEE MMAANNAAGGEEMMEENNTT AANNDDOOUUTTCCOOMMEE OOFF PPAATTIIEENNTTSS PPRREESSEENNTTIINNGG WWIITTHHPPRROOXXIIMMAALL DDVVTT TTOO AA SSIINNGGLLEE UUKK CCEENNTTRREEOOVVEERR AA 22--YYEEAARR PPEERRIIOODD D. Jayakody Arachchillage* (United Kingdom) - S. Chattree - B. Robinson - L. Rivett - P. Kesteven- K. Talks

AATTTT0099 EENNDDOOGGEENNOOUUSS TTHHRROOMMBBIINN PPOOTTEENNTTIIAALL IINNPPAATTIIEENNTTSS WWIITTHH LLOOWW IINNTTEENNSSIITTYY VVIITTAAMMIINN KKAANNTTAAGGOONNIISSTTSS TTRREEAATTMMEENNTT V. Shmeleva* (Russian Federation) - Y. Namestnikov - O. Matvienko - L. Papayan - V. Soldatenkov

EExhibition hall lower level 17:00 - 19:00

ISTH 2012 11.6.2012 14:48 Page 71


ePoster Session

72

AATTTT1100 PPRROOPPHHYYLLAAXXIISS OOFF PPOOSSTTOOPPEERRAATTIIVVEE VVEENNOOUUSSTTHHRROOMMBBOOEEMMBBOOLLIISSMM:: PPUURRSSUUIITT OOFF AARRAATTIIOONNAALL SSYYSSTTEEMMAATTIICC AAPPPPRROOAACCHH A. V. Vardanyan* (Russian Federation)- R. B. Mumladze - E. V. Roitman - D. D. Dolidze - L. I. Patrushev - M. Shieh

AATTTT1111 SSAAFFEETTYY AANNDD EEFFFFIICCAACCYY OOFF BBRRIIDDGGIINNGG WWIITTHHLLOOWW MMOOLLEECCUULLAARR WWEEIIGGHHTT HHEEPPAARRIINNSS::AA SSYYSSTTEEMMAATTIICC RREEVVIIEEWW P. Eijgenraam* (The Netherlands) - H. ten Cate - A. ten Cate-Hoek

AATTTT1122 VVAARRIIAANNCCEE GGRROOWWTTHH RRAATTEE:: AA SSUUPPEERRIIOORRMMEETTHHOODD TTOO MMOONNIITTOORR OORRAALLAANNTTIICCOOAAGGUULLAATTIIOONN TTHHEERRAAPPYY A. V. Sharda* (USA) - G. Johnson - M. Kuskowski

AATTTT1133 EEUURROOPPEEAANN AACCTTIIOONN OONN AANNTTIICCOOAAGGUULLAATTIIOONN((EEAAAA)) EEVVAALLUUAATTIIOONN OOFF TTHHEE UUKK NNAATTIIOONNAALLHHEEAALLTTHH SSEERRVVIICCEE ((NNHHSS)) IIMMPPRROOVVEEMMEENNTTGGUUIIDDEELLIINNEESS FFOORR ÒSSAAFFEETTYY IINNDDIICCAATTOORRSSÓ IINNAANNTTIICCOOAAGGUULLAATTIIOONN OOFF AATTRRIIAALL FFIIBBRRIILLLLAATTIIOONN((AAFF)) L. Poller* (United Kingdom) - S. Ibrahim - T. Baglin - J. Jespersen

AATTTT1144 IINNFFRREEQQUUEENNTT RREEMMOOVVAALL OOFF RREETTRRIIEEVVAABBLLEEIIVVCC FFIILLTTEERRSS L. Furmark* (USA) - J. El Amm - D. Mobarek - C. Faselis - F. Rickles - A. Aggarwal

AATTTT1155 PPRREEDDIICCTTIIOONN OOFF OOPPTTIIMMAALL WWAARRFFAARRIINNMMAAIINNTTEENNAANNCCEE DDOOSSEE UUSSIINNGG AADDVVAANNCCEEDDAARRTTIIFFIICCIIAALL NNEEUURRAALL NNEETTWWOORRKKSS M. Pugliano* (Italy) - E. Grossi - G. M. Podda - S. Gabba - G. Carpani - A. Verri - M. Buscema -E. M. Faioni - M. Cattaneo

AATTTT1166 EEMMEERRGGEENNCCYY RREEVVEERRSSAALL OOFF VVIITTAAMMIINN KKAANNTTAAGGOONNIISSTTSS WWIITTHH PPRROOTTHHRROOMMBBIINNCCOOMMPPLLEEXX CCOONNCCEENNTTRRAATTEE:: TTHHEE EEVVEERRYYDDAAYYPPRRAACCTTIICCEE P. Toth* (United Kingdom) - K. Robinson - S. Laidlaw - R. Maclean - J. van Veen - K. Hampton - M. Makris

AATTTT1177 BBIIOOSSIIMMIILLAARR EENNOOXXAAPPAARRIINNSS AAVVAAIILLAABBLLEE FFOORRCCLLIINNIICCAALL UUSSEE IINN BBRRAAZZIILL:: SSTTRRUUCCTTUURREE AANNDDHHAAEEMMOOSSTTAATTIICC EEFFFFEECCTTSSB. F. Glauser* (Brazil) - B. C. Vairo - S. N. Oliveira- L. P. Cinelli - M. S. Pereira - P. S. Mour� o

AATTTT1188 DDAABBIIGGAATTRRAANN EEXXPPEERRIIEENNCCEE IINN NNEEWWZZEEAALLAANNDDM. Stephens - D. Pollock - P. Harper* (New Zealand)

AATTTT1199 RROOLLEE OOFF SSUULLFFAATTEEDD GGAALLAACCTTAANNSS OONNTTHHRROOMMBBOOSSIISS AANNDD AANNTTIITTHHRROOMMBBIINNIINNTTEERRAACCTTIIOONN S. N. M. De Oliveira* (Brazil) - R. C. Fonseca - P. D. S. Mourao

AATTTT2200 DDEEVVEELLOOPPIINNGG AANN IIPPHHOONNEE AAPPPP FFOORR TTHHEEMMAANNAAGGEEMMEENNTT OOFF TTHHEE AANNTTIICCOOAAGGUULLAANNTTDDAABBIIGGAATTRRAANN P. Harper* (New Zealand)

AATTTT2211 TTHHEE RROOLLEE OOFF LLMMWWHH IINN PPRREEVVEENNTTIIOONN OOFFDDEEEEPP VVEEIINNSS TTHHRROOMMBBOOSSIISS AANNDD PPUULLMMOONNAARRYYEEMMBBOOIISSMM IINN PPAATTIIEENNTTSS WWIITTHH SSEEVVEERREEMMUULLTTIIPPLLEE TTRRAAUUMMAA D. Danchev* (Bulgaria) - N. Petrov - D. Zidarova

ISTH 2012 11.6.2012 14:48 Page 72

ePos

ters


ePoster Session

73

CCooaagguullaattiioonn ffaaccttoorrss BBaassiicc SScciieennccee

Chairperson: Henry Spronk (The Netherlands)

CCFFBBSS0011 FFIIBBRRIINN FFOORRMMAATTIIOONN UUNNDDEERR FFLLOOWW OONNBBIIOOMMIIMMEETTIICC TTIISSSSUUEE FFAACCTTOORR RRIICCHHSSUURRFFAACCEESS A. Onasoga* (USA) - K. Neeves

CCFFBBSS0022 PPRREE--AANNAALLYYTTIICCAALL RROOUUTTIINNEESS IINNCCOOAAGGUULLAATTIIOONN TTEESSTTIINNGG:: AARREE GGUUIIDDEELLIINNEESSFFOOLLLLOOWWEEDD?? A.-H. Kristoffersen* (Norway) - A. V. Stavelin - S. Vannes - G. B. Kristensen

CCFFBBSS0033 TTHHEE AATTOOMMIICC FFOORRCCEE MMIICCRROOSSCCOOPPYY AASSUUIITTAABBLLEE TTEECCHHNNIIQQUUEE TTOO CCHHAARRAACCTTEERRIIZZEEPPRROOCCOOAAGGUULLAANNTT VVEESSIICCLLEESS IINN TTHHEENNAANNOOMMEETTEERR SSCCAALLEE J. Hardij* (Belgium) - J.-M. Dogn� - B. Chatelain - F. Mullier

CCFFBBSS0055 IINNFFLLUUEENNCCEE OOFF DDAABBIIGGAATTRRAANN OONNCCOOAAGGUULLAATTIIOONN AASSSSAAYYSS,, AANN ÒIINN VVIITTRROO ÓSSTTUUDDYY M. M. Samama* (France) - C. Guinet - G. Gerotziafas - L. Le Flem

CCFFBBSS0066 RREECCOOMMMMEENNDDAATTIIOONNSS FFOORR LLAABBOORRAATTOORRYYTTEESSTTIINNGG OOFF NNEEWW AANNTTIICCOOAAGGUULLAANNTTSS IINN TTHHEENNEETTHHEERRLLAANNDDSS A. K. Stroobants* (The Netherlands) and workinggroup new anticoagulants of the VHL (VerenigingHematologische Laboratoria)

CCFFBBSS0077 DDEEVVEELLOOPPMMEENNTT OOFF AA NNOOVVEELL IIMMAAGGIINNGGTTEECCHHNNIIQQUUEE FFOORR TTHHEE QQUUAANNTTIIFFIICCAATTIIOONN OOFFMMAASSSS,, VVOOLLUUMMEE,, AANNDD DDEENNSSIITTYY OOFFTTHHRROOMMBBUUSS FFOORRMMAATTIIOONN S. M. Baker* (USA) - O. J. McCarty - K. G. Phillips- K. J. Rees

CCFFBBSS0088 AADDAAMMTTSS1133 IINN VVOONN WWIILLLLEEBBRRAANNDD FFAACCTTOORR((VVWWFF)) CCOONNCCEENNTTRRAATTEESS:: IISS AANN IINNTTAACCTT VVWWFFTTRRIIPPLLEETT SSTTRRUUCCTTUURREE IIMMPPOORRTTAANNTT FFOORR VVWWFFFFUUNNCCTTIIOONN?? C. Kannicht - B. Solecka - M. Kroening - B. Fuchs*(Germany)

CCFFBBSS0099 SSMMIIAA:: AA NNEEWW AAPPPPRROOAACCHH IINN FFVVIIIIII IINNHHIIBBIITTOORRMMEEAASSUURREEMMEENNTT AANNDD SSTTAANNDDAARRDDIISSAATTIIOONN S. Raut* (United Kingdom)

CCFFBBSS1100 TTHHRROOMMBBIINN IINNHHIIBBIITTIIOONN AACCTTIIVVIITTYY AANNDD IINNVVIITTRROO SSTTAABBIILLIITTYY IINN HHUUMMAANN PPLLAASSMMAA OOFFTTWWOO AAPPTTAAMMEERRSS I. Gribkova* (Russian Federation) - V. Spiridonova- A. Gorbatenko - E. Sinauridze

CCFFBBSS1111 TTEECCHHNNOOCCLLOOTT¤¤ DDTTII AANNDD TTEECCHHNNOOVVIIEEWW¤¤DDAABBIIGGAATTRRAANN -- EEVVAALLUUAATTIIOONN OOFF AASSSSAAYYPPEERRFFOORRMMAANNCCEE MMOONNIITTOORRIINNGG TTHHEE DDIIRREECCTTTTHHRROOMMBBIINN IINNHHIIBBIITTOORR DDAABBIIGGAATTRRAANN L. Wagner* (Austria) - V. Kaufmann - J. Mager - S. Geiter - M. Leitner

CCFFBBSS1122 TTEECCHHNNOOCCHHRROOMM AANNTTII--XXAA AANNDD TTEECCHHNNOOVVIIEEWWRRIIVVAARROOXXAABBAANN -- EEVVAALLUUAATTIIOONN OOFF AASSSSAAYYPPEERRFFOORRMMAANNCCEE OONN DDIIFFFFEERREENNTT AANNAALLYYZZEERRSS L. Wagner* (Austria) - V. Kaufmann - J. Mager - S. Geiter - M. Leitner - A. Siegemund - E. Lindhoff-Last

CCFFBBSS1133 SSTTAAPPHHYYLLOOTTHHRROOMMBBIINN--MMEEDDIIAATTEEDD FFIIBBRRIINNFFAACCIILLIITTAATTEESS SS.. AAUURREEUUSS--PPLLAATTEELLEETTIINNTTEERRAACCTTIIOONNSS T. Vanassche* (Belgium) - M. Hoylaerts - P. Verhamme

ISTH 2012 11.6.2012 14:48 Page 73


ePoster Session

74

CCFFBBSS1144 AACCUUTTEE PPHHAASSEE PPRROOTTEEIINNSS RREEDDUUCCEE HHIISSTTOONNEE--IINNDDUUCCEEDD PPLLAATTEELLEETT AAGGGGRREEGGAATTIIOONN AANNDDCCOOAAGGUULLAATTIIOONN AACCTTIIVVAATTIIOONN S. T. Abrams* (United Kingdom) - J. Manson - T. Liu - F. Baluwa - V. Barrera - K. Brohi - J. Thachil - G. Wang - C. H. Toh

CCFFBBSS1155 CCTTPP -- AA CCLLIINNIICCAALLLLYY VVAALLIIDDAATTEEDDTTEECCHHNNOOLLOOGGYY FFOORR EELLOONNGGAATTIINNGG TTHHEE HHAALLFFLLIIFFEE OOFF CCOOAAGGUULLAATTIIOONN FFAACCTTOORRSS,, EENNAABBLLIINNGGAA PPRROOLLOONNGGEEDD HHAAEEMMOOSSTTAATTIICC AACCTTIIVVIITTYY IINNHHEEMMOOPPHHIILLIICC AANNIIMMAALL MMOODDEELLG. Hart* (Israel) - M. Zakar - P. E. Monahan - A. Bar-Ilian - O. Hershkovitz - E. Fima

CCFFBBSS1166 IINNFFLLUUEENNCCEE OOFF CCRRYYSSTTAALLLLOOIIDD DDIILLUUEENNTTSSCCOONNCCEENNTTRRAATTIIOONN OONN TTHHRROOMMBBIINNGGEENNEERRAATTIIOONN:: CCOOMMPPAARRIISSOONN OOFF NNAACCLL AANNDDMMAANNNNIITTOOLL G. O. Ogweno* (Kenya) - N. K. Gikonyo - W. Mwanda - F. Bukachi - T. Peters

CCFFBBSS1177 SSPPAATTIIAALL FFIIBBRRIINN CCLLOOTT FFOORRMMAATTIIOONN IINNPPLLAASSMMAA IINNDDUUCCEEDD BBYY SSUURRFFAACCEE--IIMMMMOOBBIILLIIZZEEDD TTIISSSSUUEE FFAACCTTOORR:: AASSSSAAYYDDEEVVEELLOOPPMMEENNTT AANNDD SSTTAANNDDAARRDDIIZZAATTIIOONN N. Korotina* (Russian Federation) - O. Khrapkova- T. Vuimo - A. Balandina - E. Lipets - S. Karamzin- O. Fadeeva - I. Spiridonov - M. Panteleev - F. Attaulakhanov

CCFFBBSS1188 IINNTTEERRIIMM RREESSUULLTTSS FFRROOMM AA GGEERRMMAANNPPRROOSSPPEECCTTIIVVEE PPOOSSTT--MMAARRKKEETTIINNGGSSUURRVVEEIILLLLAANNCCEE OOFF TTRREEAATTMMEENNTT OOFF VVOONNWWIILLLLEEBBRRAANNDDÕSS DDIISSEEAASSEE WWIITTHH AA NNEEWWGGEENNEERRAATTIIOONN VVWWFF//FFVVIIIIII CCOONNCCEENNTTRRAATTEE I. Scharrer - M. v. Depka - S. Alesci - J. Feddern -O. Hegener* (Switzerland) - J. Kadar - W. Miesbach

CCFFBBSS1199 IIMMPPAACCTT OOFF TTHHRROOMMBBIINN AANNDD FFXXAA IINNHHIIBBIITTOORRSS((DDAAIIGGAATTRRAANN,, AAPPIIXXAABBAANN,, AANNDD RRIIVVAARROOXXIIBBAANN))OONN PPTT//AAPPTTTT AASSSSAAYYSS OONN IILLIINNSSTTRRUUMMEENNTT//RREEAAGGEENNTT SSYYSSTTEEMMSS J. Hammelburger* (USA) - R. Bottenus - M. Triscott

CCFFBBSS2200 SSTTRRUUCCTTUURREE OOFF TTHHEE FFXXIIII PPRROOTTEEAASSEE DDOOMMAAIINN J. Emsley* (United Kingdom) - M. Pathak

CCFFBBSS2211 IINNFFLLUUEENNCCEE OOFF VVKKAA,, UUFFHH OORR LLMMWWHHTTRREEAATTEEDD PPLLAASSMMAA IINN RRIIVVAARROOXXAABBAANNMMEEAASSUURREEMMEENNTT WWIITTHH DDIIFFFFEERREENNTT MMEETTHHOODDSSBBAASSEEDD OONN FFXX OORR FFXXAA AACCTTIIVVIITTYY M. M. Samama* (France) - C. Guinet - L. Le Flem - J. Amiral

CCFFBBSS2222 PPHHAARRMMAACCOODDYYNNAAMMIICC OOFF BBOOVVIINNEE AANNDDPPOORRCCIINNEE HHEEPPAARRIINNSS L. A. C. T. Teixeira* (Brazil) - P. A. D. S. Moura~o - A. M. F. Tovar - J. R. Lugon - S. M. Rembold

CCFFBBSS2233 SSEEMMUULLOOPPAARRIINN AANNDD IITT’’SS CCOOMMPPOONNEENNTTOOLLIIGGOOSSAACCCCHHAARRIIDDEESS RREELLEEAASSEEEENNDDOOGGEENNOOUUSS TTFFPPII IINN AA MMOOLLEECCUULLAARRWWEEIIGGHHTT DDEEPPEENNDDEENNTT FFAASSHHIIOONN..PPHHAARRMMAACCOODDYYNNAAMMIICC IIMMPPLLIICCAATTIIOONNSS J. Fareed* (USA) - H. Khan - E. Litinas - J. Cunanan - D. Hoppensteadt - C. Viskov

CCFFBBSS2244 DDIIFFFFEERREENNTTIIAATTIIOONN OOFF NNEEWWEERR OORRAALL AANNTTII--XXAAAANNDD AANNTTII--IIIIAA AAGGEENNTTSS WWIITTHH AA RREEFFEERREENNCCEETTOO TTHHEE RREEGGUULLAATTOORRYY FFUUNNCCTTIIOONNSS OOFFTTHHRROOMMBBIINN J. M. Walenga* (USA) - J. Fareed - D. Hoppensteadt - W. Jeske - O. Iqbal - A. Gray - B. Lewis

ISTH 2012 11.6.2012 14:48 Page 74

ePos

ters


ePoster Session

75

CCFFBBSS2255 CCOOMMPPAARRIISSOONN OOFF TTHHEE AANNTTIICCOOAAGGUULLAANNTT AANNDDAANNTTIITTHHRROOMMBBOOTTIICC AACCTTIIVVIITTIIEESS OOFFFFUUCCOOSSYYLLAATTEEDD CCHHOONNDDRROOIITTIINN SSUULLFFAATTEE WWIITTHHTTHHEE DDIIRREECCTT TTHHRROOMMBBIINN IINNHHIIBBIITTOORRDDAABBIIGGAATTRRAANN EETTEEXXIILLAATTEER. J. C. Fonseca* (Brazil) - R. Cortez - P. A. D. S. Moura~o

CCFFBBSS2266 SSTTAANNDDAARRDDIIZZAATTIIOONN OOFF RROOTTAATTIIOONNTTHHRROOMMBBOOEELLAASSTTOOMMEETTRRYY ((RROOTTEEMM¤¤))::EEVVAALLUUAATTIIOONN OOFF RREECCOOMMBBIINNAANNTT FFAACCTTOORR VVIIIIIIPPRROODDUUCCTTSS IINN AA MMUULLTTII--NNAATTIIOONNAALL CCLLIINNIICCAALLTTRRIIAALL F. Driessler* (USA) - X. Li - T. Liu - X. Zhang - B. Yang - H. Jiang - A. Luk - G. F. Pierce - J. Sommer

CCFFBBSS2277 TTHHEE CCOONNDDEENNSSEEDD MMCCMMDDMM--11 VVWWDD BBLLEEEEDDIINNGGQQUUEESSTTIIOONNNNAAIIRREE AASS AA PPRREEDDIICCTTOORR OOFFBBLLEEEEDDIINNGG DDIISSOORRDDEERRSS IINN WWOOMMEENN WWIITTHHUUNNEEXXPPLLAAIINNEEDD MMEENNOORRRRHHAAGGIIAA H. Azzam* (Egypt) - H. R. Ghoneim - A. Elsadeik -E. azmy - M. hassan - S. elsharawy

CCFFBBSS2288 GGEENNEETTIICC DDEEFFEECCTTSS IINN VVOONN WWIILLLLEEBBRRAANNDDDDIISSEEAASSEE TTYYPPEE 33 IINN SSOOUUTTHH WWEESSTT IIRRAANN B. Keikhaei* (Islamic Republic of Iran) - M. Nasiri -H. Galehdari - M. Yavarian

CCFFBBSS2299 OOCCTTAANNAATTEE SSHHOOWWSS LLOOWW IINNHHIIBBIITTOORRIINNCCIIDDEENNCCEE IINN TTRREEAATTMMEENNTT OOFF PPRREEVVIIOOUUSSLLYYUUNNTTRREEAATTEEDD PPAATTIIEENNTTSS WWIITTHH HHAAEEMMOOPPHHIILLIIAA AA A. Klukowska - V. Komrska - M. Jansen - J. Bichler* (Switzerland) - P. Laguna

CCFFBBSS3300 TTHHEE EEFFFFEECCTT OOFF CCPPBB OONN FFXXIIIIII LLEEVVEELLSS IINNCCHHIILLDDRREENN C. Cini - C. Attard - P. Monagle* (Australia) - V. Ignjatovic

CCFFBBSS3311 DDYYSSFFIIBBRRIINNOOGGEENNEEMMIIAA CCAAUUSSEEDD BBYY TTWWOOMMUUTTAATTIIOONNSS PPRREESSEENNTT IINN AA SSIINNGGLLEECCHHRROOMMOOSSOOMMEE L. Jiang* (China) - X. Wang

CCFFBBSS3322 DDEETTEERRMMIINNAATTIIOONN OOFF FFIIBBRRIINNOOGGEENN LLEEVVEELL TTOOGGUUIIDDEE RREEPPLLAACCEEMMEENNTT TTHHEERRAAPPYY IINNPPAATTIIEENNTTSS UUNNDDEERRGGOOIINNGGCCAARRDDIIOOPPUULLMMOONNAARRYY BBYYPPAASSSS WWIITTHH DDIIRREECCTTTTHHRROOMMBBIINN IINNHHIIBBIITTOORRSS S. G. Macdonald* (United Kingdom) - N. Bannister - E. Ortmann - D. Jenkins - F. Falter -S. Gray - R. Luddington - J. Whitbread - S. Colah - M. Besser

CCFFBBSS3333 HHOOWW DDOO HHAAEEMMOOSSTTAATTIICC VVAARRIIAABBLLEESS AAFFFFEECCTTTTHHRROOMMBBIINN GGEENNEERRAATTIIOONN DDUURRIINNGG TTHHEECCOOUURRSSEE OOFF TTHHEE MMEENNSSTTRRUUAALL CCYYCCLLEE?? R. Chaireti* (Sweden) - K. Bremme - K. M. Gustafsson - T. L. Lindahl

CCFFBBSS3344 DDEETTEECCTTIINNGG IINNTTEERRAACCTTIIOONN OOFF VVWWFF AA11DDOOMMAAIINN AANNDD AA33 DDOOMMAAIINN UUSSIINNGG SSNNAAPP//CCLLIIPP--TTAAGG TTEECCHHNNOOLLOOGGYY M. Jiang* (China) - Y. Zhao - C. Ruan

CCFFBBSS3355 IINNFFLLUUEENNCCEE OOFF TTEEMMPPEERRAATTUURREE OONN FFIIBBRRIINNCCLLOOTT FFOORRMMAATTIIOONN PPRROOCCEESSSS IINNTTHHRROOMMBBOODDYYNNAAMMIICCSS AANNDD RROOUUTTIINNEECCLLOOTTTTIINNGG TTEESSTTSS I. A. Shcherbina* (Russian Federation) - E. N. Lipets - A. N. Balandina - F. I. Ataullakhanov

ISTH 2012 11.6.2012 14:48 Page 75


ePoster Session

76

CCFFBBSS3366 IITTII WWIITTHH AA VVWWFF--SSTTAABBIILLIISSEEDD FFVVIIIIII CCOONNCCEENN--TTRRAATTEE IINN HHAAEEMMOOPPHHIILLIIAA AA PPAATTIIEENNTTSS WWIITTHHIINNHHIIBBIITTOORRSS AANNDD AA PPOOOORR PPRROOGGNNOOSSIISS FFOORRIITTII SSUUCCCCEESSSS:: PPRROOGGRREESSSS RREEPPOORRTT OONN OOCCTTAA--NNAATTEE IINN TTHHEE OOBBSSEERRVVAATTIIOONNAALL OOBBSSIITTII SSTTUUDDYY N. Zozulya - O. Plysch - V. Vdovin - T. Andreeva -P. Svirin - T. Severova - E. Shiller - N. Klimova - M. Benedik-Dolnicar - F. Velasco - M. Campos - J. Bichler* (Switzerland) - C. Escuriola - W. Kreuz

CCFFBBSS3377 EEVVAALLUUAATTIINNGG TTHHEE PPRREECCIISSIIOONN AANNDDAACCCCUURRAACCYY OOFF TTHHEE LLAABBOORRAATTOORRYYMMEEAASSUURREEMMEENNTT OOFF AANNTTII--PPOORRCCIINNEE FFAACCTTOORRVVIIIIII AANNTTIIBBOODDIIEESS M. L. Lee* (USA) - E. Gomperts - K. Biron - H. Levy

CCFFBBSS3388 TTIISSSSUUEE FFAACCTTOORR,, AA PPOOTTEENNTT SSTTIIMMUULLAATTOORR OOFFCCUULLTTUURREEDD EENNDDOOTTHHEELLIIAALL CCEELLLLSS M. M. Meiring* (South Africa) - W. Allers - E. Le Roux - P. Badenhorst

CCFFBBSS3399 QQUUAANNTTIIFFIICCAATTIIOONN OOFF MMEENNOORRRRHHAAGGIIAA IINNWWOOMMEENN WWIITTHH VVOONN WWIILLLLEEBBRRAANNDDSS DDIISSEEAASSEEAANNDD RRAARREE BBLLEEEEDDIINNGG DDIISSOORRDDEERRSS S. Halimeh* (Germany) - H. Rott - M. Siebert

CCFFBBSS4400 SSTTUUDDYY OOFF TTHHEE EEFFFFIICCAACCYY OOFF RROOUUTTIINNEE UUSSEEOOFF RREECCTTAALL MMIISSOOPPRROOSSTTOOLL IINN TTHHEEPPRREEVVEENNTTIIOONN OOFF PPOOSSTT--PPAARRTTUUMMHHAAEEMMOORRRRHHAAGGEE IINN RRUURRAALL NNIIGGEERRIIAA M. A.-R. Momoh* (Nigeria)

CCFFBBSS4411 FFRREEQQUUEENNCCYY OOFF FFAACCTTOORR XXIIIIII DDEEFFIICCIIEENNCCYYAAMMOONNGGSSTT PPAATTIIEENNTTSS WWIITTHH RRAARREE BBLLEEEEDDIINNGGDDIISSOORRDDEERRSS IINN PPAAKKIISSTTAANN:: AA MMUULLTTIICCEENNTTEERREEXXPPEERRIIEENNCCEE A. Naz* (Pakistan) - T. S. Shamsi - H. patel - K. Shaikh - M. Nadeem - M. Borhany - N. Ahmed- A. Imran - S. Amanat

CCFFBBSS4422 DDOO HHAAEEMMOOSSTTAATTIICC PPAARRAAMMEETTEERRSS VVAARRYYDDUURRIINNGG TTHHEE CCOOUURRSSEE OOFF TTHHEE MMEENNSSTTRRUUAALLCCYYCCLLEE?? R. Chaireti* (Sweden) - K. Bremme - K. M. Gustafsson - T. L. Lindahl

CCFFBBSS4433 HHOOWW DDOO FFEEMMAALLEE HHOORRMMOONNEE LLEEVVEELLSSAAFFFFEECCTT TTHHEE HHAAEEMMOOSSTTAASSIISS DDUURRIINNGG TTHHEECCOOUURRSSEE OOFF TTHHEE MMEENNSSTTRRUUAALL CCYYCCLLEE?? R. Chaireti* (Sweden) - K. Bremme - K. M. Gustafsson - T. L. Lindahl

CCFFBBSS4444 CCOOAAGGUULLAATTIIOONN AANNDD FFIIBBRRIINNOOLLYYTTIICCPPAARRAAMMEETTEERRSS IINN NNIIGGEERRIIAANN TTYYPPEE 22DDIIAABBEETTIICCSS WWIITTHH MMIICCRROOVVAASSCCUULLAARRCCOOMMPPLLIICCAATTIIOONNSS O. Awodu* (Nigeria) - J. Obieche - M. Enosolease- C. Omoti

CCFFBBSS4455 CCOOAAGGUULLAATTIIOONN MMAARRKKEERRSS AANNDD RREEHHEEOOLLOOGGYYPPRROOFFIILLEESS IINN SSOOMMEE NNIIGGEERRIIAANN PPRREEGGNNAANNTTWWOOMMEENN R. A. Anyanwu* (Nigeria) - C. K. Lele - A.-R. M. Momoh - E. Uko

CCFFBBSS4466 IIMMMMUUNNEE TTOOLLEERRAANNCCEE TTHHEERRAAPPYY IINN CCHHIILLDDRREENNWWIITTHH FFVVIIIIII IINNHHIIBBIITTOORRSS:: PPRROOGGRREESSSS RREEPPOORRTT V. Vdovin - P. Svirin - E. Shiller - T. Andreeva - N. Klimova - N. Osmulskaya - A. Momot - A. Mamaev - I. Blazhievich - Y. Smirnova - J. Bichler* (Switzerland) - L. Okladnikova

ISTH 2012 11.6.2012 14:48 Page 76

ePos

ters


ePoster Session

77

FFiibbrriinnoollyyssiiss aanndd VVaassccuullaarr BBiioollooggyy

Chairperson: Françoise Dignat-George (France)

FFVVBB0011 EEFFFFEECCTTIIVVEE TTAARRGGEETT TTHHRROOMMBBOOLLYYSSIISSMMEEDDIIAATTEEDD BBYY RREECCOOMMBBIINNAANNTT TTIISSSSUUEEPPLLAASSMMIINNOOGGEENN AACCTTIIVVAATTOORR--CCOONNJJUUGGAATTEEDDNNAANNOOPPAARRTTIICCLLEESS J. Deng* (China) - H. Mei - W. Shi - Y. Hu

FFVVBB0022 AALLPPHHAA22--AANNTTIIPPLLAASSMMIINN RREEGGUULLAATTEESS TTHHEEDDEEVVEELLOOPPMMEENNTT OOFF FFIIBBRROOSSIISS BBYY PPGGFF22AASSYYNNTTHHEESSIISS TTHHRROOUUGGHH AATTGGLL//IIPPLLAA22 AAY. Kanno* (Japan) - E. Kawashita - A. Kokado - K. Okada - S. Ueshima - H. Kaji - O. Matsuo - H. Matsuno

FFVVBB0033 RREEDDUUCCEEDD FFIIBBRRIINNOOLLYYTTIICC RREESSPPOONNSSEE TTOOTTIISSSSUUEE PPLLAASSMMIINNOOGGEENN AACCTTIIVVAATTOORRDDEEMMOONNSSTTRRAATTEEDD BBYYTTHHRROOMMBBOOEELLAASSTTOOGGRRAAPPHHYY IINN AA PPAATTIIEENNTTWWIITTHH HHYYPPOO--DDYYSSFFIIBBRRIINNOOGGEENNEEMMIIAA AANNDD AANNOOVVEELL FFIIBBRRIINNOOGGEENN MMUUTTAATTIIOONN G. Pike* (United Kingdom) - R. Seth - M. Hill - P. Bolton-Maggs - A. Cumming - J. Burthem - M. Nash

FFVVBB0044 EEFFFFEECCTT OOFF DDAABBIIGGAATTRRAANN AANNDD RRIIVVAARROOXXIIBBAANNOONN TTHHRROOMMBBOOMMOODDUULLIINN MMEEDDIIAATTEEDDAACCTTIIVVAATTIIOONN OOFF PPRROOTTEEIINN CC AANNDD TTHHRROOMMBBIINNAACCTTIIVVAATTEEDD FFIIBBRRIINNOOLLYYSSIISS IINNHHIIBBIITTOORR ((TTAAFFII))D. Hoppensteadt* (USA) - J. Cunanan - J. Fareed- B. Lewis

FFVVBB0055 TTHHEE AANNTTIICCOOAAGGUULLAANNTT EEFFFFEECCTT OOFFBBRROOMMEELLAAIINN:: AANN IINN VVIITTRROO SSTTUUDDYY UUSSIINNGGTTHHRROOMMBBOOEELLAASSTTOOGGRRAAPPHHYY M. Toukh* (Canada) - H. S. Elbatarny - M. Othman

FFVVBB0066 DD--DDIIMMEERR LLEEVVEELL,, FFAACCTTOORR XXIIII AACCTTIIVVIITTYY AANNDDXXIIIIAA--DDEEPPEENNDDEENNTT FFIIBBRRIINNOOLLYYSSIISS IINN NNOORRMMAALLPPRREEGGNNAANNCCYY N. Silina* (Russian Federation) - O. Golovina - A. Nikolaeva - L. Papayan

FFVVBB0077 TTEECCHHNNIICCAALL AANNDD CCLLIINNIICCAALL VVAALLIIDDAATTIIOONN OOFF AA MMOODDIIFFIIEEDD TTHHRROOMMBBOOEELLAASSTTOOMMEETTRRYYAAPPPPRROOAACCHH OONN AA RROOTTEEMM DDEEVVIICCEE FFOORR TTHHEEIIDDEENNTTIIFFIICCAATTIIOONN OOFF PPAATTIIEENNTTSS AATT RRIISSKK FFOORRHHYYPPOO-- AANNDD HHYYPPEERRFFIIBBRRIINNOOLLYYSSIISS G. J. A. J. M. Kuiper* (The Netherlands) - R. Oerle, van - M.-C. F. Kleinegris - H. M. H. Spronk - M. D. Lance - H. Cate, ten - Y. M. C. Henskens

FFVVBB0088 BB CCEELLLL--DDEERRIIVVEEDD VVAASSCCUULLAARR EENNDDOOTTHHEELLIIAALLGGRROOWWTTHH FFAACCTTOORR AA PPRROOMMOOTTEESSLLYYMMPPHHAANNGGIIOOGGEENNEESSIISS AANNDD HHIIGGHHEENNDDOOTTHHEELLIIAALL VVEENNUULLEE EEXXPPAANNSSIIOONN IINNLLYYMMPPHH NNOODDEESS T. Hashiguchi * (Japan) - T. Ito - B. Shrestha - N. Miura - T. Nagasato - K. Takenouchi - Y. Oyama- T. Shimizu - I. Maruyama

FFVVBB0099 RROOLLEESS FFOORR TTRRAANNSSGGLLUUTTAAMMIINNAASSEE 22 AANNDDBBLLOOOODD CCLLOOTTTTIINNGG FFAACCTTOORR XXIIIIII--AA IINN TTHHEEMMAAIINNTTEENNAANNCCEE OOFF BBLLOOOODD VVEESSSSEELLSSTTRRUUCCTTUURREE L. M. Newell* (United Kingdom) - K. F. Standeven- P. J. Grant - R. J. Pease - C. L. Jackson

FFVVBB1100 RREELLAATTIIOONNSSHHIIPP OOFF PPLLAATTEELLEETTMMIICCRROOPPAARRTTIICCLLEESS TTOO CCOOMMPPLLIICCAATTIIOONNSS AANNDDOOUUTTCCOOMMEE OOFF AACCUUTTEE LLIIVVEERR IINNJJUURRYY//AACCUUTTEELLIIVVEERR FFAAIILLUURREE ((AALLII//AALLFF)) D. A. Gabriel* (USA) - S. Glover - R. Bowling - R. T. Stravitz

ISTH 2012 11.6.2012 14:48 Page 77


ePoster Session

78

FFVVBB1111 AACCTTIIVVAATTEEDD PPRROOTTEEIINN CC ((AAPPCC)) AANNDDTTHHRROOMMBBIINN MMOODDUULLAATTEE CCAARRDDIIOOMMYYOOCCYYTTEESSCCOONNTTRRAACCTTIILLIITTYY VVIIAA AA PPRROOTTEEAASSEEAACCTTIIVVAATTEEDD RREECCEEPPTTOORR --11 ((PPAARR11))-- CCAARRDDIIAACCTTRROOPPOONNIINN II ((CCTTII)) PPAATTHHWWAAYY Y. Alhamdi* (United Kingdom) - G. Wang - C.-H. Toh

FFVVBB1122 NNIITTRRIICC OOXXIIDDEE FFRROOMM EENNOOSS RREEDDUUCCEESSAABBDDOOMMIINNAALL AAOORRTTIICC AANNEEUURRYYSSMMSSDDEEVVEELLOOPPMMEENNTT IINN AA MMOOUUSSEE MMOODDEELL WWIITTHHHHUUMMAANN--LLIIKKEE HHYYPPEERRCCHHOOLLEESSTTEERROOLLEEMMIIAA S. Momi* (Italy) - P. Gresele

FFVVBB1133 CCIILLOOSSTTAAZZOOLL IIMMPPRROOVVEESS AANN AACCCCUUMMUULLAATTIIOONNOOFF AAµµ BBYY LLRRPP--11 EEXXPPRREESSSSIIOONN OONNEENNDDOOTTHHEELLIIAALL CCEELLLLSS H. Yasui* (Japan) - Y. Kanno - E. Kawashita - H. Nakagawa - M. Yamanaka - H. Matsuno

FFVVBB1144 PPRROOCCOOAAGGUULLAANNTT PPHHOOSSPPHHOOLLIIPPIIDDSS AACCTTIIVVIITTYYIINN CCEERREEBBRROOSSPPIINNAALL FFLLUUIIDD FFRROOMM PPAATTIIEENNTTSSWWIITTHH IINNTTRRAACCEERREEBBRRAALL HHAAEEMMOORRRRHHAAGGEE P. Van Dreden* (France) - B. Woodhams - A. Rousseau - G. Hue - A. Lavoinne - M. Vasse

FFVVBB1155 CCLLEEAAVVEEDD HHIIGGHH MMOOLLEECCUULLAARR WWEEIIGGHHTTKKIINNIINNOOGGEENN SSTTIIMMUULLAATTEESS JJNNKK//FFOOXXOO//MMNNSSOODDPPAATTHHWWAAYY FFOORR IINNDDUUCCTTIIOONN OOFF EENNDDOOTTHHEELLIIAALLPPRROOGGEENNIITTOORR CCEELLLL SSEENNEESSCCEENNCCEE X. Zhu* (China) - M. C. Yoder - R. W. Colman - Y. Wu

FFVVBB1166 IISS PPRROOTTHHRROOMMBBIINN TTIIMMEE AA PPRREEDDIICCTTOORR OOFFNNEEWW--OONNSSEETT DDIIAABBEETTEESS IINN HHYYPPEERRTTEENNSSIIVVEEAANNDD CCOORROONNAARRYY HHEEAARRTT DDIISSEEAASSEEPPAATTIIEENNTTSS?? G.-P. G.-P. Jong - T. Ma* (Taiwan) - L. Tien

FFVVBB1177 TTHHRROOMMBBIINN GGEENNEERRAATTIIOONN OONN EENNDDOOTTHHEELLIIAALLCCEELLLLSS IISS IINNIITTIIAATTEEDD BBYY BBOOTTHH IINNTTRRIINNSSIICC AANNDDEEXXTTRRIINNSSIICC AACCTTIIVVAATTIIOONN AANNDD SSHHOOUULLDD BBEECCAARRRRIIEEDD OOUUTT IINN LLOOWW SSEERRUUMM CCOONNDDIITTIIOONNSSI. Geenen* (The Netherlands) - M. Post - D. Molin- R. van Oerle - H. Ten Cate - H. Spronk

FFVVBB1188 TTHHEE RREESSEEAARRCCHH OOFF IINNTTEERR--RREELLAATTIIOONNSSHHIIPPBBEETTWWEEEENN AADDAAMMTTSS1133 AANNDD HHUUMMAANNMMIICCRROOVVAASSCCUULLAARR EENNDDOOTTHHEELLIIAALL CCEELLLLSS A. Wang* (China) - Z. Yu - Z. Ma - K. Ding - X. Liu - J. Wu - Z. Sun - C. Ruan

FFVVBB1199 AANNAALLYYSSIISS OOFF SSYYNNTTHHEETTIICC AANNDD BBIIOOLLOOGGIICCAALLMMIICCRROOPPAARRTTIICCLLEESS OONN SSEEVVEERRAALL FFLLOOWWCCYYTTOOMMEETTRRIICC PPLLAATTFFOORRMMSS M. Mooberry* (USA) - N. Fisher - M. S. Carraway -C. B. Smith - R. Kasthuri - B. Udis - R. Zucker - N. Key

FFVVBB2200 SSTTAANNDDAARRDDIIZZAATTIIOONN OOFF FFLLOOWW CCYYTTOOMMEETTRRYY--BBAASSEEDD MMIICCRROOPPAARRTTIICCLLEE AANNAALLYYSSIISS FFOORRCCYYTTOOMMEETTEERRSS UUSSIINNGG SSIIDDEE SSCCAATTTTEERR FFOORRSSIIZZEE MMEEAASSUURREEMMEENNTTSS P. Poncelet* (France) - S. Robert - A.-M. Faussat - C. Gameiro - F. Mullier

FFVVBB2211 TTHHEE AANNGGIIOOGGEENNEESSIISS AANNDD AANNTTII--FFIIBBRROOSSIISSEEFFFFEECCTTSS OOFF HHUUMMAANN AADDIIPPOOSSEE--DDEERRIIVVEEDDSSTTEEMM CCEELLLLSS OOVVEERREEXXPPRREESSSSIINNGG HHUUMMAANNHHGGFF OONN AACCUUTTEE MMYYOOCCAARRDDIIAALL IINNFFAARRCCTTIIOONN X. Zhu* (China) - J. Wu - Z. Sun - X. Cai - W. Zhu- X. Liu

ISTH 2012 11.6.2012 14:48 Page 78

ePos

ters


ePoster Session

79

HHaaeemmoorrrrhhaaggiicc DDiissoorrddeerrss ((CClliinniiccaall))

Chairperson: Mike Makris (United Kingdom)

HHDDCC0011 FFAACCTTOORR XXIIIIII IINN HHAAEEMMOOPPHHIILLIIAA AA -- EEFFFFEECCTT OONNCCLLOOTT SSTTRRUUCCTTUURREE AANNDD PPEERRMMEEAABBIILLIITTYY O. O. Okaisabor* (United Kingdom) - J. Foley - B. Sorenson - C. Rea

HHDDCC0022 FFAACCTTOORR ?? AA11 DDOOMMAAIINN SSUUBBSSTTIITTUUTTIIOONNHHIISS9999AARRGG RREESSUULLTTSS IINN SSUUPPEERR--IINNSSTTAABBIILLIITTYYOOFF FFAACCTTOORR ?? AANNDD DDIISSCCRREEPPAANNCCYY BBEETTWWEEEENNOONNEE--SSTTAAGGEE AANNDD TTWWOO--SSTTAAGGEE FF??::CC AASSSSAAYY IINNAA MMIILLDD HHEEMMOOPPHHIILLIIAA AA PPAATTIIEENNTTG. You* (China) - X. Wang

HHDDCC0033 UUSSEE OOFF NNEEXXTT--GGEENNEERRAATTIIOONN DDNNAASSEEQQUUEENNCCIINNGG FFOORR GGEENNEE DDIISSCCOOVVEERRYY IINNBBLLEEEEDDIINNGG SSYYNNDDRROOMMEESS WWIITTHH DDEEFFEECCTTSS OOFFPPLLAATTEELLEETT FFUUNNCCTTIIOONN:: AA PPIILLOOTT SSTTUUDDYY L. A. Lotta* (Italy) - G. Tuana - A. Maino - A. Artoni- A. Lecchi - F. Peyvandi

HHDDCC0044 HHEEAADD--TTOO--HHEEAADD CCOOMMPPAARRIISSOONN OOFF TTHHEEOOPPTTIIMMUULL AASSSSAAYY ((9966--WWEELLLL PPLLAATTEEAAGGGGRREEGGOOMMEETTRRYY)) WWIITTHH GGOOLLDD SSTTAANNDDAARRDDLLIIGGHHTT TTRRAANNSSMMIISSSSIIOONN AAGGGGRREEGGOOMMEETTRRYY FFOORRDDEETTEECCTTIIOONN OOFF AACCQQUUIIRREEDD AANNDD IINNHHEERRIITTEEDDPPLLAATTEELLEETT DDEEFFEECCTTSS M. Lordkipanidze* (United Kingdom) - M. V. Chan- G. C. Lowe - B. B. Dawood - T. D. Warner - S. P. Watson

HHDDCC0055 HHEEMMOOSSTTAATTIICC PPRROOPPEERRTTIIEESS OOFF RREEDD CCEELLLLDDEERRIIVVEEDD MMIICCRROOPPAARRTTIICCLLEESS ((RRMMPP)):: PPRROOMMIISSEEOOFF UUNNIIVVEERRSSAALL HHEEMMOOSSTTAATTIICC AAGGEENNTT Y. S. Ahn* (USA) - W. Jy - M. E. Johansen - L. L. Horstman - C. J. Bidot

HHDDCC0066 FFVVIIIIII::CC AASSSSAAYY DDIISSCCRREEPPAANNCCYY AANNDDGGEENNOOTTYYPPEE--PPHHEENNOOTTYYPPEE CCOORRRREELLAATTIIOONN IINN AAGGRROOUUPP OOFF MMIILLDD HHAAEEMMOOPPHHIILLIIAA AA PPAATTIIEENNTTSS C. Silva Pinto* (Portugal) - H. Saturnino - T. Fidalgo - D. Marques - E. Gon�alves - P. Martinho - A. C. Oliveira - R. Salvado - N. Martins - L. Ribeiro

HHDDCC0077 DDEEVVEELLOOPPMMEENNTT OOFF AANN AALLTTEERRNNAATTIIVVEE AASSSSAAYYFFOORR TTHHEE AASSSSEESSSSMMEENNTT OOFF FFAACCTTOORR VVIIIIIIIINNHHIIBBIITTOORR BBEETTHHEESSDDAA TTIITTRREESS S. Daniels* (United Kingdom) - A. Heath - N. McMullan - S. Raut

HHDDCC0088 GGEENNEETTIICC AANNAALLYYSSIISS OOFF TTWWEENNTTYY EEGGYYPPTTIIAANNPPAATTIIEENNTTSS WWIITTHH CCOONNGGEENNIITTAALLAAFFIIBBRRIINNOOGGEENNEEMMIIAA M. Abdelwahab* (Egypt) - M. Neerman-Arbez - J. Koegel - O. Shaker

HHDDCC0099 MMUUTTAATTIIOONNSS CCAAUUSSIINNGG SSEEVVEERREE FFAACCTTOORR XXIIIIIIDDEEFFIICCIIEENNCCYY IINN PPAAKKIISSTTAANN M. Borhany* (Pakistan) - T. Shamsi - A. Cairo - F. Peyvandi

HHDDCC1100 VVWWFF EEXXEERRTTSS AA PPRROOTTEECCTTIIVVEE EEFFFFEECCTT OONNFFVVIIIIII FFRROOMM IINNHHIIBBIITTOORR IINNAACCTTIIVVAATTIIOONN BBOOTTHHIINN VVIITTRROO AANNDD IINN VVIIVVOO Q. Shi* (USA) - E. L. Kuether - J. A. Schroeder - C. L. Perry - S. A. Fahs - J. C. Gill - R. R. Montgomery

HHDDCC1111 VVOONN WWIILLLLEEBBRRAANNDD FFAACCTTOORR PPRROOPPEEPPTTIIDDEE((VVWWFFPPPP)) TTOO VVOONN WWIILLLLEEBBRRAANNDD FFAACCTTOORRAANNTTIIGGEENN ((VVWWFF::AAGG)) RRAATTIIOO IINN DDIIFFFFEERREENNTTSSUUBBTTYYPPEESS OOFF CCOONNGGEENNIITTAALL AANNDD AACCQQUUIIRREEDDVVOONN WWIILLLLEEBBRRAANNDD DDIISSEEAASSEE ((VVWWDD)) F. Stufano* (Italy) - M. T. Canciani - L. Baronciani -G. Cozzi - S. La Marca - M. T. Pagliari - I. GarciaOya - S. M. Siboni - F. Peyvandi

ISTH 2012 11.6.2012 14:48 Page 79


ePoster Session

80

HHDDCC1122 CCOOMMBBIINNEEDD AAPPTTTT AANNDD WWAAVVEEFFOORRMM AANNAALLYYSSIISSIINNCCRREEAASSEESS TTHHEE DDIIAAGGNNOOSSTTIICC CCAAPPAABBIILLIITTYYOOFF SSTTAANNDDAARRDD AAPPTTTT AASSSSAAYYSS L. Leong* (USA) - P. Ramsey - L. Tang - D. Sim - J. E. Murphy - V. Laux - T. Myles

HHDDCC1133 PPRREESSEENNTTAATTIIOONN AANNDD MMAANNAAGGEEMMEENNTT OOFFAACCUUTTEE CCOORROONNAARRYY SSYYNNDDRROOMMEESS ((AACCSS))AAMMOONNGG AADDUULLTT PPEERRSSOONNSS WWIITTHH HHEEMMOOPPHHIILLIIAA((PPWWHH)):: IINNIITTIIAALL RREESSUULLTTSS OOFF AANNIINNTTEERRNNAATTIIOONNAALL,, RREETTRROOSSPPEECCTTIIVVEE,,TTEENN--YYEEAARR SSUURRVVEEYYP. F. Fogarty* (USA) - M. E. Mancuso - R. S. Kasthuri and GEHEP, Global EmergingHemophilia Experts Panel

HHDDCC1144 FFLLUUOORREESSCCEENNTT QQUUAANNTTIITTAATTIIOONN PPCCRR MMEETTHHOODDAAPPPPLLIIEEDD TTOO DDOO CCAARRRRIIEERR AANNDD PPRREENNAATTAALLDDIIAAGGNNOOSSIISS IINN HHAAEEMMOOPPHHIILLIIAA AA AANNDD BBFFAAMMIILLIIEESS WWIITTHH LLAARRGGEE DDEELLEETTIIOONNMMUUTTAATTIIOONNSS Y. Lu* (China)

HHDDCC1155 TTHHRROOMMBBIINN GGEENNEERRAATTIIOONN,,TTHHRROOMMBBOODDYYNNAAMMIICCSS AANNDDTTHHRROOMMBBOOEELLAASSTTOOGGRRAAPPHHYY IINN TTHHEE PPAATTIIEENNTTSSWWIITTHH DDIIFFFFEERREENNTT BBLLEEEEDDIINNGG PPHHEENNOOTTYYPPEE OOFFSSEEVVEERREE HHEEMMOOPPHHIILLIIAA AA I. Tarandovskiy* (Russian Federation) - A. Balandina - M. Panteleev - M. Kumskova - K. Kopylov - F. Ataullahkanov

HHDDCC1166 GGEENNEETTIICC DDEEFFEECCTT OOFF FF99 GGEENNEE AANNDDPPOOLLYYMMOORRPPHHIISSMMSS IINN IIMMMMUUNNEE RREESSPPOONNSSEEGGEENNEESS AASSSSOOCCIIAATTEEDD WWIITTHH HHIIGGHH TTIITTEERRIINNHHIIBBIITTOORR DDEEVVEELLOOPPMMEENNTT AANNDDAANNAAPPHHYYLLAAXXIISS IINN OONNEE HHEEMMOOPPHHIILLIIAA BB CCAASSEE J. Zhou* (China) - Q. Ding - Y. Lu - J. Dai - H.Wang - X. Wang

HHDDCC1177 MMAATTEERRNNAALL HHEETTEERROODDIISSOOMMYY//IISSOODDIISSOOMMYY OOFFCCHHRROOMMOOSSOOMMEE 44 IINN AA CCHHIILLDD WWIITTHHCCOONNGGEENNIITTAALL AAFFIIBBRRIINNOOGGEENNEEMMIIAACCOONNTTAAIINNIINNGG AA NNOOVVEELL TTRRPP229933XX MMUUTTAATTIIOONN IINNFFIIBBRRIINNOOGGEENN BBµµ--CCHHAAIINN GGEENNEE Q. Ding* (China) - Q. Ouyang - X. Xi - X. Wang - H. Wang

LLaabboorraattoorryy ssttuuddiieess

Chairperson: Steve Kitchen (United Kingdom), Meyer-MichelSamama (France)

LLSSPPEE0011 DDIIFFFFEERREENNCCEESS IINN EEXXPPOOSSUURREE OOFF TTHHEEDDOOMMAAIINN II EEPPIITTOOPPEE OOFF BBEETTAA22--GGLLYYCCOOPPRROOTTEEIINN II IINN CCOOMMMMEERRCCIIAALL EELLIISSAAKKIITTSS FFOORR TTHHEE DDIIAAGGNNOOSSIISS OOFF TTHHEEAANNTTIIPPHHOOSSPPHHOOLLIIPPIIDD SSYYNNDDRROOMMEE L. Pelkmans* (The Netherlands) - H. Kelchtermans - M. Ninivaggi - T. Lindhout - P. G. de Groot - B. de Laat

LLSSPPEE0022 MMEEAASSUURREEMMEENNTT OOFF AANNTTII--AADDAAMMTTSS1133NNEEUUTTRRAALLIISSIINNGG AAUUTTOOAANNTTIIBBOODDIIEESS:: AACCOOMMPPAARRIISSOONN BBEETTWWEEEENN CCBBAA AANNDD FFRREETTAASSSSAAYYSS I. Mancini* (Italy) - C. Valsecchi - R. Palla - M. T. Bajetta - G. Casoli - L. A. Lotta - F. Peyvandi

LLSSPPEE0033 MMOODDEELLIINNGG PPHHYYSSIIOOLLOOGGIICCAALL AANNDD CCYYTTOOKKIINNEEDDAATTAA TTOO PPRREEDDIICCTT OOUUTTCCOOMMEE H. Hardway - D. Stearns-Kurosawa* (USA) - S. Kurosawa

ISTH 2012 11.6.2012 14:48 Page 80

ePos

ters


ePoster Session

81

LLSSPPEE0044 PPRREEDDIICCTTIIVVEE VVAALLUUEE OOFF HHIIGGHH FFAACCTTOORR VVIIIIIILLEEVVEELLSS FFOORR RREECCUURRRREENNTT VVEENNOOUUSSTTHHRROOMMBBOOSSIISS J. F. Timp* (The Netherlands) - W. M. Lijfering - L. E. Flinterman - A. van Hylckama Vlieg - F. R. Rosendaal - S. C. Cannegieter

LLSSPPEE0055 AACCUUSSTTAARR HHIITT--IIGGGG AANNDD HHEEPPAARRIINN--IINNDDUUCCEEDDMMUULLTTIIPPLLEE EELLEECCTTRROODDEE AAGGGGRREEGGOOMMEETTRRYY::AA UUSSEEFFUULL CCOOMMBBIINNAATTIIOONN FFOORR RRAAPPIIDDDDIIAAGGNNOOSSIISS OOFF TTYYPPEE--IIII HHIITT V. Minet - J. Douxfils* (Belgium) - N. Bailly - J.-C. Osselaer - C. Chatelain - I. Elalamy - B. Chatelain - J.-M. Dogn� - F. Mullier

LLSSPPEE0066 DDEETTEERRMMIINNAATTIIOONN OOFF DDAABBIIGGAATTRRAANN IINNPPLLAASSMMAA,, SSEERRUUMM,, AANNDD UURRIINNEE SSAAMMPPLLEESSFFRROOMM PPAATTIIEENNTT WWIITTHH AATTRRIIAALL FFIIBBRRIILLLLAATTIIOONN J. Harenberg* (Germany) - S. Marx - R. Kraemer

LLSSPPEE0077 DDEETTEERRMMIINNAATTIIOONN OOFF RRIIVVAARROOXXAABBAANN IINNPPLLAASSMMAA,, SSEERRUUMM,, AANNDD UURRIINNEE FFRROOMMPPAATTIIEENNTTSS UUNNDDEERRGGOOIINNGG TTOOTTAALL HHIIPP AANNDDKKNNEEEE RREEPPLLAACCEEMMEENNTT SSUURRGGEERRYY J. Harenberg* (Germany) - A. Schulze - S. Marx - R. Kr�mer - C. Weiss

LLSSPPEE0088 PPRREEVVAALLEENNCCEE OOFF FFAACCTTOORR VV LLEEIIDDEENN IINN 331188IIRRAANNIIAANN IINNDDIIVVIIDDUUAALL RREEFFEERRRREEDD CCAASSEESS AANNDDTTHHEE DDIIAAGGNNOOSSTTIICC PPOOWWEERR OOFF TTWWOODDIIFFFFEERREENNTT AAPPCC--RR SSCCRREEEENNIINNGG TTEESSTTSS M. Ahmadinejad* (Islamic Republic of Iran) - N. Ahmadzadeh - E. Farhadi - K. Atarodi - S. Balooch - L. Seyed Mortaz - S. Negari - M. Maghsudlu - N. Amirizadeh - Z. Ahmadinejad

LLSSPPEE0099 HHEEPPAARRIINN--IINNDDUUCCEEDD MMUULLTTIIPPLLEE EELLEECCTTRROODDEEAAGGGGRREEGGOOMMEETTRRYY IISS AA PPRROOMMIISSIINNGG AANNDDUUSSEEFFUULL FFUUNNCCTTIIOONNAALL TTOOOOLL FFOORR HHEEPPAARRIINN--IINNDDUUCCEEDD TTHHRROOMMBBOOCCYYTTOOPPEENNIIAA DDIIAAGGNNOOSSIISS::CCOONNFFIIRRMMAATTIIOONN IINN AA PPRROOSSPPEECCTTIIVVEE SSTTUUDDYY G. Gerotziafas* (France) - V. Galea - F. Robert - I. Elalamy - I. Elalamy

LLSSPPEE1100 PPRREEAANNAALLYYTTIICCAALL VVAARRIIAABBLLEESS OOFF TTHHEECCAALLIIBBRRAATTEEDD AAUUTTOOMMAATTEEDD TTHHRROOMMBBOOGGRRAAMM::TTOOWWAARRDDSS AA SSTTAANNDDAARRDDIIZZEEDD AANNDD VVAALLIIDDAATTEEDDPPRROOCCEEDDUURREE R. Loeffen* (The Netherlands) - M.-C. Kleinegris -S. T. Loubele - P. Pluijmen - D. Fens - R. van Oerle - H. ten Cate - H. M. Spronk

LLSSPPEE1111 LLAABBOORRAATTOORRYY MMOONNIITTOORRIINNGG TTEECCHHNNIIQQUUEESSFFOORR DDAABBIIGGAATTRRAANN AANNDD RRIIVVAARROOXXAABBAANN --MMEETTHHOODD SSUUIITTAABBIILLIITTYY AANNDD VVAARRIIAABBIILLIITTYYBBEETTWWEEEENN EEUURROOPPEEAANN LLAABBOORRAATTOORRIIEESS T. Helin* (Finland) - A. Pakkanen - R. Lassila - L. Joutsi-Korhonen

LLSSPPEE1122 IINN VVIITTRROO AASSSSEESSSSMMEENNTT OOFF TTHHEEAAPPPPLLIICCAABBIILLIITTYY OOFF PPRROOTTHHRROOMMBBIINN CCOOMMPPLLEEXXCCOONNCCEENNTTRRAATTEE AASS AANNTTIIDDOOTTEE FFOORR TTHHEEDDIIRREECCTT FFAACCTTOORR XXAA IINNHHIIBBIITTOORRRRIIVVAARROOXXAABBAANN A. Leyte* (The Netherlands) - J. Dinkelaar - P. J. Molenaar

LLSSPPEE1133 VVAALLIIDDAATTIIOONN OOFF TTWWOO AAGGEE AADDAAPPTTEEDD DD--DDIIMMEERRCCUUTT--OOFFFF VVAALLUUEESS FFOORR EEXXCCLLUUSSIIOONN OOFF DDEEEEPPVVEENNOOUUSS TTHHRROOMMBBOOSSIISS IINN SSUUSSPPEECCTTEEDDEELLDDEERRLLYY PPRRIIMMAARRYY CCAARREE PPAATTIIEENNTTSS H. J. Schouten* (The Netherlands) - H. L. Koek -R. Oudega - G. J. Geersing - K. J. Janssen - J. J. van Delden - K. G. Moons

ISTH 2012 11.6.2012 14:48 Page 81


ePoster Session

82

LLSSPPEE1144 TTHHEE CCOOSSTT--EEFFFFEECCTTIIVVEENNEESSSS OOFF ""PPOOIINNTT OOFFCCAARREEÓ DD--DDIIMMEERR TTEESSTTSS TTOO RRUULLEE OOUUTT DDEEEEPPVVEENNOOUUSS TTHHRROOMMBBOOSSIISS IINN PPRRIIMMAARRYY CCAARREE J. Hendriksen* (The Netherlands) - G. J. Geersing- S. van Voorthuizen - A. ten Cate-Hoek - M. Joore - K. Moons - E. Koffijberg

LLSSPPEE1155 FFIIBBRRIINN--RREELLAATTEEDD MMAARRKKEERR CCOOMMPPAARRIISSOONN IINNSSEEPPSSIISS:: CCOORRRREELLAATTIIOONN TTOO GGLLOOBBAALL AANNDDMMOOLLEECCUULLAARR PPAARRAAMMEETTEERRSS OOFFHHAAEEMMOOSSTTAATTIICC DDYYSSFFUUNNCCTTIIOONN J. M. H. Toh* (United Kingdom) - G. Ken-Dror - C. Downey

LLSSPPEE1166 LLAARRGGEE IINNTTEERR--IINNDDIIVVIIDDUUAALL VVAARRIIAATTIIOONN OOFF TTHHEEPPHHAARRMMAACCOODDYYNNAAMMIICC EEFFFFEECCTT OOFFAANNTTIICCOOAAGGUULLAANNTT DDRRUUGGSS OONN TTHHRROOMMBBIINNGGEENNEERRAATTIIOONN S. Bloemen* (The Netherlands) - C. H. Hemker -R. Al Dieri

LLSSPPEE1177 LLAABBOORRAATTOORRYY RREECCOOMMMMEENNDDAATTIIOONNSS FFOORR TTHHEEMMOONNIITTOORRIINNGG OOFF RRIIVVAARROOXXAABBAANNJ. Douxfils* (Belgium) - F. Mullier - C. Chatelain - S. Robert - B. Chatelain - J.-M. Dogn�

LLSSPPEE1188 LLAABBOORRAATTOORRYY RREECCOOMMMMEENNDDAATTIIOONNSS FFOORR TTHHEEMMOONNIITTOORRIINNGG OOFF DDAABBIIGGAATTRRAANN J. Douxfils* (Belgium) - F. Mullier - C. Chatelain - S. Robert - B. Chatelain - J.-M. Dogn�

LLSSPPEE1199 CCOOMMPPAARRIISSOONN OOFF PPRROOTTHHRROOMMBBIINNAASSEE--BBAASSEEDDAAPPCC RREESSIISSTTAANNCCEE AASSSSAAYY AANNDD FFVV LLEEIIDDEENNGGEENNOOTTYYPPIINNGG I. Horvat* (Croatia) - D. Coen Herak - R. Zadro

LLSSPPEE2200 EEVVAALLUUAATTIIOONN OOFF PPRROO CC GGLLOOBBAALL AASSSSAAYY AASS AASSCCRREEEENNIINNGG TTEESSTT FFOORR TTHHRROOMMBBOOPPHHIILLIIAA IINNWWOOMMEENN WWIITTHH AADDVVEERRSSEE PPRREEGGNNAANNCCYYOOUUTTCCOOMMEEA. Naz* (Pakistan) - N. Hossain - T. S. Shamsi - N. Khan

LLSSPPEE2211 TTHHRROOMMBBOODDYYNNAAMMIICCSS AASSSSAAYY IINN HHEEAALLTTHHYYAANNDD DDIISSEEAASSEEDD SSUUBBJJEECCTTSS A. N. Balandina* (Russian Federation) - E. N. Lipets - N. P. Soshitova - D. M. Polokhov - S. A. VasilÕev - M. A. Panteleev -F. I. Ataullakhanov

LLSSPPEE2222 CCHHAARRAACCTTEERRIIZZAATTIIOONN OOFF TTHHEE RROOLLEE OOFFCCAANNCCEERR CCEELLLLSS IINN TTHHEE PPRROOMMOOTTIIOONN OOFFTTHHRROOMMBBUUSS FFOORRMMAATTIIOONN UUNNDDEERR SSHHEEAARR S. M. Baker* (USA) - O. J. McCarty - M. A. Berny-Lang - G. W. Tormoen

LLSSPPEE2233 PPRROOLLOONNGGEEDD CCLLOOTT LLYYSSIISS TTIIMMEE IISS AA RRIISSKKFFAACCTTOORR FFOORR VVEENNOOUUSS TTHHRROOMMBBOOSSIISS A. Karasu* (The Netherlands) - A. van HylckamaVlieg - R. Luddington - C. A. Baglin - F. R. Rosendaal - T. P. Baglin

LLSSPPEE2244 LLYYOOPPHHIILLIIZZEEDD NNOORRMMAALL AANNDD AABBNNOORRMMAALLLLUUPPUUSS CCOONNTTRROOLL PPLLAASSMMAA CCAANN BBEE UUSSEEDDFFOORR AASSSSAAYY CCOONNTTRROOLL IINN DDRRVVVV AANNDD AAPPTTTTBBAASSEEDD LLUUPPUUSS AANNTTIICCOOAAGGUULLAANNTT TTEESSTTSS L. Wagner* (Austria) - V. Kaufmann - J. Mager - S. Geiter - M. Leitner

ISTH 2012 11.6.2012 14:48 Page 82

ePos

ters


ePoster Session

83

LLSSPPEE2255 VVOONN WWIILLLLEEBBRRAANNDD FFAACCTTOORR LLEEVVEELL IINN NNEEWWLLYYDDIIAAGGNNOOSSEEDD PPAATTIIEENNTT WWIITTHH MMUULLTTIIPPLLEEMMYYEELLOOMMAA AAFFTTEERR TTHHEE FFIIRRSSTT CCYYCCLLEESS OOFFIINNDDUUCCTTIIOONN TTHHEERRAAPPYY E. Hait* (Russian Federation) - K. Abdulkadyrov -L. Papayan - O. Golovina

LLSSPPEE2266 UUNNFFRRAACCTTIIOONNAATTEEDD HHEEPPAARRIINN ((UUFFHH)) AANNDD LLOOWWMMOOLLEECCUULLAARR WWEEIIGGHHTT HHEEPPAARRIINNSS ((LLMMWWHH))CCOOUUNNTTEERRAACCTT TTHHRROOMMBBIINN GGEENNEERRAATTIIOONN ((TTGG))AANNDD PPRROOAANNGGIIOOGGEENNIICC PPRROOPPEERRTTIIEESS OOFFMMDDAA..MMBB..223311 BBRREEAASSTT CCAANNCCEERR CCEELLLLSS E. Diani* (Italy) - M. Marchetti - A. Vignoli - A. Falanga

LLSSPPEE2277 TTHHEE EEUURROOPPEEAANN AACCTTIIOONN OONNAANNTTIICCOOAAGGUULLAATTIIOONN ((EEAAAA)) PPRROOTTHHRROOMMBBIINNTTIIMMEE //IINNTTEERRNNAATTIIOONNAALL NNOORRMMAALLIISSEEDD RRAATTIIOO((PPTT//IINNRR)) LLIINNEE -- AA RRAAPPIIDD MMEETTHHOODD OOFFDDEERRIIVVIINNGG LLOOCCAALL IINNTTEERRNNAATTIIOONNAALLSSEENNSSIITTIIVVIITTYY IINNDDEEXX ((IISSII)) AANNDD MMEEAANN NNOORRMMAALLPPTT ((MMNNPPTT)) FFOORR UUSSEE WWIITTHH CCOOAAGGUULLOOMMEETTEERRSS L. Poller* (United Kingdom) - S. Ibrahim - J. Jespersen

LLSSPPEE2288 EEUURROOPPEEAANN AACCTTIIOONN OONN AANNTTIICCOOAAGGUULLAATTIIOONN((EEAAAA)).. LLOOCCAALL IINNRR DDEERRIIVVAATTIIOONN SSIIMMPPLLIIFFIIEEDDBBYY TTHHEE PPTT//IINNRR LLIINNEE AANNDD AA SSPPRREEAADDSSHHEEEETTFFRROOMM TTHHEE WWOORRLLDD WWIIDDEE WWEEBB L. Poller* (United Kingdom) - S. Ibrahim - J. Jespersen

LLSSPPEE2299 CCHHAARRAACCTTEERRIIZZAATTIIOONN OOFF TTHHRROOMMBBIINNGGEENNEERRAATTIIOONN ((TTGG)) BBYY TTHHEE CCAALLIIBBRRAATTEEDDAAUUTTOOMMAATTEEDD TTHHRROOMMBBOOGGRRAAPPHHYY ((CCAATT)) IINNAATTRRIIAALL FFIIBBRRIILLLLAATTIIOONN ((AAFF)) PPAATTIIEENNTTSS OONNPPEERRMMAANNEENNTT OORRAALL AANNTTIICCOOAAGGUULLAATTIIOONNTTHHEERRAAPPYY ((OOAATT)) WWIITTHH WWAARRFFAARRIINN M. Marchetti* (Italy) - C. Giaccherini - T. Lerede -A. Maggioni - M. Cefis - A. Falanga

LLSSPPEE3300 TTHHEE EEFFFFEECCTT OOFF PPRREEAANNAALLYYTTIICCAALL AANNDDAANNAALLYYTTIICCAALL VVAARRIIAABBLLEESS OONN SSPPAATTIIAALL FFIIBBRRIINNCCLLOOTT FFOORRMMAATTIIOONN ((TTHHEE TTHHRROOMMBBOODDYYNNAAMMIICCSSAASSSSAAYY)) IINN HHEEAALLTTHHYY SSUUBBJJEECCTTSS A. N. Balandina* (Russian Federation) - E. N. Lipets - N. P. Soshitova - I. D. Tarandovskiy -I. A. Shcherbina - D. M. Polokhov - A. V. Poletaev -M. A. Panteleev - F. I. Ataullakhanov

LLSSPPEE3311 AASSSSEESSSSMMEENNTT OOFF HHAAEEMMOOSSTTAASSIISS IINN TTHHEEPPRRIIMMAARRYY MMUULLTTIIPPLLEE MMYYEELLOOMMAA PPAATTIIEENNTTSSUUSSIINNGG DDIIFFFFEERREENNTT LLAABBOORRAATTOORRYY MMEETTHHOODDSS M. Gracheva* (Russian Federation)- E. S. Urnova- L. P. Mendeleeva - E. I. Sinauridze - A. N. Balandina - E. N. Lipets - I. V. Gribkova - S. A. Vasiliev - E. N. Parovichnikova - V. G. Savchenko - F. I. Ataullakhanov

LLSSPPEE3322 IINNHHIIBBIITTOORRYY EEFFFFEECCTTSS OOFF BBOORRTTEEZZOOMMIIBB OONNPPLLAATTEELLEETT AAGGGGRREEGGAATTIIOONN IINNDDUUCCEEDD BBYY AADDPP,,CCOOLLLLAAGGEENN AANNDD RRIISSTTOOCCEETTIINN IINN PPAATTIIEENNTTSSWWIITTHH MMUULLTTIIPPLLEE MMYYEELLOOMMAA J. Rupa-Matysek* (Poland) - L. Gil - E. WojtasinÕska - K. Zajdel - A. Nowicki - D. Dytfeld- M. Komarnicki

ISTH 2012 11.6.2012 14:48 Page 83


ePoster Session

84

LLSSPPEE3333 CCOOMMPPAARRIISSOONN OOFF TTHHEE UUSSEE OOFF TTFFPPIIBBLLOOCCKKAAGGEE AANNDD PPLLAASSMMAA DDIILLUUTTIIOONN TTOOIINNCCRREEAASSEE TTHHEE SSEENNSSIITTIIVVIITTYY OOFF TTHHRROOMMBBIINNGGEENNEERRAATTIIOONN AASSSSAAYY TTOO MMEEAASSUURREE TTHHEEPPRROOCCOOAAGGUULLAANNTT AACCTTIIVVIITTYY OOFFMMIICCRROOVVEESSIICCLLEESS D. Gheldof* (Belgium) and Mullier François,Chatelain Bernard, Dogn� Jean-Michel, ChatelainChristian

LLSSPPEE3344 LLUUPPUUSS AANNTTIICCOOAAGGUULLAANNTT SSCCRREEEENN AANNDDCCOONNFFIIRRMM RREEAAGGEENNTTSS UUTTIILLIIZZIINNGG TTHHEE FFXXAACCTTIIVVAATTIINNGG VVEENNOOMM FFRROOMM VVIIPPEERRAA LLEEBBEETTIINNAA M. D. Goldford* (USA)

LLSSPPEE3355 CCOORRRREELLAATTIIOONN OOFF PPEEAAKK TTHHRROOMMBBIINNRREESSUULLTTSS OOBBTTAAIINNEEDD BBYY TTGGAA MMEEAASSUURREEMMEENNTTOONN CCEEVVEERROONN¤¤ AALLPPHHAA TTGGAA UUSSIINNGG FFAASSTTSSEETTTTIINNGG AANNDD SSTTAANNDDAARRDD SSEETTTTIINNGG L. Wagner* (Austria) - V. Kaufmann - J. Mager - G. Unzeitig

LLSSPPEE3366 IIMMPPAACCTT OOFF CCYYPP33AA44**11GG PPOOLLYYMMOORRPPHHIISSMM OONNPPLLAASSMMAATTIICC CCOONNCCEENNTTRRAATTIIOONN PPRROOFFIILLEE OOFFRRIIVVAARROOXXAABBAANN ((XXAARREELLTTOO¤¤)) AASSSSEESSSSEEDD BBYYCCOOAAGGUULLAATTIIOONN AASSSSAAYYSS J. Douxfils* (Belgium) - F. Mullier - C. Chatelain - B. Chatelain - J.-M. Dogn�

PPllaatteelleett bbaassiicc sscciieennccee

Chairperson: Yotis Senis (United Kingdom)

PPBBSS0011 DDIISSCCOOIIDD PPLLAATTEELLEETT AAGGGGRREEGGAATTIIOONNSSWWIITTHHOOUUTT EENNDDOOTTHHEELLIIUUMM DDIISSRRUUPPTTIIOONNVVIISSUUAALLIIZZEEDD BBYY IINN VVIIVVOO MMOOLLEECCUULLAARRIIMMAAGGIINNGG,, AANNDD CCOONNTTRRIIBBUUTTIIOONN OOFFIINNFFLLAAMMMMAATTOORRYY CCYYTTOOKKIINNEESS S. Nishimura* (Japan) - M. Nagasaki

PPBBSS0022 RRAAPPIIDD RREECCRRUUIITTMMEENNTT AANNDDMMIICCRROOAAGGGGRREEGGAATTEE FFOORRMMAATTIIOONN OOFF HHUUMMAANNPPLLAATTEELLEETTSS BBYY TTHHEE CCOOLLOONNIIZZIINNGGBBAACCTTEERRIIUUMM SSTTRREEPPTTOOCCOOCCCCUUSS OORRAALLIISSUUNNDDEERR SSHHEEAARR RRAATTEESS TTHHAATT MMIIMMIICCPPHHYYSSIIOOLLOOGGIICCAALL CCOONNDDIITTIIOONNSS D. Tilley* (Ireland) - C. Douglas - S. W. Kerrigan

PPBBSS0033 TTHHRREEEE DDIIMMEENNSSIIOONNAALL RREECCOONNSSTTRRUUCCTTIIOONN OOFFIINNTTAACCTT HHUUMMAANN IINNTTEEGGRRIINN AALLPPHHAAIIIIBBBBEETTAA33 IINNAA PPHHOOSSPPHHOOLLIIPPIIDD BBIILLAAYYEERR NNAANNOODDIISSCCW.-S. Choi* (USA) - W. J. Rice - B. S. Coller

PPBBSS0044 PPLLAATTEELLEETT FFLLOOWW--IINNDDUUCCEEDD PPRROOTTRRUUSSIIOONN((FFLLIIPPRR)) FFOORRMMAATTIIOONN IISS AA SSHHEEAARR AANNDDCCAALLPPAAIINN IINNDDUUCCEEDD PPRROOCCEESSSS LLEEAADDIINNGG TTOOPPLLAATTEELLEETT DDIISSIINNTTEEGGRRAATTIIOONN AANNDD TTHHEEFFOORRMMAATTIIOONN OOFF PPRROOCCOOAAGGUULLAANNTTMMIICCRROOPPAARRTTIICCLLEESS C. Tersteeg* (The Netherlands) - H. Heijnen - G. Pasterkamp - C. Floris - R. T. Urbanus - C. Maas - I. Hoefer - E. M. Mak-Nienhuis - V. De Angelis - P. G. de Groot - M. Roest

PPBBSS0055 SSYYNNEERRGGYY OOFF PPLLAATTEELLEETT RREECCEEPPTTOORRSS IINNTTHHRROOMMBBUUSS FFOORRMMAATTIIOONN:: AA MMIICCRROOAARRRRAAYYAAPPPPRROOAACCHH S. M. De Witt* (The Netherlands) and Moniek M. Lamers, Frauke Swieringa, Roger Kruchten,Richard, W. Farndale, Kenneth J. Clemetson,Judith M. E. M. Cosemans, Johan W. M. Heemskerk

PPBBSS0066 DDEEPPLLEETTIIOONN OOFF PPLLAATTEELLEETTSS IINN BB1166//FF1100MMEELLAANNOOMMAA TTUUMMOORR BBEEAARRIINNGG MMIICCEEPPRREEVVEENNTTSS MMAATTUURRAATTIIOONN OOFF NNEEWWLLYYFFOORRMMEEDD TTUUMMOORR BBLLOOOODD VVEESSSSEELLSSJ. Wu* (China) - R. Li - M. Ren - N. Chen - M. Luo

ISTH 2012 11.6.2012 14:48 Page 84

ePos

ters


ePoster Session

85

PPBBSS0077 EEXXAACCEERRBBAATTIIOONN OOFF GGPPVVII--DDEEPPEENNDDEENNTTPPLLAATTEELLEETT RREESSPPOONNSSEESS IINN AA RRHHEESSUUSSMMOONNKKEEYY MMOODDEELL OOFF TTYYPPEE II DDIIAABBEETTEESS J. F. Arthur* (Australia) - Y. Shen - J. Qiao - R. Ni - Y. Chen - R. K. Andrews - Y. Lu - E. E. Gardiner - J. Cheng

PPBBSS0088 AA NNEEWW MMIICCRROOFFLLUUIIDDIICC PPOOIINNTT--OOFF--CCAARREE TTEESSTTFFOORR MMUULLTTII--SSHHEEAARR PPLLAATTEELLEETT TTHHRROOMMBBOOSSIISS D. N. Ku* (USA) - M. Li - C. Forest - K. Hefelfinger- S. Gurnani - O. Martinez - N. Turturro - P. Gandhi

PPBBSS0099 NNIITTRRIICC OOXXIIDDEE EENNHHAANNCCEESS TTHHEE AANNTTII--IINNFFLLAAMMMMAATTOORRYY AANNDD AANNTTII--AATTHHEERROOGGEENNIICCAACCTTIIVVIITTYY OOFF AATTOORRVVAASSTTAATTIINN IINN AA MMOOUUSSEEMMOODDEELL OOFF AACCCCEELLEERRAATTEEDDAATTHHEERROOSSCCLLEERROOSSIISS S. Momi* (Italy) - E. Falcinelli - V. Conti - E. Ongini- P. Gresele

PPBBSS1100 MMOORRPPHHOO--FFUUNNCCTTIIOONNAALL CCHHAARRAACCTTAARRIIZZAATTIIOONNOOFF PPLLAATTEELLEETTSS BBYY AATTOOMMIICC FFOORRCCEEMMIICCRROOSSCCOOPPYY L. Drozd* (Belarus) - L. Kuharenko - S. Syroezhkin - L. Gelis - E. Medvedeva - I. Lazareva - S. Chizhik

PPBBSS1111 SSHHOORRTTEERR CCAARROOTTIIDD AARRTTEERRYY OOCCCCLLUUSSIIOONN IINNAA TTHHAALLAASSSSEEMMIICC MMOOUUSSEE MMOODDEELL::AA PPOOTTEENNTTIIAALL RROOLLEE FFOORR OOXXIIDDAATTIIVVEE SSTTRREESSSSAAFFFFEECCTTIINNGG BBOOTTHH RRBBCCSS AANNDD PPLLAATTEELLEETTSS Z. Malyutin - E. Shai - M. Dana - E. Rachmilewitz- E. Fibach - D. Varon* (Israel)

PPBBSS1122 IISSOOTTHHEERRMMAALL TTIITTRRAATTIIOONN CCAALLOORRIIMMEETTRRYYCCOONNFFIIRRMMSS PPRROOTTEEIINN--PPRROOTTEEIINNIINNTTEERRAACCTTIIOONNSS IINN TTHHEE HHUUMMAANN PPLLAATTEELLEETT

S. Allen* (Ireland) - N. MoranPPBBSS1133 TTWWOO TTYYPPEESS OOFF PPHHOOSSPPHHAATTIIDDYYLLSSEERRIINNEE--

EEXXPPRREESSSSIINNGG PPLLAATTEELLEETTSS AARREE FFOORRMMEEDDUUPPOONN PPHHYYSSIIOOLLOOGGIICCAALL AACCTTIIVVAATTIIOONN AANNDDAARREE CCOONNTTRROOLLLLEEDD BBYY IINNTTEEGGRRIINN ∞∞LLPPHHAAIIIIBBBBEETTAA33 SSIIGGNNAALLIINNGG N. N. Topalov* (Russian Federation) - A. O. Yakimenko - M. Canault - M. Loosveld - F. I. Ataullakhanov - A. T. Nurden - M.-C. Alessi -M. A. Panteleev

PPBBSS1144 MMOOLLEECCUULLAARR MMEECCHHAANNIISSMMSS IINNVVOOLLVVEEDD IINN TTHHEEAANNTTIITTHHRROOBBOOTTIICC AACCTTIIVVIITTYY OOFF AAEEGGYYPPTTIINN,,AA NNOOVVEELL MMOOSSQQUUIITTOO--DDEERRIIVVEEDD CCOOLLLLAAGGEENN--BBIINNDDIINNGG PPRROOTTEEIINN D. Mizurini* (Brazil) - E. Calvo - I. Francischetti - R. Monteiro

PPBBSS1155 CCOOMMPPAARRIISSOONN OOFF TTHHEE NNEEWW FFLLOOWWCCYYTTOOMMEETTRRIICC BBEEAADD AASSSSAAYY FFOORR VVAASSPP--PPHHOOSSPPHHOORRYYLLAATTIIOONN TTOO AA CCOOMMMMEERRCCIIAALLLLYYAAVVAAIILLAABBLLEE TTEESSTT IINN AASSSSEESSSSMMEENNTT OOFFPPLLAATTEELLEETT IINNHHIIBBIITTIIOONN BBYY PP22YY1122AANNTTAAGGOONNIISSTTSS N. Dovlatova* (United Kingdom) - J. Glenn - S. Heptinstall - S. Fox

PPBBSS1166 MMUULLTTIIPPLLAATTEE AANNAALLYYZZEERR AASS AA VVAALLIIDD TTOOOOLLFFOORR PPLLAATTEELLEETT ((PPLLTT)) AAGGGGRREEGGAATTIIOONNSSTTUUDDIIEESS IINN AACCIIDD--CCIITTRRAATTEE--DDEEXXTTRROOSSEE ((AACCDD))DDOONNOORR BBLLOOOODD BBAAGGSS C. J. Tartari* (Italy) - M. Marchetti - L. Russo - A. Vignoli - E. Diani - C. Giaccherini - C. Verzeroli- E. Baldoli - L. Da Prada - N. Coffetti - A. Rosti -A. Falanga

ISTH 2012 11.6.2012 14:48 Page 85


ePoster Session

86

PPBBSS1177 CCHHAANNGGEESS IINN PPLLAATTEELLEETT ((PPLLTT)) AAGGGGRREEGGAATTIIOONNAANNDD AACCTTIIVVAATTIIOONN SSTTAATTUUSS DDUURRIINNGG SSTTOORRAAGGEEIINN PPLLAATTEELLEETT CCOONNCCEENNTTRRAATTEESS ((PPCC)) FFOORRTTRRAANNSSFFUUSSIIOONN UUSSEE A. Vignoli* (Italy) - M. Marchetti - C. J. Tartari - L. Russo - E. Diani - C. Giaccherini - C. Verzeroli -L. Da Prada - S. Marziali - A. Falanga

PPBBSS1188 EEVVAALLUUAATTIIOONN OOFF BBAABBOOOONN PPLLAATTEELLEETTAAGGGGRREEGGAATTIIOONN IINN AA MMUULLTTIIPPLLAATTEE¤¤PPLLAATTEELLEETT FFUUNNCCTTIIOONN AANNAALLYYZZEERR W. J. Janse Van Rensburg* (South Africa) - R. van Zyl - J. Roodt - S. Lamprecht

PPllaatteelleett cclliinniiccaall

Chairperson: Beng Chong (Australia)

PPCC0011 AA MMUUTTAATTIIOONN IINN AANNKKRRDD1188AA,, AANNKKYYRRIINNRREEPPEEAATT DDOOMMAAIINN 1188AA,, CCAAUUSSEESS AA SSEEVVEERREEFFOORRMM OOFF CCOONNGGEENNIITTAALLTTHHRROOMMBBOOCCYYTTOOPPEENNIIAA G. C. Lowe* (United Kingdom) - J. Motwani - M. Williams - M. Simpson - S. P. Watson - N. V. Morgan

PPCC0022 AACCQQUUIIRRIINNGG AANN ÒIINNHHEERRIITTEEDDÓTTHHRROOMMBBOOCCYYTTOOPPEENNIIAA:: CCLLOONNAALLCCHHRROOMMOOSSOOMMEE AANNOOMMAALLIIEESS AAFFFFEECCTTIINNGG FFLLII11MMIIMMIICC IINNHHEERRIITTEEDD TTHHRROOMMBBOOCCYYTTOOPPEENNIIAA OOFFTTHHEE PPAARRIISS--TTRROOUUSSSSEEAAUU TTYYPPEE P. Noris* (Italy) - R. Valli - B. Pressato - A. Pecci - C. Marletta - R. Invernizzi - L. Mare - C. L. Balduini - F. Pasquali - E. Maserati

PPCC0033 SSTTIICCKKYY PPLLAATTEELLEETT SSYYNNDDRROOMMEE AANNDD TTHHEEGGEENNEETTIICC VVAARRIIAABBIILLIITTYY OOFF TTHHEEGGLLYYCCOOPPRROOTTEEIINN 66 GGEENNEE IINN PPAATTIIEENNTTSS WWIITTHHVVEENNOOUUSS TTHHRROOMMBBOOSSIISS AANNDD PPUULLMMOONNAARRYYEEMMBBOOLLIISSMM P. Kubisz* (Slovakia) - D. Kotulicova’ - P. Chudy’ -M. Skerenova’ - R. Pullmann, Sr. - J. Stasko

PPCC0044 IIDDEENNTTIIFFIICCAATTIIOONN OOFF 6611 NNOOVVEELL MMUUTTAATTIIOONNSS IINNTTHHEE IITTGGAA22BB AANNDD IITTGGBB33 GGEENNEESS OOFF 9900PPAATTIIEENNTTSS WWIITTHH GGLLAANNZZMMAANNNNTTHHRROOMMBBAASSTTHHEENNIIAA:: AANN AANNAALLYYSSIISS OOFFSSTTRRUUCCTTUURREE--FFUUNNCCTTIIOONN RREELLAATTIIOONNSSHHIIPPSS X. Pillois* (France) - C. Vinciguerra - R. Heilig - P. Nurden - M. Fiore - A. Nurden

PPCC0055 PPLLAATTEELLEETT SSUURRFFAACCEE HHIIGGHH MMOOBBIILLIITTYY GGRROOUUPPBBOOXX PPRROOTTEEIINN--11 BBIINNDDSS RREECCEEPPTTOORR FFOORRAADDVVAANNCCEEDD GGLLYYCCAATTIIOONN EENNDDPPRROODDUUCCTTSS IINNPPLLAASSMMAA OORR OONN MMOONNOOCCYYTTEESS IINN SSEEPPTTIICCPPAATTIIEENNTTSS J. Thachil* (United Kingdom) - V. Barrera - B. Djebabri - S. T. Abrams - G. Wang - C. H. Toh

PPCC0066 AA NNOOVVEELL MMEECCHHAANNIISSMM OOFF PP--SSEELLEECCTTIINNIINNDDEEPPEENNDDEENNTT MMOONNOOCCYYTTEE--PPLLAATTEELLEETTAAGGGGRREEGGAATTIIOONN IINN CCHHIILLDDRREENN C. Yip - V. Ignjatovic - P. Monagle* (Australia) - C. Attard - M. D. Linden

PPCC0077 AA NNOOVVEELL DD223355YY MMUUTTAATTIIOONN IINN TTHHEE GGPP11BBAAGGEENNEE EENNHHAANNCCEESS PPLLAATTEELLEETT IINNTTEERRAACCTTIIOONNWWIITTHH VVWWFF IINN AANN IIRRAANNIIAANN FFAAMMIILLYY WWIITTHHPPLLAATTEELLEETT TTYYPPEE VVOONN WWIILLLLEEBBRRAANNDD DDIISSEEAASSEE S. Enayat* (Iran) - S. Ravanbod - M. Rassoulzadegan - M. Jazebi - S. Tarighat - F. Ala - J. Emsley - M. Othman

ISTH 2012 11.6.2012 14:48 Page 86

ePos

ters


ePoster Session

87

PPCC0088 MMAACCRROOTTHHRROOMMBBOOCCYYTTOOPPEENNIIAA AASSSSOOCCIIAATTEEDDWWIITTHH PPHHYYTTOOSSTTEERROOLLEEMMIIAA:: AA PPOOTTEENNTTIIAALLNNEEWW PPLLAATTEELLEETT DDIISSOORRDDEERR Z. Wang* (China) - G. Wang - L. Cao - C. Ruan

PPCC0099 PPRREETTRREEAATTMMEENNTT AADDAAMMTTSS1133 AANNTTIIBBOODDYYCCOONNCCEENNTTRRAATTIIOONN AANNDD AAGGEE PPRREEDDIICCTTSSRREELLAAPPSSEE IINN PPAATTIIEENNTTSS WWIITTHH NNEEWWLLYYDDIIAAGGNNOOSSEEDD AACCQQUUIIRREEDD TTHHRROOMMBBOOTTIICCTTHHRROOMMBBOOCCYYTTOOPPEENNIICC PPUUPPUURRAA ((TTTTPP)) S. R. Cataland* (USA) - S. Yang - H. Wu

PPCC1111 AANNTTII--PPLLAATTEELLEETT MMEEDDIICCAATTIIOONN FFOORR TTHHEEPPRROOGGRREESSSSIINNGG SSTTRROOKKEE WWIITTHH SSMMAALLLLVVEESSSSEELLSS OOCCCCLLUUSSIIOONN T. Nakase* (Japan) - M. Sasaki - S. Yoshioka - Y. Ikeda - A. Suzuki

PPCC1122 AA NNOOVVEELL PPLLAATTEELLEETT AASSSSAAYY TTHHAATT MMEEAASSUURREESSTTHHEE EEFFFFEECCTT OOFF CCLLOOPPIIDDOOGGRREELL IINN VVIIVVOO A. Lopez* (Ireland) - D. Kenny - L. Basabe-Desmonts - S. Ramstrom - B. Jose -M. Somers

PPCC1133 GGLLOOBBAALL HHEEMMOOSSTTAASSIISS TTEESSTTSS IINN PPAATTIIEENNTTSSWWIITTHH CCIIRRRRHHOOSSIISS BBEEFFOORREE AANNDD AAFFTTEERRPPRROOPPHHYYLLAACCTTIICC PPLLAATTEELLEETT TTRRAANNSSFFUUSSIIOONN V. Chantarangkul* (Italy) - M. Primignani - L. Lemma - M. Clerici - M. Jovani - P. Rebulla - P. M. Mannucci - A. Tripodi

PPCC1144 UUTTIILLIITTYY OOFF TTEEGG AANNDD FFLLOOWWCCYYTTOOMMEETTRRYY TTOOGGUUIIDDEE PPLLAATTEELLEETT TTRRAANNSSFFUUSSIIOONNRREEQQUUIIRREEMMEENNTT IINN PPAATTIIEENNTTSS WWIITTHHHHAAEEMMAATTOOLLOOGGIICCAALL MMAALLIIGGNNAANNCCIIEESS S. Debono* (Malta) - F. Bonello - R. Buttigieg - P. Brincat - C. Grima - T. Lofaro - S. Laspina - A. Gatt

PPCC1155 HHEEMMOORRRRHHAAGGIICC RRIISSKK DDUUEE TTOO PPLLAATTEELLEETTDDYYSSFFUUNNCCTTIIOONN IINN MMYYEELLOODDYYSSPPLLAATTIICCPPAATTIIEENNTTSS.. TTHHEE CCOORRRREELLAATTIIOONNSS WWIITTHHAANNEEMMIIAA SSEEVVEERRIITTYY AANNDD IIRROONN OOVVEERRLLOOAADD V. M. Popov* (Romania) - A. M. Vladareanu - H. Bumbea - M. Begu - A. M. Iova - M. Gaman -M. Popescu - C. Stocheci - E. Kovacs

PPCC1166 PPRREEOOPPEERRAATTIIVVEE BBLLEEEEDDIINNGG RRIISSKK FFAACCTTOORRSS IINNTTAAVVII PPAATTIIEENNTTSS K. CzerwinÕska - Jelonkiewicz* (Poland) - A. Witkowski - M. D�browski - M. Banaszewski -E. Ksie,zÕycka- MajczynÕska - Z. Chmielak - K. Kunmierski - T. Hryniewiecki - M. Demkow - J. Ste,pinÕska

PPCC1177 TTOOLLEERRAABBIILLIITTYY AANNDD EEFFFFIICCAACCYY OOFFRROOMMIIPPLLOOSSTTIIMM AASS MMAANNAAGGEEMMEENNTT OOFFSSEEVVEERREE,, RREEFFRRAACCTTOORRYY IIMMMMUUNNEETTHHRROOMMBBOOCCYYTTOOPPEENNIIAA ((IITTPP)) DDUURRIINNGGPPRREEGGNNAANNCCYY A. Giermasz* (USA) - J. Knoche - P. F. Fogarty

PPCC1188 EEVVAALLUUAATTIIOONN OOFF PPLLAATTEELLEETT DDYYSSFFUUNNCCTTIIOONN IINNVVIIRRAALL LLIIVVEERR DDIISSEEAASSEE::RREELLAATTIIOONNSSHHIIPP TTOODDIISSEEAASSEE SSEEVVEERRIITTYY M. F. Ghozlan* (Egypt) - A. A. Saad - D. S. mohamed - E. A. husseen - H. A. abdella

PPCC1199 RREELLAATTIIOONNSSHHIIPP BBEETTWWEEEENN VVOONN WWIILLLLEEBBRRAANNDDFFAACCTTOORR AANNDD PPLLAATTEELLEETT PPAARRAAMMEETTEERRSS IINNAADDUULLTT DDEENNGGUUEE IINNFFEECCTTIIOONN PPAATTIIEENNTTSS U. Sukorini* (Indonesia) - S. Setyawati - R. El Khair

ISTH 2012 11.6.2012 14:48 Page 87


ePoster Session

88

PPCC2200 TTHHRROOMMBBIINN GGEENNEERRAATTIIOONN TTEESSTT IINN TTHHEEMMOONNIITTOORRIINNGG OOFF AANNTTIIPPLLAATTEELLEETT TTHHEERRAAPPYYEEFFFFEECCTTIIVVEENNEESSSSO. Smirnova* (Russian Federation) - Y. Namestnikov - O. Matvienko - G. Berezovskaya - O. Golovina - L. Papayan

PPCC2211 TTHHRROOMMBBOOEELLAASSTTOOGGRRAAPPHHIICC TTEESSTTIINNGG TTOODDEETTEERRMMIINNEE IINNDDIIVVIIDDUUAALL RREESSPPOONNSSEE TTOOCCLLOOPPIIDDOOGGRREELL B. J. Bryant* (USA) - J. Treat - F. Scalia - I. McQueen - P. Sharks

PPCC2222 EEFFFFEECCTT OOFF CCYYTTOOCCHHRROOMMEE PP445500PPOOLLYYMMOORRPPHHIISSMM OONN PPLLAATTEELLEETT RREEAACCTTIIVVIITTYYAAFFTTEERR TTRREEAATTMMEENNTT WWIITTHH CCLLOOPPIIDDOOGGRREELL IINNPPAATTIIEENNTTSS SSCCHHEEDDUULLEEDD FFOORR PPEERRCCUUTTAANNEEOOUUSSCCOORROONNAARRYY IINNTTEERRVVEENNTTIIOONN A. A. Saad* (Egypt) - A. M. Abd Elsalam - G. M. Kamal - N. F. Abou El-Ezz - R. S. El-Hagracy

TThhrroommbbooeemmbboolliicc DDiissoorrddeerrss

Chairperson: Paul Kyrle (Austria)

PPEE0011 MMAARRKKEERRSS OOFF CCOOAAGGUULLAATTIIOONN AANNDDIINNFFLLAAMMMMAATTIIOONN IINN RREELLAATTIIOONN TTOO TTHHEE PPOOSSTTTTHHRROOMMBBOOTTIICC SSYYNNDDRROOMMEE A. Bouman* (The Netherlands) - J. Smits - H. ten Cate - A. ten Cate-Hoek

PPEE0022 AALLTTEERRNNAATTIIVVEE DDIIAAGGNNOOSSEESS OOFF PPUULLMMOONNAARRYYEEMMBBOOLLIISSMM IINN PPRRIIMMAARRYY CCAARREE P. M. Erkens* (The Netherlands) - W. Lucassen -M. V. Heugten - L. Rietjens - G.-J. Geersing - M. Prins - H. T. Cate - J. Stoffers

PPEE0044 CCOOMMPPLLIIAANNCCEE OOFF RREECCOOMMMMEENNDDAATTIIOONNSS WWIITTHHFFRREENNCCHH CCLLIINNIICCAALL PPRRAACCTTIICCEE IINN TTHHEEMMAANNAAGGEEMMEENNTT OOFF TTHHRROOMMBBOOEEMMBBOOLLIISSMM IINNPPAATTIIEENNTTSS WWIITTHH CCAANNCCEERR:: TTHHEE CCAARRMMEENNSSTTUUDDYYM. Sevestre* (France) - D. Farge - P. Debourdeauand Groupe Francophone Thrombose et Cancer

PPEE0055 DD--DDIIMMEERR AANNDD UULLTTRRAASSOOUUNNDD IINNCCOOMMBBIINNAATTIIOONN IITTAALLIIAANN SSTTUUDDYY ((DDUULLCCIISS)) TTOOEESSTTAABBLLIISSHH TTHHEE OOPPTTIIMMAALL DDUURRAATTIIOONN OOFFAANNTTIICCOOAAGGUULLAATTIIOONN FFOORR VVEENNOOUUSSTTHHRROOMMBBOOEEMMBBOOLLIISSMM:: PPRREELLIIMMIINNAARRYYRREESSUULLTTSS B. Cosmi* (Italy) - C. Legnani - A. Ghiraduzzi - S. Testa - P. Vittorio - E. Favaretto - G. Palareti

PPEE0066 UUNNUUSSUUAALL TTHHRROOMMBBOOSSEESS AANNDDTTHHRROOMMBBOOPPHHIILLIIAA:: AA CCAASSEE--CCOONNTTRROOLL SSTTUUDDYY J. Chapin* (USA) - P. Christos - M. T. DeSancho

PPEE0077 MMIICCRROOPPAARRTTIICCAALL--AASSSSOOCCIIAATTEEDD TTHHRROOMMBBIINNGGEENNEERRAATTIIOONN IINN PPAATTIIEENNTTSS WWIITTHHPPOOSSTTTTHHRROOMMBBOOPPHHLLEEBBIITTIICC SSYYNNDDRROOMMEE O. Matvienko* (Russian Federation) - Y. Namestnikov - O. Golovina - N. Saltykova

PPEE0099 OONNEE YYEEAARR EEVVEENNTT RRAATTEE OOFF SSEERRIIOOUUSSTTHHRROOMMBBOOSSIISS AANNDD BBLLEEEEDDIINNGG IINN JJAAPPAANNEESSEEPPAATTIIEENNTTSS WWIITTHH MMYYOOCCAARRDDIIAALL IINNFFAARRCCTTIIOONN,,SSTTRROOKKEE AANNDD AATTRRIIAALL FFIIBBRRIILLLLAATTIIOONN E. Toda* (Japan) - S. Uchiyama - K. Shimada - H. Origasa - H. Kobayashi - A. Kawamura - T. Nagao - Y. Ikeda - S. Goto and the JapanThrombosis Registry for Atrial Fibrillation,Coronary, or Cerebrovascular Events (J-TRACE)

ISTH 2012 11.6.2012 14:48 Page 88

ePos

ters


ePoster Session

89

PPEE1100 TTHHEE VVAALLUUEE OOFF DD--DDIIMMEERR AASS AA MMAARRKKEERR FFOORRCCAARRDDIIOOVVAASSCCUULLAARR AANNDD AARRTTEERRIIAALLTTHHRROOMMBBOOTTIICC EEVVEENNTTSS IINN PPAATTIIEENNTTSS WWIITTHHPPEERRIIPPHHEERRAALL AARRTTEERRIIAALL DDIISSEEAASSEE;; AASSYYSSTTEEMMAATTIICC RREEVVIIEEWW M.-C. Kleinegris* (The Netherlands) - A. ten Cate-Hoek - H. ten Cate

PPEE1111 VVEENNOOUUSS TTHHRROOMMBBOOEEMMBBOOLLIISSMMPPRROOPPHHYYLLAAXXIISS IINN EELLDDEERRLLYY PPAATTIIEENNTTSSAADDMMIITTTTEEDD TTOO IITTAALLIIAANN IINNTTEERRNNAALL MMEEDDIICCIINNEEWWAARRDDSS M. Marcucci* (Italy) - F. Violi - A. Iorio - M. Tettamanti - L. Pasina - A. Nobili - C. D. Djade - A. Marengoni - F. Salerno - S. Corrao - P. M.Mannucci and REPOSI (REgistro POliterapieSociet� Italiana di Medicina Interna) Investigators

PPEE1122 RREEAADDMMIISSSSIIOONN AANNDD DDEEAATTHH RRAATTEESS FFRROOMMVVEENNOOUUSS TTHHRROOMMBBOOEEMMBBOOLLIISSMM WWIITTHHIINN 9900DDAAYYSS OOFF HHOOSSPPIITTAALL AADDMMIISSSSIIOONN:: WWHHAATT CCAANNWWEE LLEEAARRNN FFRROOMM MMEEAASSUURRIINNGG RREEAALLOOUUTTCCOOMMEESS AATT AA NNAATTIIOONNAALL LLEEVVEELL?? W. A. Lester* (United Kingdom) - S. Khosla - D. Ray - M. Richardson - D. Pagano and Qualityand Outcomes Research Unit, UniversityHospitals Birmingham

PPEE1133 CCOOFFFFEEEE CCOONNSSUUMMPPTTIIOONN AANNDD AA RREEDDUUCCEEDDRRIISSKK OOFF VVEENNOOUUSS TTHHRROOMMBBOOSSIISS:: MMEEDDIIAATTEEDDTTHHRROOUUGGHH HHEEMMOOSSTTAATTIICC FFAACCTTOORRSS R. E. Roach* (The Netherlands) - B. Siegerink - S. le Cessie - F. R. Rosendaal - S. C. Cannegieter - W. M. Lijfering

PPEE1144 VVEENNOOUUSS TTHHRROOMMBBOOSSIISS IINN AA PPAATTIIEENNTT WWIITTHHCCOONNGGEENNIITTAALL AAFFIIBBRRIINNOOGGEENNEEMMIIAA:: CCLLIINNIICCAALLIIMMPPLLIICCAATTIIOONNSS AANNDD MMAANNAAGGEEMMEENNTT J. Chapin* (USA) - M. DeSancho

PPEE1155 AACCQQUUIIRREEDD AANNDD GGEENNEETTIICC RRIISSKK FFAACCTTOORRSSAASSSSEESSSSMMEENNTT FFOORR DDEEEEPP VVEENNOOUUSSTTHHRROOMMBBOOSSIISS IINN 338899 OOFF HHOOSSPPIITTAALLIIZZEEDDCCHHIINNEESSEE PPAATTIIEENNTTSS:: AA SSIINNGGLLEE CCEENNTTEERREEXXPPEERRIIEENNCCEESS M.-Y. Deng* (China) - G.-S. zhang - Y.-Y. luo

PPEE1166 QQUUAALLIITTYY OOFF LLIIFFEE IINN AACCUUTTEE DDEEEEPP VVEEIINNTTHHRROOMMBBOOSSIISS AANNDD PPUULLMMOONNAARRYY EEMMBBOOLLIISSMM K. Hogg* (Canada) - M. Kimpton - M. Carrier - D. Coyle - P. Wells

PPEE1177 EEXXPPLLIICCIITT AASSSSEESSSSMMEENNTT OOFFTTHHRROOMMBBOOEEMMBBOOLLIICC RRIISSKK AANNDDPPRROOPPHHYYLLAAXXIISS FFOORR MMEEDDIICCAALL PPAATTIIEENNTTSS IINNSSWWIITTZZEERRLLAANNDD ((EESSTTIIMMAATTEE)):: PPRREELLIIMMIINNAARRYYRREESSUULLTTSS D. Spirk - D. Aujesky - D. Hayoz - J. Beer - M. Husmann - B. Frauchiger - W. Korte - W. Wuillemin - H. Bounameaux - M. Nendaz*(Switzerland)

PPEE1188 PPRROOPPHHYYLLAAXXIISS GGUUIIDDEELLIINNEESS AASS AASSSSEESSSSEEDDRREETTRROOSSPPEECCTTIIVVEELLYY OONN AA CCOOHHOORRTT OOFFHHOOSSPPIITTAALL--AACCQQUUIIRREEDD VVEENNOOUUSS TTHHRROOMMBBOOSSIISSMMEEDDIICCAALL PPAATTIIEENNTTSS WWIITTHHOOUUTTTTHHRROOMMBBOOPPRROOPPHHYYLLAAXXIISS H. J. Ng* (Singapore) - Y. H. Leong - L. K. Siow - S. H. Yeang - S. Y. Wong - L. H. Lee

ISTH 2012 11.6.2012 14:48 Page 89


ePoster Session

90

PPEE1199 SSIIGGNNIIFFIICCAANNCCEE OOFF TTIISSSSUUEE FFAACCTTOORR--PPOOSSIITTIIVVEEMMIICCRROOPPAARRTTIICCLLEESS IINN TTHHEE PPAATTIIEENNTTSS WWIITTHHAACCUUTTEE PPRROOMMYYEELLOOCCYYTTIICC LLEEUUKKEEMMIIAA Y. Han* (China) - L. Zhou - X. Bai - D. Wu - Z. Wang - C. Ruan

PPEE2200 SSIIGGNNIIFFIICCAANNTTLLYY HHIIGGHHEERR LLEEVVEELL OOFFLLIIPPOOPPRROOTTEEIINN ((AA)) AAMMOONNGG AACCUUTTEECCOORROONNAARRYY SSYYNNDDRROOMMEE ((AACCSS)) TTHHAANN SSTTAABBLLEEAANNGGIINNAA PPEECCTTOORRIISS ((SSAAPP)) PPAATTIIEENNTTSS OORRHHEEAALLTTHHYY SSUUBBJJEECCTTSS IINN IINNDDOONNEESSIIAANNPPOOPPUULLAATTIIOONN I. Puspitawati* (Indonesia) - S. Setyawati - D. W. Anggrahini - E. H. Herningtyas

PPEE2211 IILL--1188 AANNDD VVAASSCCUULLAARR MMIINNEERRAALLIIZZAATTIIOONN IINNCCOORROONNAARRYY AARRTTEERRYY DDIISSEEAASSEE PPAATTIIEENNTTSS A. De La Pe�a* (Mexico) - B. Valente-Acosta - J. Reese-Parada - A. Contreras-Villase�or - L. Quintanar-Trejo - M. Pe�a-Duque - M. Martinez-Rios - V. Herrera-Alarcon - C. Linares-Lopez - H. Delgado-Granados - M. Flores-Garcia - F. Santiba�ez-Escobar

PPEE2222 SSTTUUDDYY OONN GGEENNEE MMAARRKKEERRSS OOFF TTHHRROOMMBBOOSSIISSIINN CCOORROONNAARRYY HHEEAARRTT DDIISSEEAASSEE BBYY MMUULLTTII--AANNAALLYYTTEE SSUUSSPPEENNSSIIOONN AARRRRAAYYTTEECCHHNNOOLLOOGGYY W. He* (China) - Y. HU - J. Yu - T. Guo - X. Zhang

PPEE2233 RREESSUULLTTSS FFRROOMM TTHHEE NNAATTIIOONNAALL RREEGGIISSTTRRYYOOFF TTHHRROOMMBBOOPPHHIILLIICC SSTTAATTEESS IINN SSLLOOVVAAKKIIAA J. Stas~ko* (Slovakia) - I. Plamen~ov� - J. Sokol - P. ChudyÕ - M. Dobrotov� - P. Kubisz

PPEE2244 VVEENNOOUUSS TTHHRROOMMBBOOEEMMBBOOLLIISSMM:: AA RREEFFIINNEEDDUUNNIITTEEDD SSTTAATTEESS CCOOSSTT MMOODDEELL WWIITTHH LLOONNGG--TTEERRMM AATTTTAACCKK RRAATTEESS C. E. Mahan* (USA) - A. L. Woersching - M. E. Borrego - R. Federici - A. C. Spyropoulos

PPEE2255 CCOOAAGGUULLAATTIIOONN FFAACCTTOORR XXIIIIII--BB HHIISS9955AARRGGPPOOLLYYMMOORRPPHHIISSMM AANNDD TTHHEE RRIISSKK OOFFCCOORROONNAARRYY AARRTTEERRYY DDIISSEEAASSEE IINN AACCRROOAATTIIAANN PPOOPPUULLAATTIIOONN A. Bronic* (Croatia) - G. Ferencak - R. Bernat - J. Dumic - S. Dabelic

PPEE2266 NNOO CCOORRRREELLAATTIIOONN BBEETTWWEEEENN MMEEAANNPPLLAATTEELLEETT VVOOLLUUMMEE AANNDD TTHHEE RRIISSKK OOFFRREECCUURRRREENNTT VVEENNOOUUSS OORR AARRTTEERRIIAALLTTHHRROOMMBBOOSSIISS IINN PPAATTIIEENNTTSS WWIITTHHAANNTTIIPPHHOOSSPPHHOOLLIIPPIIDD SSYYNNDDRROOMMEE J. Rupa-Matysek* (Poland) - L. Gil - E. Wojtasin~ska - K. Zajdel - K. Ciepluch - M. Lewandowska - M.. Komarnicki

PPEE2277 DDEEVVEELLOOPPIINNGG AANNIIMMAALLMMOODDEELLSS OOFF HHEEMMOOLLYYTTIICC UURREEMMIICC SSYYNNDDRROOMMEE

D. Stearns-Kurosawa* (USA) - C. Leibowitz - C. Mayer - S. Kurosawa

PPEE2288 CCOOMMPPLLIICCAATTIIOONNSS AASSSSOOCCIIAATTEEDD WWIITTHH PPIICCCCIINNSSEERRTTIIOONN IINN AA HHOOSSPPIITTAALL FFOORR HHIIGGHH LLEEVVEELLOOFF CCOOMMPPLLEEXXIITTYY OOFF TTHHEE CCIITTYY OOFF MMEEDDEELLLLIINN-- CCOOLLOOMMBBIIAA J. F. Combariza* (Colombia) - S. Roldan - K. Galvez - V. Olaya - L. ballesteros - V. palacios

ISTH 2012 11.6.2012 14:48 Page 90

ePos

ters


ePoster Session

91

PPEE2299 UUSSIINNGG HHAAEEMMOOSSTTAATTIICC AANNDD RRHHEEOOLLOOGGIICCFFAACCTTOORRIIAALLSS AASS DDIIAAGGNNOOSSTTIICC AANNDDPPRROOGGNNOOSSTTIICC MMAARRKKEERRSS OOFF AACCUUTTEEMMYYOOCCAARRDDIIAALL IINNFFAARRCCTTIIOONNSS IINN NNIIGGEERRIIAANNSS I. O. Ajayi* (Nigeria) - G. Nwaeke - O. E. Ihejirika

PPEE3311 NNOOVVEELL HHEEMMOOSSTTAATTIICC MMAARRKKEERRSS FFOORRTTHHRROOMMBBOOEEMMBBOOLLIICC RRIISSKK IINN PPAATTIIEENNTTSS WWIITTHHPPRROOSSTTAATTEE CCAANNCCEERR M. Toukh* (Canada) - A. Black - R. D. Siemens - M. Othman

PPEE3322 FFIIBBRRIINNOOGGEENN--LLIIKKEE PPRROOTTEEIINN 22 ((FFGGLL--22)) -- AA NNOOVVEELL BBIIOOMMAARRKKEERR FFOORR CCAANNCCEERR A. Inbal* (Israel) - E. Rabizadeh - D. Lederfine - E. Rosenbaum - B. Brenner

PPEE3333 CCAASSEE SSEERRIIEESS:: PPAATTIIEENNTTSS WWIITTHH JJAAKK22PPOOSSIITTIIVVEE MMYYEELLOOPPRROOLLIIFFEERRAATTIIVVEENNEEOOPPLLAASSMMSS AASSSSOOCCIIAATTEEDD WWIITTHHTTHHRROOMMBBOOTTIICC EEVVEENNTTSS J. F. Combariza* (Colombia) - V. Olaya - K. Galvez- L. Ballesteros

PPEE3344 FFIIBBRRIINNOOGGEENN,, CC--RREEAACCTTIIVVEE PPRROOTTEEIINN AANNDDIINNTTEERRLLEEUUKKIINN--66 IINN PPRREEDDIICCTTIIOONN OOFFCCAARRDDIIOOVVAASSCCUULLAARR CCOOMMPPLLIICCAATTIIOONNSS AANNDDDDEEAATTHH IINN TTYYPPEE 22 DDIIAABBEETTEESS:: TTHHEE AADDVVAANNCCEESSTTUUDDYY G. D. Lowe* (United Kingdom) - G. Hillis - J. Chalmers - M. Woodward - A. Rumley

TThhrroommbboo--HHaaeemmoorrrrhhaaggiicc IIssssuueess

iinn WWoommeenn && CChhiillddrreenn

Chairpersons: Paul Monagle (Australia), Sabine Eichinger (Austria)

PPEEWWCC0011 TTHHEE AASSSSOOCCIIAATTIIOONN OOFF SSMMOOKKIINNGG WWIITTHHVVEENNOOUUSS TTHHRROOMMBBOOSSIISS AANNDD IITTSSMMOODDIIFFIICCAATTIIOONN BBYY HHOORRMMOONNEERREEPPLLAACCEEMMEENNTT TTHHEERRAAPPYY M. Blondon* (USA) - K. L. Wiggins - K. M. Rice - S. R. Heckbert - B. M. Psaty - N. L. Smith

PPEEWWCC0022 LLOONNGG TTEERRMM FFOOLLLLOOWW UUPP OOFF HHOOMMOOZZYYGGOOTTEEPPRROOTTEEIINN CC DDEEFFIICCIIEENNCCYY FFOOLLLLOOWWIINNGG MMUULLTTIIMMOODDAALL TTHHEERRAAPPYYK. E. Monagle* (Australia) - V. Ignatovic - W. Hardikar - F. Newall - P. Monagle

PPEEWWCC0033 AADDMMIINNIISSTTRRAATTIIOONN OOFF AANNTTIITTHHRROOMMBBIINNCCOONNCCEENNTTRRAATTEE IINN IINNFFAANNTTSS AANNDD CCHHIILLDDRREENNOONN EECCLLSS IIMMPPRROOVVEESS AANNTTIICCOOAAGGUULLAATTIIOONN L. Ryerson - A. A. Bruce* (Canada) - P. M. Massicotte - M. L. Bauman - S. Ghotra - L. Lequier - M. E. Bauman

PPEEWWCC0044 CCLLIINNIICCAALL FFIINNDDIINNGGSS IINN AA PPRROOSSPPEECCTTIIVVEECCOOHHOORRTT OOFF WWOOMMEENN IINN CCHHIILLDDBBEEAARRIINNGG AAGGEEWWIITTHH TTHHRROOMMBBOOSSIISS AANNDD//OORR PPRREEGGNNAANNCCYYAADDVVEERRSSEE OOUUTTCCOOMMEESS A. S�nchez-Luceros* (Argentina) - S. S. Meschengieser - S. H. Grosso - A. Blanco -M. Ingratti - M. F. Alberto - M. A. Lazzari

PPEEWWCC0055 AANNTTIICCOOAAGGUULLAATTIIOONN OOFF CCAARRDDIIOOMMYYOOPPAATTHHYY IINNCCHHIILLDDRREENNK. E. Monagle* (Australia) - S. Jones - I. King - R. Weintraub - P. Monagle - F. Newall

ISTH 2012 11.6.2012 14:48 Page 91


ePoster Session

92

PPEEWWCC0066 PPRREEDDIICCTTIINNGG DDEEEEPP VVEENNOOUUSS TTHHRROOMMBBOOSSIISS IINNPPRREEGGNNAANNCCYY:: EEXXTTEERRNNAALL VVAALLIIDDAATTIIOONN OOFFTTHHEE ÒLLEEFFTTÓ CCLLIINNIICCAALL PPRREEDDIICCTTIIOONN RRUULLEE M. Righini* (Switzerland) - G. Le Gal

PPEEWWCC0077 TTHHEE EECCOONNOOMMIICC CCOOSSTTSS OOFF RROOUUTTIINNEE IINNRRMMOONNIITTOORRIINNGG IINN IINNFFAANNTTSS AANNDD CCHHIILLDDRREENN J. Gaw - S. Crowley - P. Monagle* (Australia) - S. Jones - F. Newall

PPEEWWCC0088 CCEERREEBBRRAALL TTEE IINN IITTAALLIIAANN IINNFFAANNTTSS AANNDDCCHHIILLDDRREENN:: DDAATTAA FFRROOMM TTHHEE IITTAALLIIAANNRREEGGIISSTTRRYY OOFF CCHHIILLDDHHOOOODD TTHHRROOMMBBOOSSIISS((RRIITTII)) C. Gentilomo* (Italy) - P. Saracco - R. Bagna - B. Bassi - M. Agostini - P. Giordano - L. A. Ramenghi - A. C. Molinari - A. M. Laverda -M. Grassi - M. C. Putti - A. Suppiej - S. Sartori - P. Simioni and Italian Group Of ChildhoodThrombosis Registry

PPEEWWCC0099 PPRROOSSPPEECCTTIIVVEE SSTTUUDDYY OONN IINNCCIIDDEENNCCEE RRAATTEEOOFF NNEEOONNAATTAALL AANNDD PPEEDDIIAATTRRIICCTTHHRROOMMBBOOEEMMBBOOLLIISSMM IINN AA SSIINNGGLLEE TTEERRTTIIAARRYYCCAARREE HHOOSSPPIITTAALL IINN IITTAALLYY DDUURRIINNGG AA 55--YYEEAARRPPEERRIIOODD P. Saracco* (Italy) - A. Viano - R. Bagna - B. Bassi- M. Agostini - G. Agnoletti - E. Barisone - D. Farinasso - M. T. Cascarano - L. Barberis - F. Magnetti - E. Gallo - C. Plazzotta - R. Bonaudo- G. Migliore - C. Gentilomo - B. Pollio - P. Simioniand RITI, Registo Italiano Trombosi Infantili

PPEEWWCC1100 OOBBSSTTEETTRRIICCSS OOUUTTCCOOMMEESS AASSSSOOCCIIAATTEEDD WWIITTHHAANN IINNCCRREEAASSEEDD LLEEVVEELL OOFF LLIIPPOOPPRROOTTEEIINN--AA((LLPP--AA)) IINN TTHHRROOMMBBOOPPHHIILLIICC PPAATTIIEENNTTSS D. Recchi - V. V. Barros* (Brazil) - F. S. Baptista - M. R. D. F. L. Bortolotto - R. P. V. Francisco - M. Zugaib

PPEEWWCC1111 MMOOLLEECCUULLAARR BBAASSIISS OOFF TTYYPPEE IIAANNTTIITTHHRROOMMBBIINN DDEEFFIICCIIEENNCCYY IINN TTWWOO WWOOMMEENNWWIITTHH RREECCUURRRREENNTT VVEENNOOUUSSTTHHRROOMMBBOOEEMMBBOOLLIISSMM IINN TTHHEE FFIIRRSSTTTTRRIIMMEESSTTEERR OOFF PPRREEGGNNAANNCCYY Y. Xia* (China) - Q. Ding - X. Wang - Y. Lu - J. Dai

PPEEWWCC1122 HHIIGGHHEERR DDOOSSEESS OOFF LLOOWW MMOOLLEECCUULLAARRWWEEIIGGHHTT HHEEPPAARRIINN ((LLMMWWHH)) AARREE NNEEEEDDEEDD TTOOAACCHHIIEEVVEE GGOOAALL AANNTTII--XXAA LLEEVVEELLSS IINNCCRRIITTIICCAALLLLYY IILLLL CCHHIILLDDRREENN N. J. Schloemer* (USA) - S. Abu-Sultaneh - S. Hanson - K. Yan - R. G. Hoffmann - R. Punzalan - P. Havens

PPEEWWCC1133 TTHHEE EEFFFFEECCTT OOFF AANNTTIITTHHRROOMMBBIINNCCOONNCCEENNTTRRAATTEESS OONN AANNGGIIOOGGEENNEESSIISS IINNSSEERRIIOOUUSSLLYY IILLLL CCHHIILLDDRREENNV. Karlaftis* (Australia) - C. Attard - P. Monagle - V. Ignjatovic

PPEEWWCC1144 TTHHEE PPRREEVVAALLEENNCCEE AANNDD RROOLLEE OOFF EELLEEVVAATTEEDDCCOOAAGGUULLAATTIIOONN FFAACCTTOORRSS VVIIIIII,, IIXX AANNDD XXII IINNAARRTTEERRIIAALL TTHHRROOMMBBOOSSIISS IINN CCHHIILLDDRREENN M. Avila* (Canada) - A. Zanette - T. Canil - S. Williams - W. Kahr - L. R. Brandao andPaediatric Haemostasis Thrombosis

PPEEWWCC1155 AASSSSIISSTTEEDD RREEPPRROODDUUCCTTIIOONN TTEECCHHNNOOLLOOGGIIEESSFFAAIILLUURREE AANNDD AACCQQUUIIRREEDD TTHHRROOMMBBOOPPHHIILLIIAA::EEXXPPEERRIIEENNCCEE OOFF AA SSIINNGGLLEE SSPPEECCIIAALLIIZZEEDDAARRGGEENNTTIINNIIAANN CCEENNTTEERRG. Begue* (Argentina) - A. S�nchez-Luceros - S. S. Meschengieser - S. H. Grosso - A. Blanco -M. F. Alberto - M. A. Lazzari

ISTH 2012 11.6.2012 14:48 Page 92

ePos

ters


ePoster Session

93

HHaaeemmoorrrrhhaaggiicc DDiissoorrddeerrss ((LLaabb ssttuuddiieess)) aanndd VVoonn WWiilllleebbrraanndd ddiisseeaassee

Chairperson: David Lillicrap (Canada)

VVWWFF0011 DDEETTEECCTTIIOONN OOFF NNOONN IINNHHIIBBIITTOORRYY BBIINNDDIINNGGAANNTTIIBBOODDIIEESS TTOO VVOONN WWIILLLLEEBBRRAANNDD FFAACCTTOORRAAFFFFEECCTTIINNGG TTHHEE CCLLEEAARRAANNCCEE OOFF VVWWFF::AAGG IINNVVOONN WWIILLLLEEBBRRAANNDD DDIISSEEAASSEE T. Suiter* (Austria) - P. M. Mannucci - C. L. Kempton - M. Laffan - E. H. Romond - A. D. Shapiro - I. Birschmann - M. V. Ragni - J. C. Gill - T. T. Yee - R. Klamroth - F. M. Horling -B. M. Reipert - P. L. Turecek - K. Varadi - M. Chapman - W. Engl - W. Y. Wong - B. M. Ewenstein and rhVWF Study Team

VVWWFF0022 BBIIOOCCHHEEMMIICCAALL AANNDD MMOOLLEECCUULLAARRCCHHAARRAACCTTEERRIIZZAATTIIOONN OOFF 1100 IITTAALLIIAANNSSPPAATTIIEENNTTSS AAFFFFEECCTTEEDD BBYY VVOONN WWIILLLLEEBBRRAANNDDDDIISSEEAASSEE TTYYPPEE 22AA//IIIIEE M. T. Pagliari* (Italy) - I. Garcia Oya - F. Stufano - G. Cozzi - S. La Marca - M. T. Canciani - F. Peyvandi - L. Baronciani

VVWWFF0033 TTWWOO CCAASSEESS OOFF CCOONNGGEENNIITTAALL TTHHRROOMMBBOOTTIICCTTHHRROOMMBBOOCCYYTTOOPPEENNIICC PPUURRPPUURRAAAASSSSOOCCIIAATTEEDD WWIITTHH PPRREEGGNNAANNCCYY X. Bai* (China) - J. Su - Z. Yu - Z. Wang - C. Ruan

VVWWFF0044 AA NNEEWW AAUUTTOOMMAATTEEDD CCHHEEMMIILLUUMMIINNEESSCCEENNTTMMEETTHHOODD FFOORR TTHHEE DDEETTEERRMMIINNAATTIIOONN OOFF VVOONNWWIILLLLEEBBRRAANNDD FFAACCTTOORR RRIISSTTOOCCEETTIINNCCOOFFAACCTTOORR AACCTTIIVVIITTYY ((VVWWFF::RRCCOO)) AANNDD VVOONNWWIILLLLEEBBRRAANNDD FFAACCTTOORR AANNTTIIGGEENN ((VVWWFF::AAGG)) K. D. Friedman* (USA) - P. M. Jacobi - M. E. Shaw- J. L. Endres - S. L. Haberichter

VVWWFF0055 HHEEAADD--TTOO--HHEEAADD CCOOMMPPAARRAATTIIVVEE SSTTUUDDYY OOFFTTHHEE PPHHAARRMMAACCOOKKIINNEETTIICC BBEEHHAAVVIIOORR OOFF AAHHIIGGHH--PPUURRIITTYY FFAACCTTOORR IIXX CCOONNCCEENNTTRRAATTEE((AALLPPHHAANNIINNEE¤¤)) AANNDD AA RREECCOOMMBBIINNAANNTTFFAACCTTOORR IIXX ((BBEENNEEFFIIXX¤¤)) IINN PPAATTIIEENNTTSS WWIITTHHSSEEVVEERREE HHEEMMOOPPHHIILLIIAA BB J. A. Aznar* (Spain) - A. Moret - N. Cabrera - Matysiak - K. Zavilska - L. Gercheva - A. Antonov - M. K. Woodward - A. P�ez - T. Lissitchkov

VVWWFF0066 GGEENNEETTIICC DDIIAAGGNNOOSSIISS IINN SSPPOORRAADDIICCHHAAEEMMOOPPHHIILLIIAA AA FFAAMMIILLIIEESS IINN CCHHIINNAA Y. Lu* (China)

VVWWFF0077 PPRREEVVAALLAANNCCEE AANNDD TTRREEAATTMMEENNTT OOUUTTCCOOMMEEOOFF TTRRAANNSSFFUUSSIIOONN TTRRAANNSSMMIITTTTEEDDIINNFFEECCTTIIOONNSS IINN HHEEMMOOPPHHIILLIIAA AA S. Alkindi - M. Kashoob - A. Balkhair - N. Al Obaidani - A. Pathare* (Oman)

VVWWFF0088 TTHHEE MMIISSSSIINNGG PPIIEECCEESS FFOORR UUNNDDEERRSSTTAANNDDIINNGGFFVVIIIIII IINNHHIIBBIITTOORR DDEEVVEELLOOPPMMEENNTT:: HHEEMMOOPPHHIILLIIAAIINNHHIIBBIITTOORR PPUUPP SSTTUUDDYY C. J. Hofbauer* (Austria) - C. Male - D. Brown - E. Santagostino - J. Oldenburg - F. Scheiflinger -B. M. Reipert

VVWWFF0099 PPRREENNAATTAALL DDIIAAGGNNOOSSIISS FFOORR CCOONNGGEENNIITTAALLFFAACCTTOORR VVIIII DDEEFFIICCIIEENNCCYY:: OONNEE CCAASSEE RREEPPOORRTTD. Jing* (Canada)

VVWWFF1100 FFXXII DDEEFFIICCIIEENNCCYY:: GGEENNOOTTYYPPEE--PPHHEENNOOTTYYPPEERREELLAATTIIOONNSSHHIIPP G. Favuzzi* (Italy) - G. L. Tiscia - F. Cappucci - L. Fischetti - V. Bafunno - G. Vecchione - E. Chinni- P. Vergura - D. Colaizzo - M. Villani - M. Margaglione - E. Grandone

ISTH 2012 11.6.2012 14:48 Page 93


ePoster Session

94

VVWWFF1177 PPHHAARRMMAACCOOKKIINNEETTIICCSS AANNDD SSAAFFEETTYY PPRROOFFIILLEEOOFF AA SSIINNGGLLEE IINNTTRRAAVVEENNOOUUSS DDOOSSEE OOFFRREECCOOMMBBIINNAANNTT FFAACCTTOORR XXIIIIII IINN PPAAEEDDIIAATTRRIICCPPAATTIIEENNTTSS WWIITTHH CCOONNGGEENNIITTAALL FFAACCTTOORR XXIIIIII AA--SSUUBBUUNNIITT DDEEFFIICCIIEENNCCYY M. Williams* (United Kingdom) - C. Stenmo - A. Rosholm - R. Tehranchi

VVWWFF1188 PPHHAARRMMAACCOOKKIINNEETTIICCSS OOFF AA NNEEWW RRFFVVIIIIII,,TTUURROOCCTTOOCCOOGG AALLFFAA,, IINNAADDUULLTT//AADDOOLLEESSCCEENNTT AANNDD PPAAEEDDIIAATTRRIICCPPAATTIIEENNTTSS WWIITTHH SSEEVVEERREE HHAAEEMMOOPPHHIILLIIAA AA..DDAATTAA FFRROOMM TTHHEE GGUUAARRDDIIAANN““ 11 AANNDDGGUUAARRDDIIAANN““ 33 TTRRIIAALLSS E. Santagostino - U. Martinowitz - V. Vdovin - S. Glamocanin - M. Morfini - F. Abdul-Karim - G. Dobaczewski - B. Brand - A. Tiede - C. B. Stenmo* (Denmark) - J. Mo/ ss

VVWWFF1199 EEFFFFEECCTT OOFF AAPPTTTT RREEAAGGEENNTT AANNDD SSTTAANNDDAARRDDOONN PPLLAASSMMAA--DDEERRIIVVEEDD AANNDD RREECCOOMMBBIINNAANNTTFFAACCTTOORR IIXX PPOOTTEENNCCYY EESSTTIIMMAATTEESS H. Wilmot* (United Kingdom)- J. Hogwood - E. Gray

VVWWFF2200 CCOOMMPPAARRIISSOONN OOFF QQUUAALLIITTYY OOFF LLIIFFEE IINN AANNAAMMIISSHH AANNDD NNOONN--AAMMIISSHH CCOOHHOORRTT AAFFFFEECCTTEEDDWWIITTHH VVOONN WWIILLLLEEBBRRAANNDD DDIISSEEAASSEE S. Gupta* (USA) - M. Heiman - N. Duncan - P. Yoder - R. Montgomery - J. Hinckley - J. DiPaola- A. D. Shapiro

VVWWFF1111 AA MMAACCHHIINNEE LLEEAARRNNIINNGG AAPPPPRROOAACCHH TTOOMMEERRGGIINNGG AANNDD AANNAALLYYZZIINNGG DDAATTAA FFRROOMM TTHHEECCOONNDDEENNSSEEDD MMCCMMDDMM11--VVWWDD BBLLEEEEDDIINNGGQQUUEESSTTIIOONNNNAAIIRREE P. James* (Canada) - J. Grabell - M. Bowman - S. Mollah - B. Coller

VVWWFF1122 PP..EE11554499KK:: AA NNEEWW MMUUTTAATTIIOONN RREESSPPOONNSSIIBBLLEEOOFF VVOONN WWIILLLLEEBBRRAANNDD DDIISSEEAASSEE TTYYPPEE 22MM A. I. Woods* (Argentina) - A. Sanchez-Luceros - A. C. Kempfer - E. I. Bermejo - J. C. Calderazzo -A. N. Blanco - S. S. Meschengieser - M. A. Lazzari

VVWWFF1133 PP..MM11330044VV:: AA NNEEWW MMUUTTAATTIIOONN IINN TTHHEE AA11DDOOMMAAIINN AASSSSOOCCIIAATTEEDD TTOO AATTYYPPIICCAALL VVOONNWWIILLLLEEBBRRAANNDD 22BB PPHHEENNOOTTYYPPEE A. I. Woods* (Argentina) - A. Sanchez-Luceros - A. C. Kempfer - E. I. Bermejo - J. C. Calderazzo -S. H. Grosso - S. S. Meschengieser - M. A. Lazzari

VVWWFF1144 CCOOMMPPAARRIISSOONN OOFF RREECCOOMMBBIINNAANNTT FFVVIIIIIIUUTTIILLIISSAATTIIOONN IINN AA CCOOHHOORRTT OOFF UUKK PPAATTIIEENNTTSSFFOOLLLLOOWWIINNGG AA SSWWIITTCCHH FFRROOMM AA FFUULLLLLLEENNGGTTHH TTOO BB--DDOOMMAAIINN DDEELLEETTEEDD FFVVIIIIII:: AARREETTRROOSSPPEECCTTIIVVEE AANNAALLYYSSIISS OOFF HHOOMMEECCAARREEDDEELLIIVVEERRYY DDAATTAA S. Verma* (United Kingdom) - J. Gama

VVWWFF1155 SSTTAANNDDAARRDDIIZZAATTIIOONN OOFF AANN AAPPTTTT--BBAASSEEDD FFVVIIIIIIIINNHHIIBBIITTOORR SSCCRREEEENNIINNGG AASSSSAAYY P. Pinto* (India) - S. Shetty - K. Ghosh

VVWWFF1166 IINNHHEERRIITTEEDD BBLLEEEEDDIINNGG DDIISSOORRDDEERRSS IINNPPAAKKIISSTTAANNII WWOOMMEENN PPRREESSEENNTTIINNGG WWIITTHHMMEENNOORRRRHHAAGGIIAA N. Hossain* (Pakistan) - T. Shamsi - A. Naz - A. James

ISTH 2012 11.6.2012 14:48 Page 94

ePos

ters


ePoster Session

95

PPEEWWCC1166 HHEERREEDDIITTAARRYY AANNTTIITTHHRROOMMBBIINN DDEEFFIICCIIEENNCCYYAANNDD PPRREEGGNNAANNCCYY M. T. Desancho* (USA) - R. Levine - J. Cohen - J. Chapin - R. Kalish - S. Shah

PPEEWWCC1177 VVEENNOOUUSS TTHHRROOMMBBOOEEMMBBOOLLIISSMM IINN IITTAALLIIAANNIINNFFAANNTTSS AANNDD CCHHIILLDDRREENN:: DDAATTAA FFRROOMM TTHHEEIITTAALLIIAANN RREEGGIISSTTRRYY OOFF CCHHIILLDDHHOOOODDTTHHRROOMMBBOOSSIISS ((RRIITTII)) C. Gentilomo* (Italy) - P. Saracco - P. Giordano - R. Bagna - A. C. Molinari - M. Grassi - M. C. Putti- D. Lasagni - G. Indolfi - P. Simioni and ItalianGroup Of Childhood Thrombosis Registry

PPEEWWCC1188 TTHHRROOMMBBOOEEMMBBOOLLIICC CCOOMMPPLLIICCAATTIIOONNSS IINNIITTAALLIIAANN IINNFFAANNTTSS AANNDD CCHHIIDDRREENN::CCOOMMPPAARRIISSOONN OOFF DDAATTAA FFRROOMM RRIITTII RREEGGIISSTTRRYYWWIITTHH AA SSIINNGGLLEE CCEENNTTRREE CCOONNSSEECCUUTTIIVVEESSEERRIIEE P. Saracco - C. Gentilomo* (Italy) - R. Bagna - A. Viano - M. Agostini - P. Simioni and ItalianGroup Of Childhood Thrombosis Registry

PPEEWWCC1199 LLOOWW LLEEVVEELLSS OOFF VVIITTAAMMIINN DD IINN PPRREEGGNNAANNTTWWOOMMEENN WWIITTHHTTHHRROOMMBBOOEEMMBBOOLLIISSMM//TTHHRROOMMBBOOPPHHIILLIIAA L. Gallo - V. V. Barros* (Brazil) - F. S. Baptista - M. R. D. F. L. Bortolotto - R. P. V. Francisco - M. Zugaib

PPEEWWCC2200 PPLLAACCEENNTTAALL AABBRRUUPPTTIIOONN AANNDDTTHHRROOMMBBOOPPHHIILLIIAA K. Arissa - V. V. Barros* (Brazil) - F. S. Baptista - M. R. D. F. L. Bortolotto - R P. V. Francisco - M. Zugaib

PPEEWWCC2211 PPEEDDIIAATTRRIICC TTHHRROOMMBBOOSSIISS EEDDUUCCAATTIIOONNAALLTTOOOOLL ((PP--TTEETT)):: AANN EEDDUUCCAATTIIOONNAALL PPRROOJJEECCTTIINN DDEEVVEELLOOPPMMEENNTT FFOORR CCHHIILLDDRREENNRREECCEEIIVVIINNGG OORRAALL AANNTTIICCOOAAGGUULLAATTIIOONN F. R. Cassis - J. D. Carneiro - E. A. D’Amico - L. R. Brandão* (Canada)

PPEEWWCC2222 TTHHRROOMMBBOOPPRROOPPHHYYLLAAXXIISS WWIITTHH TTWWOODDIIFFFFEERREENNTT DDOOSSAAGGEESS OOFF LLWWMMHH ((CCAALLCCIICCNNAADDRROOPPAARRIINN)) IINN PPRREEGGNNAANNTT WWOOMMEENN WWIITTHHTTHHRROOMMBBOOPPHHIILLIIAA:: AA SSIINNGGLLEE CCEENNTTEERREEXXPPEERRIIEENNCCEE P. Samantha* (Italy) - G. Barillari - U. Venturelli - M. Turello

PPEEWWCC2233 TTHHEE RRIISSKK OOFF VVEENNOOUUSS TTHHRROOMMBBOOEEMMBBOOLLIICCDDUURRIINNGG PPRREEGGNNAANNCCYY Y. Y. Ouarhlent* (Algeria) - N. Boudjerra - H. Bounecer

ISTH 2012 11.6.2012 14:48 Page 95

ISTH 2012 11.6.2012 14:50 Page 96

Spon

sor

&Ex

hibi

tor

Prof

iles

Sponsor and Exhibitor Profiles

97

44SS DDAAWWNN CClliinniiccaall SSooffttwwaarree BOOTH N°20

The Square, Milnthorpe 4Cumbria LA7 7QJUnited Kingdom

[email protected]

Over 300 clients worldwide use DAWN AC anticoa-gulation management software with an estimated500,000 patients. Many of our clients are large health-care organizations managing many thousands ofpatients and realize the benefits of the software withincreased productivity, improved quality of care andpatient safety.

Come and see our new modules for managing:New Oral AnticoagulantsVTE AssessmentWeb Browser based Benchmarking ServiceClinical Haematology - MPD, Venesection,Haemochromatosis, MGUS and Stable ChronicLeukemia - Anaemia / ESAs - Hepatitis

AAFFFFIINNIITTYY BBIIOOLLOOGGIICCAALLSS,, IInncc.. BOOTH N°17

1395 Sandhill Dr.Ancaster, Ontario L4G 3Z9Canada

[email protected]

Affinity Biologicals, Inc. is a primary manufacturer ofproducts used worldwide in thrombosis and haemo-stasis research and medical diagnostics. Products

include an extensive line of antibodies, conjugates,antibody pairs for immunoassay of human and animalanalytes, the VisuLize™ line of complete ELISA kits,and a full line of immuno-depleated human plasmaproducts, VisuCal™ Calibrator Plasma and VisuCon™Normal & Abnormal Control Plasmas. Services includeprotein purification, antibody production, assay deve-lopment, custom lyophilization and custom plasmaproduction.

AALLEEXXIIOONN BOOTH N°26

Unit 14 Horizon Business VillageBrooklands Road, Weybridge 1SurreyKT13 0TJ United Kingdom

[email protected]

Alexion is a global biopharmaceutical company thatcombines groundbreaking science with a steadfastcommitment to meeting the needs of patients livingwith severe, often life-threatening, ultra-rare diseases.These diseases may be chronic, progressive, degene-rative, and difficult to diagnose and treat.For further information on relevant disease areas,presenting signs and symptoms, differential diagnosis,and treatment, please visit the Alexion stand at themeeting.

ISTH 2012 11.6.2012 14:50 Page 97


98

AAMMGGEENN BOOTH N°19

240 Cambridge Science ParkMilton Road Cambridge CB4 0WDUnited Kingdom

Amgen discovers, develops, manufactures, and deli-vers innovative human therapeutics. A biotechnologypioneer since 1980, Amgen was one of the first com-panies to realise the new science’s promise bybringing safe, effective medicines from the lab tomanufacturing plant to patient.Amgen therapeutics have changed the practice ofmedicine, helping millions of people around the worldin the fight against cancer, kidney disease, bonedisease, and other serious illnesses. With a deep andbroad pipeline of potential new medicines, Amgenremains committed to advancing science to helpimprove people’s lives.For more information about Amgen, our pioneeringscience and our vital medicines, visit:www.amgen.co.uk

BBAAXXTTEERR HHEEAALLTTHHCCAARREE,, IInncc.. BOOTH N°1

One Baxter ParkwayDeerfield, IL 60015 United States

www.baxter.com

Baxter International Inc., through its subsidiaries,develops, manufactures and markets products thatsave and sustain the lives of people with hemophilia,immune disorders, infectious diseases, kidney disease,

trauma, and other chronic and acute medical conditions.As a global, diversified healthcare company, Baxterapplies a unique combination of expertise in medicaldevices, pharmaceuticals and biotechnology to createproducts that advance patient care worldwide.

BBAAYYEERR HHEEAALLTTHHCCAARREE AAGG SPONSOR

Bayer Healthcare Pharmaceuticals13353 BerlinGermany

www.bayer.com

AAbboouutt BBaayyeerr HHeeaalltthhCCaarree The Bayer Group is a global enterprise with corecompetencies in the fields of health care, nutrition andhigh-tech materials. Bayer HealthCare, a subgroup ofBayer AG with annual sales of EUR 16.913 billion(2010), is one of the world’s leading, innovativecompanies in the healthcare and medical productsindustry and is based in Leverkusen, Germany. Thecompany combines the global activities of the AnimalHealth, Consumer Care, Medical Care and Pharma-ceuticals divisions. Bayer HealthCare’s aim is todiscover and manufacture products that will improvehuman and animal health worldwide. Bayer Health-Care has a global workforce of 55,700 employees(Dec 31, 2010) and is represented in more than 100countries.

ISTH 2012 11.6.2012 14:50 Page 98

Spon

sor

& E

xhib

itor

Pro

files


99

BBIIOOGGEENN IIDDEECC && SSWWEEDDIISSHH OORRPPHHAANN BBIIOOVVIITTRRUUMMSPONSOR

133 Boston Post RdWeston, MA 02493United States

www.BiogenIdecHemophilia.com

BBiiooggeenn IIddeeccThrough cutting-edge science and medicine, BiogenIdec discovers, develops and delivers to patientsworldwide innovative therapies for the treatment ofneurodegenerative diseases, hemophilia and auto-immune disorders. For additional information about thecompany, please visit www.biogenidec.com

SSwweeddiisshh OOrrpphhaann BBiioovviittrruumm ((SSoobbii))a leading integrated biopharmaceutical companybringing innovative therapies and services to improvethe lives of patients with rare diseases and theirfamilies. Based on our long history in hemophilia wecontinue the search for improved treatment, and nowin a successful partnership with BiogenIdec, we aredeveloping the next generation hemophilia therapies.Please visit also - www.sobi.com

BBOOEEHHRRIINNGGEERR IINNGGEELLHHEEIIMM LLIIMMIITTEEDD BOOTH N°18

Ellesfield AvenueBracknell BerkshireRG12 8YSUnited Kingdom

www.boehringer-ingelheim.co.uk

The Boehringer Ingelheim group is one of the world’s20 leading pharmaceutical companies. Headquartered

in Ingelheim, Germany, it operates globally with 145affiliates and more than 44,000 employees. Since itwas founded in 1885, the family-owned company hasbeen committed to researching, developing, manu-facturing and marketing novel products of hightherapeutic value for human and veterinary medicine.A central element of Boehringer Ingelheim’s culture isto be socially responsible. Involvement in socialprojects, caring for employees and their families, andproviding equal opportunities for all employees formthe foundation of the global operations. Mutualcooperation and respect, as well as environmentalprotection and sustainability are intrinsic factors in allof Boehringer Ingelheim’s endeavors.For more information please visit:www.boehringer-ingelheim.co.uk

CCSSLL BBEEHHRRIINNGG BOOTH N°2

P.O. Box 1230 35002 Marburg Germany

[email protected]

CSL Behring is a leader in the plasma protein thera-peutics industry. Committed to saving lives andimproving the quality of life for people with rare andserious diseases, the company manufacturers andmarkets a range of plasma-derived and recombinanttherapies worldwide. CSL Behring therapies areindicated for the treatment of coagulation disordersincluding hemophilia and von Willebrand disease,primary immune deficiencies and inherited respiratorydisease. The company’s products are also used in

ISTH 2012 11.6.2012 14:50 Page 99


100

cardiac surgery, organ transplantation, burn treatmentand to prevent hemolytic diseases in newborns. CSLBehring operates one of the world’s largest plasmacollection networks, CSL Plasma. CSL Behring is asubsidiary of CSL Limited (ASX: CSL), a biophar-maceutical company headquartered in Melbourne,Australia.For more information, visit www.cslbehring.com

DDAAIIIICCHHII SSAANNKKYYOO EEUURROOPPEE GGmmbbHH BOOTH N°14

Zielstattstrasse 4881379, MunichGermany

[email protected]

The Daiichi Sankyo Group is dedicated to the creationand supply of innovative pharmaceutical pro¬ducts toaddress the diversified, unmet medical needs ofpatients in both mature and emerging markets. Thecompany was created in 2005 through the merger oftwo traditional Japanese enterprises, Daiichi andSankyo. With net sales of more than €8.5 billion,Daiichi Sankyo is one of the world’s 20 leading phar-maceutical companies. While maintaining its portfolioof marketed pharmaceuticals for hypertension, hyper-lipidemia, and bacterial infections, the Group is enga-ged in the development of treatments for thromboticdisorders and focused on the discovery of noveloncology and cardiovas¬cular-metabolic therapies.Furthermore, the Daiichi Sankyo Group has created a“Hybrid Business Model”, which will respond to marketand customer diversity and optimize growth opportuni-ties across the value chain.

Daiichi Sankyo Europe has affiliates in 12 Europeancountries in addition to a global manufacturing sitelocated in Pfaffenhofen, Germany.For more information, please visit:www.daiichisankyo.com or www.daiichi-sankyo.eu

EENNZZYYMMEE RREESSEEAARRCCHH// RR22 DDIIAAGGNNOOSSTTIICCSSBOOTH N°24

1801 Commerce DriveSouth Bend, IN 46628United States

[email protected]@r2diagnostics.comwww.enzymeresearch.com www.r2diagnostics.com

Enzyme Research Laboratories provides coagulationand fibrinolytic proteins from human plasma, othersource plasmas and platelets. We also offer mono-clonal and polyclonal antibodies, immunodepletedplasmas and ELISA reagents. Custom purificationsand contract services are also available. r2 Diagnos-tics strives to provide high quality, innovative andeconomical products for the hemostasis market. Weplace major emphasis on the production of optimizedand versatile products for the detection of throm-bophilia. We offer clot-based kits for quantitation of PC,PS, and Lupus Anticoagulants.

ISTH 2012 11.6.2012 14:50 Page 100

Spon

sor

& E

xhib

itor

Pro

files


101

GGLLAAXXOOSSMMIITTHHKKLLIINNEE BOOTH N°5a

Ironbridge Road 1-3 Stockley Park West, Middlesex UB11 1BTUnited Kingdom

[email protected]

GSK is dedicated to producing innovations inhaematological malignancies that will make profounddifference to the lives of patients. Through GSK’srevolutionary “bench to bedside” approach we aretransforming the way treatments are discovered anddeveloped, resulting in one of the most robust pipe-lines in the oncology/haematology sector. Our world-wide research in this sector includes collaborationswith more than 160 cancer centers. GSK is developinga new generation of patient-focused cancer treatmentsin prevention, supportive care, chemotherapy and tar-geted therapies.

HHAAEEMMAATTOOLLOOGGIICC TTEECCHHNNOOLLOOGGIIEESS,, IInncc..BOOTH N°6

River Road 57Essex JunctionVermont 05452United States

[email protected]

Haematologic Technologies, Inc. (HTI) is a manu-facturer of research reagents, specializing in theplasma proteins involved in the regulation of bloodcoagulation and fibrinolysis. Our product line of highly

purified proteins includes zymogens, enzymes, cofac-tors, and inhibitors as well as monoclonal and poly-clonal antibodies.

HHAAEEMMOONNEETTIICCSS CCOORRPPOORRAATTIIOONN BOOTH N°15

400 Wood RoadBraintree, MA, 02184United States

www.haemonetics.com

Haemonetics is a global healthcare company dedi-cated to providing innovative blood managementsolutions for our customers. Together, our devices andconsumables, IT products, and consulting servicesdeliver a suite of business solutions to help our cus-tomers improve clinical outcomes and reduce the costof healthcare for blood collectors, hospitals, andpatients around the world. Our technologies addressimportant medical markets: blood and plasma com-ponent collection, the surgical suite, and hospitaltransfusion services.To learn more about Haemonetics visit our web site atwww.haemonetics.com

HHEELLEENNAA BBIIOOSSCCIIEENNCCEESS EEUURROOPPEE BOOTH N°10

Queensway SouthTeam Valley Trading EstateGateshead - Tyne and WearNE11 0SDUnited Kingdom

[email protected] www.helena-biosciences.com

Helena Biosciences' unparalleled clinical diagnosticsexperience extends over thirty years, driven by a com-

ISTH 2012 11.6.2012 14:50 Page 101


102

mitment to excellence, value and the best customerservice. Specialising in Clinical Electrophoresis andHaemostasis, Helena Biosciences manufacture andmarket the most innovative diagnostic products,providing clinicians worldwide with a comprehensiveportfolio of blue-chip instrumentation, software andassays.Helena Biosciences Europe delivers integratedcapillary and agarose gel electrophoresis systems - inaddition to a range of haemostasis instrumentationand reagents.

HHEEMMAACCOORREE LLLLCC BOOTH N°7

34th street of 8 March125319, MoscowRussia

[email protected]

HemaCore LLC - biotech company, develops medicaldevices and methods for hematology. Main product isThrombodynamics assay - a new global blood test formonitoring and prognosis of clotting disorders:bleeding and thrombosis. Thrombodynamics assay ishighly sensitive both to pro- and anticoagulantchanges in hemostatic balance.Thrombodynamics analyzer and disposables sales inRussia will start in November 2012.Planned launch date in Europe is April 2013.

HHEERRMMAANNSSKKYY--PPUUDDLLAAKK SSYYNNDDRROOMMEE NNEETTWWOORRKK UUKK((HHPPSS NNEETTWWOORRKK UUKK)) BOOTH N°13

Howards Drive, Hemel Hempstead 49 Herts, HP1 3NWUnited Kingdom

[email protected]

The HPS Network UK was established in 2010. Weare affiliated to the US based HPS Network Inc. Weare a not-for-profit group working for the benefit ofindividuals and families affected by Hermansky-PudlakSyndrome - and those who seek diagnostic testing.We aim to work with health professionals to develop:A) quicker consistent routes to reliable testing, B)standards of care and referral for those affected byHPS. We encourage affected individuals and familiesto adopt a proactive role in their healthcare by pro-viding information and support. HPS involves: a plate-let bleeding disorder, albinism, visual impairment withphotophobia and nystagmus, life limiting pulmonaryfibrosis, a granulomatous ‘Crohns-like’ colitis, immu-nodeficiency and HLH (HPS-2 only).

ISTH 2012 11.6.2012 14:50 Page 102

Spon

sor

& E

xhib

itor

Pro

files


103

automated, chemiluminescent analyzer for hemostasisspecialty testing. Combined with the HemosIL line ofreagents, a comprehensive panel of fully automatedassays, IL offers complete disease state managementfor the hemostasis lab.

MMIICCRROOVVIISSKK TTEECCHHNNOOLLOOGGIIEESS BOOTH N°22

Unit 4 Innovation HouseFfordd Richard DaviesSt Asaph Business ParkSt Asaph, LL170LJUnited Kingdom

[email protected]

Microvisk Technologies is a UK based developer ofmicroviscometry products. First to market are theCoagMax® and CoagLite® point of care coagulationmonitoring systems. Currently in the process of finalclinical trials it is expected that these will be availablefor sale under the CE mark shortly and in the UStowards the end of the year. The highly patentedMEMS (Micro Electro Mechanical System) sensoruses a form of mechanical clot detection to accuratelychart the formation of a clot in both whole blood andcalcified plasma. CoagMax® is designed for theprofessional INR tester with the function to uploadoperator and patient ID’s. The CoagLite® is designedto be as simple as possible for the self-tester andbrings the simplicity of blood glucose testing to thepoint of care INR market for the first time.

IINNSSPPIIRRAATTIIOONN BBIIOOPPHHAARRMMAACCEEUUTTIICCAALLSS,, IInncc..SPONSOR

One Kendall Square, Building 1400 EastCambridge, MA 02139United States

www.inspirationbio.com

IInnssppiirraattiioonn BBiioopphhaarrmmaacceeuuttiiccaallssInspiration was founded by families with hemophilia,with a mission to improve the lives of people withhemophilia around the world. We are the onlybiopharmaceutical company focused exclusively onhemophilia. We are working with the community todrive innovation and expand global access torecombinant therapies. Inspiration is led by a mana-gement team with extensive experience bringingbiopharmaceuticals to market. We have two late-stageproducts in clinical studies: a recombinant factor IXand a recombinant porcine factor VIII

IINNSSTTRRUUMMEENNTTAATTIIOONN LLAABBOORRAATTOORRYY BOOTH N°27

Hartwell Road 180 Bedford, MA 01730United States

www.ilww.com

Instrumentation Laboratory (IL) is passionate aboutdelivering the most innovative solutions to address arange of hemostasis testing needs. The advancedACL™ family of systems brings complete automationto the hemostasis lab - including the ACL TOP® Familyof Hemostasis Testing Systems, featuring the new ACLTOP 300 CTS; and, the ACL AcuStar®, the first fully

ISTH 2012 11.6.2012 14:50 Page 103


104

predictivity for stent thrombosis after PCI and allowsfor superior stratification of major bleeding risk andtransfusion requirements in cardiac surgery.Multiplate® enables the rapid verification or exclusionof drug induced or disease related platelet disorders.The clinical predictivity of the perioperative use ofMultiplate® has been validated in several clinicalstudies.

NNOOVVOO NNOORRDDIISSKK SPONSOR

Novo Nordisk A/SNovo Allé, 2880 BagsvaerdDenmark

www.novonordisk.com

Novo Nordisk is a global healthcare company with 89years of innovation and leadership in diabetes care.The company also has leading positions withinhaemophilia care, growth hormone therapy andhormone replacement therapy. Headquartered inDenmark, Novo Nordisk employs approximately32,700 employees in 75 countries, and markets itsproducts in more than 190 countries. Novo Nordisk’s Bshares are listed on NASDAQ OMX Copenhagen(Novo-B). Its ADRs are listed on the New York StockExchange (NVO). For more information, visit novo-nordisk.com.

MMIITTSSUUBBIISSHHII PPHHAARRMMAA BOOTH N°5b

Dashwood HouseOld Broad Street 69 London, EC2M 1QSUnited Kingdom

[email protected]://www.mitsubishi-pharma.eu

Mitsubishi Pharma Europe is the European Head-quarters of one of Japan’s largest pharmaceuticalcompanies, Mitsubishi Tanabe Pharma Corporation.Based in London, Mitsubishi Pharma Europe isengaged in the clinical development of new drugs forthe European markets. Mitsubishi Pharma Europe isconducting trials in Europe in the following therapyareas; cardiovascular, diabetes, CNS and renalconditions. The staff include regulatory, QA, clinical,biostatistics, medical information, pharmacovigilance,pharmaceutical technology and marketing.

MMUULLTTIIPPLLAATTEE -- VVEERRUUMM DDIIAAGGNNOOSSTTIICCAA GGmmbbHHBOOTH N°8

Reichenbachstrasse 2780469 MunichGermany

[email protected]

With more than 900 installations Multiplate® is themost widely applied platelet aggregometer in Europefor the monitoring of antiplatelet therapy and thedetection of platelet disorders. The POC and labo-ratory use of Multiplate® delivers superior clinical

ISTH 2012 11.6.2012 14:50 Page 104

Spon

sor

& E

xhib

itor

Pro

files


105

PPAATTHHWWAAYY DDIIAAGGNNOOSSTTIICCSS LLttdd BOOTH N°23

Eclipse House, Curtis RoadDorking, Surrey RH4 1EJUnited Kingdom

[email protected]

Pathway Diagnostics Ltd was established in 1999 as adistribution and manufacturing company specialisingin the field of haemostasis. The company is the exclu-sive distribution partner in the UK and Ireland forTechnoclone GmbH and markets their coagulation andfibrinolysis reagents, and instrumentation to clinical,research and industry clientsPathway Diagnostics markets its own range ofhaemostasis tests, including assays for PrekallikreinActivator, and those of Unicorn Diagnostics Ltd inter-nationally through local distributors or directly from theUK. The company's product ranges are available inIreland and Northern Ireland through its Dublin baseddistributor, LanganBach Services LtdWith many years of experience in the IVD industry,Pathway Diagnostics is highly focused on the needs ofits customers and in providing the highest qualityproducts and service.

OOCCTTAAPPHHAARRMMAA AAGG BOOTH N°29

Seidenstrasse 28853 LachenSwitzerland

[email protected]

Octapharma AG, a Swiss-based company, is the lar-gest privately owned plasma fractionation specialist inthe world. Since 28 years, its core business is thedevelopment, production and sale of high qualityplasma derivatives. The Octapharma product portfolio,produced in our five manufacturing facilities in Austria,Sweden, France, Germany and Mexico, is focused onplasma derivatives for treatment in coagulation disor-ders, immunotherapy and intensive care and emer-gency medicine.Our coagulation product portfolio consists of: wilate®,

new generation treatment for von Willebrand patients.octanate®, VWF-stabilized FVIII to prevent and cureFVIII-Inhibitors. octanine F® high purity SD-treatedand nano-filtered Factor IX concentrates. octaplex®,state-of-the-art human PCC.

ISTH 2012 11.6.2012 14:50 Page 105


106

strive to set the standard for quality, safety and valuein the discovery, development and manufacturing ofmedicines for people and animals. Our diversifiedglobal health care portfolio includes human and animalbiologic and small molecule medicines and vaccines,as well as nutritional products and many of the world’sbest-known consumer products. Every day, Pfizercolleagues work to advance wellness, prevention,treatments and cures that challenge the most feareddiseases of our time.

PPRREECCIISSIIOONN BBIIOOLLOOGGIICC BOOTH N°12

Eileen Stubs Avenue 140DartmouthNS, B3B 0A9Canada

[email protected]

Precision BioLogic develops, manufactures and mar-kets diagnostic products used for testing in routine andspecial coagulation laboratories around the globe. Ourunique approach to doing business is built on oursuperior products, commitment to customer serviceand attention to detail. Over the past 20 years, ourcryocheck™ frozen controls, calibrators and reagentshave become synonymous with quality. Today, we aregrowing our product base to help meet customers’needs by adding more in vitro diagnostics, includingour line of clot-based diagnostic kits. Learn more atwww.precisionbiologic.com.

PPEENNTTAAPPHHAARRMM // DDSSMM BOOTH N°16

PostfachCH-4002 BaselSwitzerland

[email protected]

The Branch Pentapharm, since 2007 part of DSM, is amanufacturer of haemeostasis diagnostics:Test kits e.g. Pefakit® APC-R Factor V Leiden, PiCT®(for UFH, LMWH and/or anti-FIIa and FXa drug moni-toring), Reptilase Time, in-TDT® (for thrombin gene-ration), or OEM products.Reagents (from research to bulk quantities) includingcustomer manufacturing n: synthetic chromogenic,fluorogenic and amperogenic substrates, proteaseinhibitors and snake venom enzymes.Active pharmaceutical ingredients: aprotinin, peptidesand snake venom derived enzymes (Batroxobin,Haemocoagulase) and synthesis of peptides and smallorganic molecules.

PPFFIIZZEERR BOOTH N°25

Pfizer LimitedIPC 4-1, Walton Oaks, Dorking Road, Walton-on-the-Hill, Tadworth, Surrey KT20 7NS United Kingdom

www.Pfizer.co.uk

Pfizer: Working Together for a Healthier World™At Pfizer, we apply science and our global resources toimprove health and well-being at every stage of life.We

ISTH 2012 11.6.2012 14:50 Page 106

Spon

sor

& E

xhib

itor

Pro

files


107

SSIIEEMMEENNSS HHEEAALLTTHHCCAARREE DDIIAAGGNNOOSSTTIICCSS PPRROODDUUCCTTSS GGmmBBHH BOOTH N°3

Emil-von-Behring-Straße 7635041 MarburgGermany

[email protected]/healthcare

Siemens Healthcare Diagnostics offers a compre-hensive portfolio of performance-driven systems,unmatched test menu, and information technologysolutions for the in vitro diagnostic needs of hospitallabs, reference labs, physician office labs, and point-of-care testing. We provide clinicians with the vitalinformation they need for accurate diagnosis, treat-ment, and monitoring of patients. Our diagnosticsolutions - chemistry, immunoassay, automation,hematology, hemostasis, microbiology, diabetes,urinalysis, blood gas, and molecular testing - aredesigned to streamline workflow, enhance operationalefficiency, and support improved patient care.

SSTTAAGGOO BOOTH N°28

HeadquartersRue des Frères Chausson 992600 Asnières sur SeineFrance

www.stago.com

Stago dedicates its research and innovative skills todevelop and improve the accuracy of the medicaldiagnostic.The firm formulates manufactures and mar-kets worldwide, a broad range of reagents (routine &

SSAANNOOFFII SPONSOR

Rue de la Boetie 5475008 ParisFrance

[email protected]://en.sanofi.com/home.asp

Sanofi a diversified global healthcare leader, focusedon patients’ needs Sanofi has core strengths in thefield of healthcare with growth platforms: emergingmarkets, human vaccines, consumer healthcare, dia-betes, innovative products and animal health. Throughthe acquisition of Genzyme, Sanofi has reinforced itsfootprint in biotechnology and rare diseases.Sanofi’ strategy is based on three key principles inorder to deliver long-term sustainable growth: increa-sing innovation in Research & Development, seizingexternal growth opportunities, adapt to future challen-ges and opportunities.Sanofi:- More than 110,000 employees in 100 countries- 2011 net sales: €33.4 billionFor more information: http://en.sanofi.com/home.asp

ISTH 2012 11.6.2012 14:50 Page 107


108

TTEECCHHNNOOCCLLOONNEE BOOTH N°23

Brunner Strasse 671230 ViennaAustria

[email protected]

Technoclone is a world leading producer of global andspecial coagulation tests, calibration and controlplasmas and Ceveron machines. Ceveron® alphaTGA is not only a fully automated coagulation analyzerfor clotting, photometric and immunological, latexbased coagulation tests but also offers the uniquefeature of fully automated thrombin generationmeasurement in the routine: CV <5% and assay times<20min Peak Thrombin.Another innovation is the Ceveron® MFU 500, a microparticle filtration unit which can identify micro parti-cles thombogenicity in conjunction with the assayTechnothrombin® MP. Furthermore Technocloneprovides a complete range of ADAMTS13 ELISAs andFXIII assays, as well a complete portfolio for the newanticoagulants such as for Xa inhibitors and directthrombin inhibitors.

research) and fully automated systems for haemo-stasis & thrombosis.Thanks to its haemostasis expertise, Stago is recogni-zed and is in position to cooperate with the scientificcommunity worldwide.Affiliates in USA, Canada, China, Australia/NZ, UK,France (Headquarters), Germany, Italy, Spain, Portu-gal, Austria, Switzerland, the Netherlands, Belgium -wide network of distributors (> 100 countries) BioCytexand Thrombinoscope are Stago Group companies:- Biocytex develops advanced research tools in field

of cellular biology.- Thrombinoscope develops systems and reagents in

field of Thrombin Generation (TGT).

SSYYSSMMEEXX UUKK LLttdd BOOTH N°3

Sysmex House, Garamonde Drive,Wymbush, Milton Keynes, MK88DFUnited Kingdom

[email protected]

Sysmex supply automated in-vitro diagnostic haema-tology and coagulation analysers, reagents and infor-mation systems for laboratories and healthcarefacilities in the UK and Ireland. We work closely withour customers to provide a range of technologies andsupport services designed specifically to meet yourneeds, either in a laboratory or in a point of care envi-ronment. The new additions to the Product Portfolioinclude the revolutionary XN-Series of HaematologyAnalysers and the ground-breaking CS-5100 Coagu-lation Analyser; all are designed to provide maximumefficiency and optimum workload management.

ISTH 2012 11.6.2012 14:50 Page 108

ISTH 2012 11.6.2012 14:50 Page 109

Exhibition Floor Plan

110

20 4S DAWN Clinical Software17 Affinity Biologicals Inc.26 Alexion19 Amgen1 Baxter Healthcare Inc.18 Boehringer Ingelheim Limited2 CSL Behring14 Daiichi Sankyo Europe GmbH24 Enzyme Research / r2 Diagnostics5a GlasxoSmithKline6 Haematologic Technologies, Inc.15 Haemonetics Corporation10 Helena Biosciences Europe7 Hemacore LLC13 HPS Network UK27 Instrumentation Laboratory22 Microvisk Technologies5b Mitsubishi Pharma8 Multiplate - Verum Diagnostica

GmbH29 Octapharma AG16 Pentapharm / DSM25 Pfizer12 Precision BioLogic3 Siemens - Healthcare Diagnostics

Products GmbH / Sysmex UK Ltd.28 Stago23 Technoclone / Pathway

Diagnostics Ltd.

ExhibitorsList correct as at 22 May 2012

Booth Number Company Name

ISTH 2012 11.6.2012 14:50 Page 110

Floo

r Pl

ans

Congress Centre Floor Plan

111

Cityside

CitysideEntrance

RiversideEntrance

Riverside

ISTH 2012 11.6.2012 14:50 Page 111

ISTH 2012 11.6.2012 14:50 Page 112

isth couverture 6.6.2012 10:21 page 1 - cdn.ymaws.com · anish sharda usa wie shi china jane skov...

Documents